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ABSTRACT 
Recent studies have shown the importance of microRNAs (miRNAs) as key 
regulators in several human disease, and also their great potential as new class 
of therapeutics cancer therapeutics. However, a major obstacle to their 
translation to clinic is actually represented by the lack of a robust and reliable 
way to selectively deliver them to the target malignant tumor cells. 
Today, nucleic-acid aptamers represent an expanding new class of 
biomolecules which is revealing as an interesting and highly promising for the 
specific delivery of RNA-based therapeutics. 
In this study, I intend to validate the use of aptamers as cell-specific 
delivery molecules for “therapeutic” miRNAs. I identified a tumor-suppressive 
miRNA in non-small cell lung cancer (NSCLC), miR-34c. I validated that the 
expression of miR-34c is low in NCSCL and when transfected into cell lines is 
able to impact on cell survival. 
By applying methods successfully used in our laboratory, I conjugated the 
tumor-suppressor miR-34c to a nucleic acid aptamer, that selectively recognize 
the AXL receptor and is rapidly internalized (GL21.T), generating a 
“molecular chimera”. With stick-end annealing, the aptamer and a single chain 
anti-miRNA (or the passenger strand of the miRNA) are annealed by the mean 
of complementary sticky ends elongated at the 3’ end of the aptamer and at the 
5’ end of the single chain of the miRNA, respectively. 
I demonstrated that the GL21.T/miR-34c chimera is able to bind and to 
carry the miRNA within the NSCLC cells. Interestingly, I demonstrated that a 
miR-34c target is the AXL receptor. Thus, the GL21.T/miR-34c chimera is 
able to exert a dual inhibition of AXL, either at functional or at transcriptional 
level. 
Finally, I evaluated the functional effects of the chimera NSCLC cells that 
selectively express AXL receptor. 
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involvement (N), and the presence or absence of metastases (M). The T, N, and 
M combination determines the appropriate stage, numbered I through IV. 
 
 
 
Table 1. NSCLC staging based on TNM system classification.  
 
 
These tumors, unfortunately, spread throughout the entire body at an early 
stage. Frequently, metastasis may be the first manifestation of a still occult 
primary lung cancer. No organ or tissue is safe from the tumor spread, but 
more frequent sites of metastasis are liver (30-50%), brain (20%) and bones 
(20%). 
Symptoms related to disseminated disease include weight loss, abdominal 
pain due to involvement of the liver, adrenals and pancreas, and pain due to 
bone marrow metastases. 
 Basically, there are three possible treatments for lung cancer, depending on 
the stage: 
1. Surgery 
2. Radiotherapy 
3. Chemotherapy. 
When the diagnosis is early (I or II stages), the best results are obtained with 
the first method, but radiotherapy could be an alternative treatment option for 
patients who refuse surgery or are not eligible for a standard lobectomy. 
Chemotherapy provides only modest survival benefits (1 to 2 months) when 
the patients are diagnosed with an incurable advanced/metastatic stage disease. 
One of the features that most affects the survival rate is the resistance to 
chemotherapeutic drugs. In fact, the treatment has a successful clinical 
response only in 20-30% of cases; it is therefore necessary to develop new 
therapies [Travis 2011]. 
During the last decade a novel treatment approach has been generated, the 
targeted therapy, a type of treatment that blocks tumor cell proliferation and 
the spread of cancer cells, by interfering with specific molecules ("molecular 
targets") that play a key role in the cancer progression, and in metastases 
development. The fundamental aim of targeted therapies is the identification of 
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good targets, that are present, or at least more abundant in cancer cells, 
compared to normal cells. 
Many different targeted therapies have already been approved by Food and 
Drug Administration (FDA) for lung cancer treatment, such as Bevacizumab 
(Avastin®), a monoclonal antibody that targets vascular endothelial growth 
factor (VEGF), Erlotinib (Tarceva®) and Gefitinib (Iressa®), both EGFR 
inhibitors used in NSCLC with epidermal growth factor receptor (EGFR) gene 
mutations. As for chemotherapy, also in this kind of therapies cancer cells can 
acquire resistance within 1 or 2 years, so it is necessary to develop new 
therapeutic strategies [Chan and Hughes 2015]. 
Finally, there are also palliative treatment approaches that improve the 
survival and the quality of life of these patients, especially looking to reduce 
the symptoms of the disease in the lungs [Travis 2011]. 
 
 
1.2 MicroRNAs 
 
In the last two decades, many non-coding RNAs (ncRNAs) were found to 
regulate a wide variety of biological processes. Among these, microRNAs 
(miRNAs) are the most investigated and best characterized.  
MiRNAs are members of a family of small RNAs, which includes small 
nuclear RNA (snRNA) involved in mRNA splicing, small nucleolar RNA 
(snoRNA) which directs modification of ribosomal RNA and short interfering 
RNA (siRNA) produced from long double-stranded RNA precursors. Similar 
to miRNA, siRNA also functions to regulate gene expression. 
MiRNAs are small non-protein-coding molecules (19-24 nucleotides), 
highly conserved through the evolution, that negatively regulate gene 
expression by a post-translational repression mechanism. They bind to a 
specific site of a target mRNA in the 3’UTR allowing the degradation of the 
messenger if there is a perfect complementarity between the miRNA and its 
3’UTR, or translational repression in case of a not perfect complementarity 
[Bartel 2004].  
Since their discovery, thousands of microRNAs have been cloned and 
characterized from different organisms, including arthropods, nematodes, 
vertebrates and plants. Currently there are over 1800 human microRNAs listed 
in the miRBase database, accounting for about 1% of the human transcriptome, 
although it is predicted that the true figure is likely to be closer to one thousand 
[Griffiths-Jones et al. 2006]. 
 
 
1.2.1 miRNAs biogenesis 
 
Despite some differences in miRNA biogenesis between animals and plants, 
the most important events in miRNA biogenesis remain similar.  
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The biogenesis of miRNAs starts with the transcription of genomic regions 
located within or between protein-coding genes, resulting in the synthesis of a 
long precursor molecules (pri-miRNAs), over 1 kb in size, which have a stem-
loop structure, are capped at the 5’-end and have a 3’-poly (A) tail. Pri-
miRNAs are currently thought to be transcribed primarily by RNA polymerase 
II and, less frequently by RNA polymerase III [Lee et al. 2002].  
A single pri-miRNA may contain a "cluster" of different miRNAs or a 
single miRNA and can contain from 200 to several thousands of nucleotides. 
Subsequently, pri-miRNA transcripts undergo to a two steps maturation 
process involving RNase III enzymes and companion double-stranded RNA-
binding domain (dsRBD) proteins.  
In the nucleus, the RNAse III enzyme, Drosha, cleaves both strands of the 
pri-miRNA transcript in a staggered manner, producing a stem-loop precursor 
molecule (pre-miRNA), a 60-70 nt long hairpin RNA with 2-nt overhangs at 
the 3’ end.  
These pre-miRNA molecules are transported into the cytoplasm for further 
processing to become mature miRNAs. The transport occurs through a nuclear 
pore complex and is mediated by the RanGTP-dependent nuclear transport 
receptor, exportin-5 (EXP5). EXP5 exports the pre-miRNA out of the nucleus, 
where hydrolysis of the GTP results in the release of pre-miRNA. In the 
cytoplasm the pre-miRNA is subsequently processed by Dicer, an 
endonuclease RNAse III enzyme, which cuts both strands of the pre-miRNA at 
the base of the stem-loop, producing a duplex molecule 21-25 nt long. 
The duplex molecule contains the single-stranded mature miRNA and a 
fragment termed miRNA*, which is derived from the opposite complementary 
arm of the pre-miRNA. The mature miRNA is then incorporated into a large 
protein-effector complex, called RISC (RNA-induced silencing complex), 
while the miRNA* strand is subsequently degraded. 
RISC complex facilitates the interaction between miRNA and its target 
mRNA and function as an endonuclease that cuts the target mRNA, or, for 
steric hindrance, can block the binding of mRNA with the complex of protein 
synthesis (Figure 4) [Bartel 2004, Lee et al. 2002, Gregory and Shiekhattar 
2005]. 
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Figure 4. Model of miRNA biogenesis and mechanisms of gene expression 
regulation.  
 
 
1.2.2 Role of miRNAs  
 
With the finding of the first miRNA, lin-4, in 1993 [Lee et al. 1993] and 
later, let-7, in 2000 [Pasquinelli et al. 2000], the information on miRNAs has 
grown exponentially and suggested them as one of the crucial players of gene 
expression regulation. As master gene regulators, miRNAs are able to impact a 
variety of cellular pathways and functions. Early studies have shown that 
miRNAs are critical to developmental timing, cell death, cell proliferation, 
immunity and patterning of the nervous system [Ambros 2004]. 
MiRNAs are expressed in a tissue-specific manner and a deregulation of 
miRNAs expression within a tissue type can lead to a variety of human 
diseases. Thus, it is critical to understand how miRNAs are regulated in normal 
cellular processes as well as during disease processes. 
The identified mechanisms for this observed alteration include impaired 
miRNA processing, chromosomal alterations, effects of environmental factors 
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and/or genes that control cell differentiation or apoptosis. On the other hand, 
some tumor suppressor miRNAs may prevent tumor development by 
negatively inhibiting oncogenes and/or genes that control cell differentiation or 
apoptosis. Their expression is decreased in cancerous cells [Zhang et al. 2007). 
For example, it has been demonstrated that let-7 family contains miRNAs 
regulating the RAS family of oncogenes in different type of cancer including 
breast, prostate, glioma and non-small cell lung cancers (NSCLCs) [Johnson et 
al. 2005]. Constinean reported, for the first time, that a miRNA by itself could 
induce a neoplastic disease. In fact, by using a transgenic mouse model, they 
demonstrated that overexpression of miR-155 in B cells was able to induce a 
pre-B leukemia [Costinean et al. 2006].  
MiRNAs play a key role also in tumor metastasis. Indeed, for example miR-
139 suppresses metastasis of hepatocellular carcinoma [Tavazoie et al. 2008], 
while miR10-b was found highly expressed in metastatic breast cancer cells 
[Ma et al. 2007] even if its clinical utility is still questioned [Gee et al. 2008].  
Evidence now indicates that the involvement of miRNAs in cancer is much 
more extensive than initially expected. Studies that investigated the expression 
of the entire microRNAome in various human solid tumors and hematologic 
malignancies have revealed differences in miRNAs expression between 
neoplastic and normal tissues [Calin et al. 2005; Ciafrè et al. 2005; Pallante et 
al. 2006; Weber et al. 2006]. These studies show that each neoplasia has a 
distinct miRNAs signature that differs from that of other neoplasms and that of 
the normal tissue counterpart. 
More recently, many evidences are emerging that tumor-derived miRNAs 
are present and detectable in serum, plasma, urine and other human body 
fluids. Because of their abundance, tissue specificity and relative stability, 
circulating miRNAs hold a great promise as not invasive or minimally invasive 
biomarkers in cancer [Kosaka et al. 2010]. 
 
 
1.2.4 miRNAs and NSCLC 
 
The aberrant expression of miRNAs has been texted in various human 
cancers including lung cancer. There are significant differential expressions of 
miRNAs between lung cancer and normal lung tissues. 
miRNAs status in lung cancer, as in other types of cancer, can be classified 
into two categories: down-regulation of tumor suppressive miRNAs that target 
oncogenes, and up-regulation of oncogenic miRNAs that target tumor 
suppressors. 
 By increasing our knowledge of cancer, it is evident that besides 
involvement of miRNA in cancer development, they can also be used in the 
diagnosis and treatment. 
Several studies have recognized a number of miRNA associated with 
NSCLC [Lin et al. 2010; Markou et al. 2013], among them miR-34c holds 
tumor suppressor activity. 
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miR-34c is a member of the miR-34 family, consisting of three homologous 
miRNAs that are encoded by two different genes: miR-34a is encoded by its 
specific transcript, whereas miR-34b and miR-34c share a common primary 
transcript. Several reports have highlighted a decreased expression of miR-34s 
in numerous malignancies, such as miR-34c in lung cancer [Garofalo et al. 
2013]. 
 
 
1.2.5 MiRNAs en route to the clinic 
 
In light of recent advances in the field, it is likely that I will see the 
transition of therapeutics that are based on miRNAs into the clinic in the not-
so-distant future. 
They are similar to protein-coding genes in that they regulate many 
survival-signaling pathways, are themselves subject to mutagenesis and often 
have conflicting roles in various disease states. They differ, however, in their 
therapeutic potential. In essence, miRNA replacement therapies may do what 
protein-coding gene replacement therapies have tried to do, but with fewer 
obstacles to overcome. MiRNA are much smaller and less antigenic than their 
protein-coding counterparts and, as such, cellular delivery is possible without 
the use of potentially harmful viral-based delivery mechanisms that are needed 
for the cellular uptake of larger protein-coding genes. 
Likewise, effective tools for systemically silencing miRNAs have been 
developed, that specifically and safely target miRNAs. These antagomirs act as 
small sponges that soak-up miRNAs, resulting in subsequent miRNA 
degradation and, thus, the upregulation of predicted targets with an in vivo 
effect that can be sustained for over 3 weeks. This is in contrast to standard 
antisense miRNA targeting, which has a limited ability to suppress miRNA 
functions and often leads to toxicity. Thus far, antagomirs have proven to 
efficiently silence miRNA function with limited side effects. 
Although the initial proof-of-principle studies using miRNAs as 
therapeutics took advantage of adenoviral-based and lentiviral-based delivery 
methods, translation into clinical practice requires the development of safer 
delivery vehicles. These include packaging mature miRNAs into lipid-based 
nanoparticles (neutral or charged) that can be delivered locally to the tumor 
tissue or systemically, in which case they have been found to accumulate and 
to therapeutically regulate their targets in the lung, pancreas and prostate. 
Expanding on this, physical and chemical moieties of the particles that 
facilitate the targeted distribution and the controlled and sustained release of 
miRNA – including liposomes, polymers and dendrimer conjugates – are under 
clinical investigation. 
Certainly, I must be cautious of the possible side effects of these molecules 
in human trials, independently of the side effects that could be associated with 
the delivery agents. Even in situations in which the miRNA is delivered 
directly to the tumour, miRNA could escape from the tumor cells and become 
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systemic. It is plausible that miRNA overexpression could lead to the 
saturation of the miRNA machinery and non-specific effects. Furthermore, 
increasing the cellular concentration of miRNAs may suppress lower-affinity 
targets that might not be targeted at endogenous miRNA levels.  
Similarly to current chemotherapies, concentration and dose schedules need 
to be evaluated for efficacy and toxicity, and the long-term effects following 
treatment must be assessed [Nana-Sinkam and Croce 2012]. 
Given all these problems, fewer studies using directed miRNA targeting 
have reached clinical trial. 
 
 
1.3 Aptamers 
 
For a long time nucleic acids were mainly considered as linear carriers of 
information, whereas most cell functions were ascribed to protein molecules 
possessing complex three-dimensional structure. 
It was found that single-stranded RNA molecules are able to form very 
different three-dimensional structures, which allows them to recognize 
specifically various molecular targets. They were called aptamers.  
The term aptamer is derived from the Latin word ‘‘aptus’’—which means 
fitting [Ellington and Szostak 1990] and the Greek word ‘‘meros’’ meaning 
particle. 
Aptamers are short non-naturally occurring single stranded oligonucleotides 
(DNA or RNA) with a specific and complex three-dimensional shape. 
Based on their three-dimensional structures, aptamers are characterized by 
two important properties: the ability to fold into complex tertiary structures 
[Hermann and Patel 2000] and to bind with high affinity and specificity to their 
target (Figure 6). 
Antisense, ribozymes, siRNAs, miRNAs recognize the target nucleic acid 
by complementary base pairing and, by activating an intracellular molecular 
machinery, impair the expression of the corresponding protein. Instead, 
aptamers act by directly binding the target protein without interfering with its 
expression [Cerchia and de Franciscis 2006]. 
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automating in vitro selection procedures [Eulberg et al. 2005], thereby 
accelerating aptamers generation. 
 
 
1.3.2 Post-SELEX modifications of aptamers 
 
Aptamers generated by SELEX method have many limitations for direct use 
in downstream applications. Natural, unmodified oligonucleotides, especially 
RNA-based aptamers, are unstable in biological fluids. In order to protect them 
from digestion by nucleases, and to optimize their pharmacokinetic and 
pharmacodynamic profiles, chemically modified nucleotides are incorporated 
into the oligonucleotide backbone [Klein et al. 1990]. 
The endonucleases that target RNA in biological fluids are generally 
specific for pyrimidines; therefore, the introduction of modified pyrimidine 
residues is sufficient to stabilize it towards nucleases. The most commonly 
employed functional group modifications are 2′-fluoro (2’-F), 2’-methoxy (2’-
OMe), or 2’-amino (2’-NH2) modifications of the pyrimidine nucleotides, all of 
which can be introduced at either the pre- or post-SELEX step (Figure 9).  
Even with extensive nucleotide modifications to hinder nuclease attack, 
aptamers can be cleared from the circulation within minutes (Hicke et al. 
2006). The short circulating half-life due to the small size of RNA and DNA 
aptamers is a serious obstacle to administering of aptamers to patients for 
therapeutic applications. While a low molecular weight can be an advantage as 
it allows economical chemical synthesis and better target accessibility of 
aptamers, it promotes rapid clearance by the renal system [Rusconi et al. 2002; 
Willis et al. 1998]. The most common method to increase the size of aptamers 
is to add a polyethylene glycol (PEG) moiety [Farokhzad et al. 2004].  
 
 
 
Figure 9. Scheme of the most typical modifications used to improve aptamer nuclease 
resistance (red) or its pharmacokinetic profile (green). 
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1.3.3 Aptamers as therapeutics 
 
The development of aptamers as therapeutics has principally involved 
aptamers that bind and inhibit the activity of their protein targets.  
The list of aptamers against important therapeutic targets is growing rapidly 
and some aptamers is now in clinical trials as therapeutic agents (Table 2).  
 
Aptamer name Target Disease indication Clinical status 
Macugen VEGF-165 AMD Diabetic retinopathy Approved 
AS1411 Nucleolin AML Phase II 
E10030 PDGF-B AMD Phase II 
ARC1905 C5 AMD Phase I 
ARC1779 vWF TMA Phase II 
NU172 Thrombin Acute coronary artery bypass Phase II 
NOX-A12 SDF-1α Lymphoma Phase I 
NOX-E36 CCL2 Type 2 diabetes Phase I 
 
Table 2. Aptamers in the clinical trials. (Abbreviations: AMD, age-related macular 
degeneration; AML, acute myeloid leukemia; TMA, thrombotic microangiograpathie) 
 
 
To date, the most successful therapeutic application of an aptamer has been 
an RNA molecule, known as Macugen, that binds and antagonizes the action of 
VEGF-165, the VEGF isoform preferentially involved in pathological ocular 
neovascularization.  
This aptamer has been fully approved by the FDA in December 2004, for 
the treatment of age-related macular degeneration (AMD), characterized by the 
formation of a neovascular membrane leaking blood and fluid under the retina 
with consequent destruction of the macula and loss of vision [Ng et al. 2006].  
In phase III clinical trials Macugen demonstrated to be effective for diabetic 
retinopathy treatment, resulting in improved vision and reduced macular 
edema. Furthermore, Macugen is also a potential candidate for the treatment of 
highly vascularized tumors, even if the effectiveness of a systemic 
administration is still unclear. 
Many other aptamers, not yet approved by the FDA, are currently in clinical 
trials (see Table 2). Among them, it is very interesting for cancer therapy the 
DNA aptamer AS1411, directed against nucleolin, a protein often 
overexpressed on the surface of cancer cells [Bates et al. 2009]. 
Once bound to nucleolin, AS1411 moves within the cancer cell, where it 
triggers cellular death by apoptosis, inhibiting NF-κB [Girvan et al. 2006] and 
Bcl-2 [Soundararajan et al. 2008] pathways.  
Different studies have been carried out to assess the effectiveness of 
AS1411 as tumor treatment for different solid human malignancies (such as 
AML) and it is currently in phase IIb clinical trial.  
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AXL overexpression has been reported in many human cancers and is 
associated with invasiveness and/or metastasis in lung [Shieh et al. 2005], 
prostate [Sainaghi et al. 2005], breast [Zhang et al. 2008], gastric [Wu et al. 
2002] and pancreatic cancers [Koorstra et al. 2009]. 
Furthermore, by a phosphoproteomic approach based on the profiling of 
phosphotyrosine signaling, activated AXL protein was detected in ~5% 
primary tumors of non-small-cell lung cancer [Rikova et al. 2007]. Using a 
rational approach based on its predicted secondary structure they designed a 
34-mer truncated version of the 92-mer original molecule, named GL21.T, 
which contains the active site of GL21 and preserves high binding affinity to 
the U87MG cells. 
Determining the cell type specificity, GL21.T cannot bind cells without 
AXL receptor, while it is able to bind also other human cancer cell types that 
present the receptor on the cellular surface. It is also capable of being 
endocytosed into target cells, getting ~30% of cell internalization following 15-
minute incubation and reached ~60% following 2 hours of aptamer treatment 
[Cerchia et al. 2012]. 
 
 
1.3.5 Aptamers in diagnosis 
 
Aptamers have also started to play increasingly important roles in human 
disease diagnosis [Soontornworajit et al. 2011]. Indeed, once aptamers are 
selected, they can be functionalized using a wide variety of fluorophores, as 
well as cobalt or iron paramagnetic particles, gold nonoparticles, radio-isotopes 
and biotin. These characteristics render the aptamers suitable as ligands for 
protein detection in a great number of different methodologies. 
Due to their relatively small size (8-25 kDa) in comparison to antibodies 
(150 kDa), aptamers should be better suited for rapid tumor penetration and 
blood clearance, two excellent characteristics for contrast agents in imaging 
(Figure 11). 
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Aptamer-mediated targeted delivery can enhance the therapeutic efficacy 
and reduce the toxic effects of drugs.  
To date, different aptamers have been used for the creation of a molecular 
chimera (Figure 12). 
The best characterized for targeted delivery is a 2’F-Py RNA aptamer 
against the extracellular domain of PSMA. This aptamer has been used by 
independent groups to specifically deliver siRNAs to target cells [Chu et al. 
2006; McNamara et al. 2006; Dassie et al. 2009; Wullner et al. 2008]. 
In addition to siRNAs, the anti-PSMA aptamer has been further use to 
deliver toxins or chemotherapeutic agents encapsulated within nanoparticles or 
directly intercalated into the aptamer [Dhar et al. 2008].  
Another promising delivery molecule is the anti-CD4 RNA aptamer that 
was non-covalently joined to siRNAs via phi29 RNAs (ncRNA molecules of 
the bacteriophage phi29) containing complementary loop domains. 
Two pRNA molecules were respectively fused with siRNAs and the anti-
CD4 aptamer. Through the interaction of right and left interlocking loops, the 
two chimeric pRNAs could dimerized into a stable nanovector of 
approximately 25 nm in diameter [Guo et al. 2005]. 
Also, John Rossi’s group used a RNA aptamer against gp120 for targeted 
delivery of siRNA against Human Immunodeficiency Virus (HIV) infections 
[Zhou et al. 2009]. 
27-mer Dicer substrate RNA duplex and the aptamer were attached with 
complementary ‘sticky’ sequence. After a simple annealing, they formed stable 
base pairs. 
In this design format, one pair of complementary GC-rich sticky bridge 
sequences was chemically attached to the 3’ end of the aptamer. The 
complement to this sequence was attached to one of the two siRNA strands and 
the aptamer and siRNA were joined by Watson-Crick base pairing. A flexible 
three-carbon atom hinge (C3) was added as a spacer between the adhesive 
(sticky) sequence and the aptamer to allow spatial and structural flexibility. 
Importantly, this sticky bridge-based strategy can be used to facilitate the 
effective interchange of different siRNAs with a single aptamer, which is 
required to avoid viral resistance to the siRNA component. 
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2. AIM OF THE STUDY 
 
 
Despite the great increase in the knowledge and the innovations in standard 
treatment, NSCLC is still one of the more aggressive and lethal malignant 
diseases worldwide. The lack of a complete comprehension of molecular 
mechanisms involved in NSCLC progression and development, and the 
absence of an effective targeted therapy system could be the reasons of this 
failure.  
Recent studies have demonstrated that several miRNAs are deregulated in 
NSCLC, acting both as oncogenes or tumor-suppressors. They represent 
attractive candidates as therapeutic targets in cancer, but the main problem in 
their therapeutic use is the lack of a robust and reliable way to selectively 
deliver them within the cancer cells. 
Thus, it is crucial to develop and validate cell specific delivery agents. A 
promising approach for the carrying is now represented by the use of aptamers.  
The aim of this work is primarily to individuate a miRNA down-regulated 
in NSCLC patients and, then, to use the previously described RNA aptamer 
inhibitor of the tyrosine kinase receptor AXL (GL21.T), as a means to deliver 
the selected miRNA into NSCLC cells expressing AXL. 
The results achieved by this project could be a good starting point to 
develop novel ncRNA-based therapies for NSCLC. 
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3. MATERIALS AND METHODS 
 
 
3.1 TCGA miRNA dataset and patients’ information 
 
miRNA expression data and corresponding clinical information for NSCLC 
datasets were downloaded from the Cancer Genome Atlas (TCGA) data portal 
in June 2013 (http://tcga-data.nci.nih.gov). The collection of the data from 
TCGA platform was compliant with laws and regulation for the protection of 
human subjects, and necessary ethical approvals were obtained. 
The level 3 data for the 218 NSCLC patients were quantile normalized and 
log2 transformed. Only patients with overall survival (OS) information were 
took into account. 
The association between continuous miRNA expression and OS was carried 
out using univariable Cox regression analysis. The difference in the survival 
outcome between risk groups was estimated by log-rank Mantel-Cox test and 
plotted by Kaplan-Meier curve. The analyses were performed with BRB-Array 
Tools - R/BioConductor (version 2.10). For the multivariable analysis, the Cox 
proportional hazard model was applied, and a backward stepwise selection 
procedure (Wald) was used to identify miRNAs with independent prognostic 
value. All reported p-values were two-sided. The analyses were performed 
using SPSS (version 2.1). 
 
 
3.2 Cell lines 
 
All the human NSCLC cell lines were purchased from American Type 
Culture Collection (ATCC). MRC-5, Calu-1 and MCF-7 cells were cultured 
under standard conditions in Dulbecco's Modified Eagle's Medium (DMEM), 
while A549 and H460 cells in RPMI-1640 Medium, all supplemented with 
10% heat-inactivated fetal bovine serum (FBS), 2 mM L-glutamine, and 100 
U/ml penicillin/streptomycin. All media and supplements were from Sigma 
Aldrich (Milan (MI)-Italy). Cells were maintained at 37°C in a humidified 
atmosphere with 5% CO2.  
 
 
3.3 Isolation of primary cell cultures from human lung biopsies 
 
For primary cell-culture experiments, human lung biopsies (samples from 
“Azienda Ospedaliera Universitaria Primo Policlinico”, NA) were cut by 
mechanical fragmentation with sterile scissors and tongs. Isolated cells were 
routinely seeded onto 100mm dishes and grown in Dulbecco’s Modified 
Eagle’s Medium/Nutrient F12-Ham (DMEM-F12). Media were supplemented 
with 10% heat-inactivated fetal bovine serum (FBS) and 100 U/ml 
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penicillin/streptomycin. All media and supplements were from Sigma Aldrich 
(Milan (MI)-Italy). Primary cells were maintained at 37°C in a humidified 
atmosphere with 5% CO2. 
 
  
3.4 Cell transfection 
 
For miRNAs transient transfection, cells were seeded in a 6-well plate one 
day ahead, grown to 50-70% confluence and then transfected with 100 nM 
(final concentration) of pre-miR-34c, pre-miR-Negative Control #1 (miR-NC), 
anti-miR-34c or anti-miR-NC (Ambion®, Life Technologies, Monza (MB)-
Italy), using Oligofectamine (Invitrogen, Life Technologies, Monza (MB)-
Italy), according to the manufacturer’s protocol. 
To transiently knockdown AXL gene expression, si-AXL or siRNA Control 
(Santa Cruz Biotechnologies, D.B.A. ITALIA srl, Segrate (MI)-Italy)) were 
transfected, using Oligofectamine, at a final concentration of 50 nM (Santa 
Cruz Biotechnologies, D.B.A. ITALIA s.r.l., Segrate (MI)-Italy)). 
For transient overexpression of AXL (4 µg, final concentration), cells were 
transfected using Lipopfectamine 2000 (Invitrogen, Life Technologies, Monza 
(MB)-Italy), according to the manufacturer’s protocol. 
 
 
3.5 Aptamer-miRNA chimera 
 
The following sequence were used for the chimera production:  
- GL21.T sticky: 
5’AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCACXXXXGUAC
AUUCUAGAUAGCC 
- miR-34c guide: 5’AAUCACUAACCACACGGCCAGG  
- miR-34c passenger sticky: 
5’ACUAGGCAGUGUAGUUAGCUGAUUGC/GGCUAUCUAGAAUGU
AC  
All RNA were modified with 2’-F pyrimidines, and synthesized by TriLink 
Biotechnologies (San Diego (CA)-USA). Stick sequences, consisting of 2′-F-
Py and 2′-OMe purines, are underlined. The italic X indicates a covalent 
spacer, a three-carbon linker ((CH2)3). 
Before each treatment, aptamer was subjected to a short denaturation-
renaturation step (5 min 85°C, 2 min on ice, 10 min at 37°C). To prepare 
GL21.T/miR34c, 5 µM of miR-34c strands (miR-34c guide and miR-34c 
passenger sticky)were incubated at 95°C for 15 min, 55°C for 10 min, and RT 
for 20 min, in Binding Buffer 10X (200 mM HEPES, pH 7.4, 1.5 M NaCl, 20 
mM CaCl2). 5µM of sticky aptamer was then annealed by incubating together 
at 37 °C for 30 min. 
For all the experiments, treatments with GL21.T aptamer or 
GL21.T/miR34c chimera were performed at 400 nM (final concentration). 
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3.6 RNA extraction and Real-time PCR 
 
Total RNAs (microRNA and mRNA) were extracted using Trizol reagent 
(Invitrogen, Life Technologies, Monza (MB)-Italy), according to protocols 
recommended by the manufacturer.  
Reverse transcription of total miRNA was performed starting from equal 
amounts of total RNA/sample (500 ng), using miScript reverse Transcription 
Kit (Qiagen, D.B.A. ITALIA s.r.l., Segrate (MI)-Italy)). Quantitative analysis 
of miR-34c and RNU6B (as internal reference) was performed by Real-Time 
PCR using specific primers (Qiagen, D.B.A. ITALIA s.r.l., Segrate (MI)-Italy)) 
and miScript SYBR Green PCR Kit (Qiagen, D.B.A. ITALIA s.r.l., Segrate 
(MI)-Italy)). The reaction for detection of miRNAs was performed as follow: 
95°C for 15’, 40 cycles of 94°C for 15’’, 55°C for 30’’ and 70°C for 30’’. 
For reverse transcription of mRNA was used SuperScript® III Reverse 
Transcriptase (Invitrogen, Life Technologies, Monza (MB)-Italy). Quantitative 
analysis of AXL and β-actin (as internal reference), was performed by Real-
time PCR using specific primers and iQTM SYBR Green Supermix (Bio-Rad, 
Segrate (MI)-Italy)). The reaction for detection of mRNAs was performed as 
follow: 95°C for 15’, 40 cycles of 94°C for 15’’, 57°C for 30’’ and 72°C for 
30’’. All reactions, for detection of mRNAs or miRNAs, were run in a final 25 
µl volume. 
The threshold cycle (CT) is defined as the fractional cycle number at which 
the fluorescence passes the fixed threshold. For quantization, the 2(-∆∆CT) 
method was used [Livak and Schmittgen 2001]. Experiments were carried out 
in triplicate for each data point, and data analysis was performed by using 
Applied Biosystems StepOne Plus™ Real-Time PCR Systems. 
 
 
3.6 Protein isolation and Western blotting 
 
Cells were washed twice in ice-cold PBS, and lysed in Lysis buffer 
(containing 50 mM HEPES pH 7.5, 150 mM NaCl, 1% Glycerol, 1% Triton 
X100, 1.5 mM MgCl2, 5 mM EGTA, 1 mM Na3VO4, and 1X protease inhibitor 
cocktail).  
Protein concentration was determined by the Bradford assay (BioRad, 
Segrate (MI)-Italy)) using bovine serum albumin (BSA) as the standard, 
considering that 5 ug of BSA show a value of absorbance of 0.333 at a 
wavelength of 595 nm. Equal amounts of proteins were denatured in Sample 
Buffer (containing 10% SDS, 87% glycerol, 5% β-mercaptoethanol and 0,1% 
Bromophenol Blue) for 5min at 100°C, and then analyzed by SDS-PAGE 
(10% acrylamide). 
Gels were electroblotted into nitrocellulose membranes (G&E Healthcare, 
Milan (MI)-Italy) and, after the transfer, membranes were blocked for 1 hour 
with a solution of 5% non-fat dry milk in Tris Buffered Saline (TBS) 
containing 0.1% Tween-20. 
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Filters were probed with the primary antibodies shaking over night at 4°C.  
Detection was performed by peroxidase-conjugated secondary antibodies, 
using the enhanced chemiluminescence system (ThermoFisher, Life 
Technologies, Monza (MB)-Italy). 
Primary antibodies used were: anti-AXL (R&D systems, Milan (MI)-Italy), 
and anti-βActin (Sigma Aldrich, Milan (MI)-Italy). 
 
 
3.7 In vitro proliferation assay 
 
Cell viability was evaluated with the CellTiter 96® AQueous One Solution 
Cell Proliferation Assay (Promega, Milan (MI)-Italy), according to the 
manufacturer’s protocol. The assay is based on reduction of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium, inner salt (MTS) to a colored product that is measured 
spectrophotometrically, as optical density. 
Cells were transfected with miRNAs (or anti-miRNAs) or treated with 
chimera or aptamer alone, for 24hrs. Subsequently cells were trypsinized, and 
plated in 96-well plates in triplicate, and incubated at 37°C in a 5% CO2 
incubator. 
Metabolically active cells were detected by adding 20 µl of MTS reagent to 
each well. After 30 min of incubation, the plates were analyzed on a Multilabel 
Counter (Bio-Rad, Segrate (MI)-Italy)). The optical density is related to the 
percentage of viable cells. 
 
 
3.8 Colony formation assay 
 
Colony formation assay was performed for studying the ability of a single 
cell to grow into a colony. 
Cells were firstly transfected with miRNAs (or anti-miRNAs) or treated 
with chimera or aptamer alone, for 24hrs, then they were plated in duplicate in 
6-well plates. After the incubation at 37°C in humidified 5% CO2, colonies 
composed of at least 50 cells were visualized by staining with 0.1% crystal 
violet in 25% methanol solution for 30 min at 4°C. Dishes were washed with 
water and then let dry on bench. 
 
 
3.9  Luciferase reporter assay 
 
A549 cells (120.000 cells per well) were seeded in a 6-well plate and co-
transfected with 1 µg of  3’UTR AXL plasmid (and miR-34c or miR-NC), 
using Lipofectamine 2000. 
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Both firefly and Renilla luciferase expression was measured 48 hrs post-
transfection, using the Dual Luciferase Assay (Promega, Milan (MI)-Italy), 
according to the manufacturer’s instructions. 
Three independent experiments were performed in triplicate. 3’UTR AXL 
plasmid is a kind gift of Konrad E. Huppi (National Cancer Institute, Bethesda, 
USA). 
 
 
3.10 Rescue experiments 
 
To determine whether AXL mediate the effects of miR-34c, rescue 
experiments were performed in which the effects of miR-34c were measured in 
the setting of overexpression of a deletion mutant of AXL lacking the 3’UTR. 
A549 cells were transfected with miR-34c and with the mutant AXL lacking 
the 3’UTR using X-tremeGENE 9 DNA Transfection Reagent (Roche), as 
described. Protein levels were then analyzed by Western blotting, as illustrated 
above. 
 
 
3.11 In vitro Dicer assay 
 
GL21.T or GL21.T/miR34c (1 µg) were left undigested or digested using 
Recombinant Human Turbo Dicer Kit (Genlantis, San Diego, CA) according to 
the supplier’s instructions. RNAs were then loaded on a 15% non-denaturing 
polyacrylamide gel electrophoresis gel, stained with ethidium bromide and 
visualized with GEL.DOC XR (BioRad) gel camera. 
 
 
3.12 Chimera stability in human serum 
 
GL21.T/miR34c chimera was incubated 4 µM in 80% human serum from1 
to 8 hrs. Type AB Human Serum provided by Euroclone (Cat. ECS0219D) was 
used. At each time point 4 µl (16 pmol RNA) was withdrawn and incubated for 
1 h at 37 °C with 5 µl of proteinase K solution (600 mAU/ml) in order to 
remove serum proteins that interfere with electrophoretic migration. Following 
proteinase K treatment, 9 µl TBE1X and 2 µl gel loading buffer (Invitrogen, 
Waltham, MA, USA) were added to samples that were then stored at −80 °C. 
All time point samples were separated by electrophoresis into 10% non-
denaturing polyacrylamide gel. The gel was stained with ethidium bromide and 
visualized GEL.DOC XR (BioRad) gel camera. 
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3.13 Transwell migration assay 
 
Transwell Permeable Supports, 6.5 mm diameter inserts, 8.0 µM pore size, 
polycarbonate membrane (Corning Incorporated, Euroclone Spa, Pero (MI)-
Italy) were used to perform migration assay. 
Cells were transfected or treated for 24 hrs, re-suspended in serum free 
medium, and plated into the upper chamber of a 24-well transwell (Corning 
Incorporated, Euroclone Spa, Pero (MI)-Italy). Lower chamber of the transwell 
was filled with 600 µl of culture medium containing 10% FBS.  
Cells were incubated at 37°C for 20-24 hrs. The transwell were then 
removed from the 24-well plates and stained with 0.1% Crystal Violet in 25% 
methanol. Percentage of migrated cells was evaluated by eluting crystal violet 
solution with 1% sodium dodecyl sulfate and reading the absorbance at 570 nm 
wavelength. 
 
 
3.14 Clonogenic cell survival assay 
 
The clonogenic assay was performed on Calu-1 cells, transfected or treated, 
seeded in six-well plates and incubated for 12 days after irradiation at different 
doses (0, 2, 4 and 6 Gy). Following the incubation, media were removed and 
colonies with at least 50 cells were washed with PBS, and stained with 0.1% of 
crystal violet solution. Plate efficiency (PE) was calculated by dividing the 
number of colonies formed by the number of cells plated. The survival factor 
(SF) was calculated by dividing the PE of irradiated samples by the PE of the 
respective non-irradiated samples. SF values were plotted as a function of 
radiation dose. 
 
 
3.15 Statistical analysis 
 
All experiments were performed at least three times. Continuous variables 
are given as mean ± standard deviation. For comparisons between two groups, 
the Student’s t test was used to determine differences between mean values for 
normally distributed. Comparisons among more than three groups were 
determined by one-way ANOVA followed by Bonferroni’s post hoc testing.  
NSCLC patient survival was illustrated by Kaplan-Meier curves; survival 
differences between groups were examined with log-rank test. Analyses were 
conducted with GraphPadPrism 6 software. P values<0.05 were considered 
statistically significant. 
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4. RESULTS 
 
 
4.1 miR-34c is downregulated in NSCLC tissues and cell lines 
 
Among oncosuppressor miRNAs reported for NSCLC, I focused my 
attention on miR-34c since its oncosuppressive role has been already well 
demonstrated in NSCLC [Garofalo et al. 2013], as well as in other types of 
cancer [Gallardo et al. 2009; Cai et al. 2010; Corney et al. 2007; Ji et al. 2009; 
Corney et al. 2010; Hagman et al. 2013]. 
I analyzed miR-34c expression in a large cohort of NSCLC patients in data 
collected from TCGA database (515 NSCLC and 46 normal lung samples) by 
bioinformatic analysis. MiR-34c levels resulted significantly downregulated in 
NSCLC tissues compared with normal lung tissues (Figure 13). 
 
 
 
Figure 13. miR-34c is down-regulated in NSCLC. Significant increase of miR-34c 
expression was identified in normal lung vs adenocarcinoma tissues collected from the 
TCGA database. 
 
 
Furthermore, Log-Rank Mantel-Cox test showed that patients with higher 
levels of miR-34c had a longer overall survival, suggestive of a prognostic role 
of miR-34c (p-value<0.05). The correlation of miRNA-34c expression profiles 
with NSCLC patient survival are represented by a Kaplan–Meier curve (Figure 
14). 
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Figure 14. High miR-34c expression predicted a better prognosis in NSCLC. 
Kaplan-Meier survival analysis for TCGA NSCLC patients with -high and -low miR-
34c expression. 
 
 
I then analyzed by Real-time PCR miR-34c expression levels in different 
NSCLC (A549, Calu-1, H460 and Calu-3) and normal (MRC-5) cell lines. 
As shown in Figure 15, the endogenous levels of miR-34c in all NSCLC 
cell lines examined were significantly lower compared to MRC-5. 
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Figure 15. miR-34c downregulation in NSCLC cell lines. The expression level of 
miR-34c in NSCLC cell lines (Calu-1, A549, Calu-3 and H460) was lower than in 
normal lung cell line (MRC-5). miR-34c expression level was assessed by Real-Time 
PCR. The transcript level was normalized over RNU6B expression, used as an internal 
reference. *** P-value<0.005; **** P-value<0.001, compared with MRC-5 cells. 
 
 
These results indicated a strong down-regulation of miR-34c in NSCLC, 
and reveal the potential role of this miRNA as a biomarker for NSCLC 
prognosis. 
 
 
4.2 Overexpression of miR-34c inhibits in vitro growth of 
NSCLC cells 
 
To better understand the tumor suppressive role of miR-34c in NSCLC, I 
selected two NSCLC cell lines, Calu-1 and A549, among those evaluated, for 
their low expression of miR-34c.  
Calu-1 and A549 cells were transfected with miR-34c (or miR-NC), and 
miR-34c effects on cell proliferation were analyzed. As shown in Figure 16, 
the growth rate, measured by MTS assay, of miR-34c overexpressing cells was 
reduced, compared to the negative control (untreated cells or transfected with 
miR-NC). 
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Figure 16. MiR-34c decreases proliferation in NSCLC. Calu-1 and A549 cells were 
transfected with miR-NC or miR-34c and cell proliferation was analyzed by MTS 
assay 3, 4, 5 and 6 days upon transfection. P-value<0.005 compared with the non-
transfected cells (Unt). 
 
 
I also evaluated a long term effect on proliferation, performing a colony 
formation assay. The colony number of Calu-1 and A549 cells transfected with 
miR-NC was significantly higher compared to the cells transfected with miR-
p<0.005 
p<0.005 
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34c mimic (Figure 17). Thus, upregulation of miR-34c induces long-term 
growth inhibition in NSCLC cells. 
 
      
 
Figure 17. MiR-34c decreases long-term proliferation in NSCLC. Calu-1 and 
A549 cells were transfected with miR-NC or miR-34c. Overexpression of miR-34c 
significantly inhibited colony formation. 
 
 
To confirm the data, I evaluated the effect of miR-34c knockdown in MRC-
5 cells, which express high levels of miR-34c. This resulted in an increase of 
cell proliferation and colony formation capability compared with control cells 
(untreated or transfected with anti-miR-NC) (Figure 18). 
 
 
p<0.01 
A 
A549 
  miR-NC     miR-34c  
Calu-1 
  miR-NC     miR-34c  
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Figure 18. Anti-miR-34c increases proliferation in normal lung cells. (A) MTS 
assay determined cell proliferation in MRC5 cells following downregulation of miR-
34c. P-value<0.01, compared with non-transfected cells (Unt). (B) Colony formation 
assay determined the effect of downregulated miR-34c on colony forming ability in 
MRC5 cell lines. Downregulation of miR-34c in normal lung cells promotes cell 
proliferation and allows colony formation. 
 
 
Thus, these results indicated that miR-34c upregulation induces growth 
inhibition in NSCLC cells. 
 
 
4.3 AXL as direct target of miR-34c 
 
To identify the molecular mechanisms by which miR-34c affects post-
transcriptional regulatory functions, I used miRNA target prediction algorithms 
(Targetscan, Miranda, Pictar), that revealed a putative miR-34c binding site 
within the 3’-UTR of AXL (Figure 19). 
 
 
 
Figure 19. miR-34c directly targets AXL. The predicted miR-34c binding sites in 
the 3’-UTR of AXL mRNA (predicted by the MiRanda program). 
 
 
To determine whether the binding of miR-34c to AXL 3′UTR resulted in 
mRNA degradation, I examined the expression of AXL in Calu-1 cells 72 hrs 
upon transfection with pre-miR-34c. As shown in Figure 20, the exogenous 
expression of miR-34c induced a significant reduction of AXL protein level, 
compared with controls. 
 
MRC-5 
anti-miR-NC anti-miR-34c 
B 
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Figure 20. MiR-34c overexpression decreased AXL protein levels. The expression 
was analyzed in Calu-1 cells untreated or transfected with miR-NC or miR-34c for 72 
hrs, by Western blot analysis. β-Actin was used as internal control. 
 
 
In addition, to validate if miR-34c directly binds the putative region of the 
3’UTR of AXL mRNA, I conducted a dual luciferase reporter assay. When I 
transiently co-transfected A549 cells with AXL-3’UTR in the presence of miR-
34c, I observed a significant and consistent reduction in the luciferase activity 
(>50%) after 48 hrs, if compared to cells transfected with AXL-3’UTR in the 
presence of miR-NC, used as negative control (Figure 21). 
 
 
 
Figure 21. MiR-34c directly targets AXL. A549 cells were transiently transfected 
with the AXL-3’UTR in the presence of miR-34c or miR-NC. Luciferase activity was 
evaluated 48 hrs upon transfection. ** P-value<0.01. 
 
 
In order to demonstrate a relationship between miR-34c and AXL, I 
employed a rescue experiment transfecting A549 cells with miR-34c and an 
AXL plasmid lacking the 3’UTR region. AXL protein levels were detected by 
Western Blot. Interestingly, the transfection of AXL plasmid, in presence of 
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miR-34c, was able to rescue AXL protein levels to a situation similar to AXL 
overexpressing cells (Figure 22). 
 
 
 
Figure 22. Rescue of AXL expression levels. Western blot analysis of AXL protein 
expression in A549 cells co-transfected with vector control (VV) or AXL plasmid 
lacking the 3’UTR region, and miR-34c or miR-NC. β-Actin was used as internal 
control. 
 
 
These data suggest that miR-34c regulates proliferation of NSCLC cells 
through AXL direct targeting. 
 
 
4.4 Design and folding of an aptamer-miRNA conjugate 
 
I generated, via stick-end annealing, a molecular chimera (termed 
GL21.T/miR-34c), consisting of a duplex miRNA cargo and a nucleic acid 
aptamer, used as delivery carrier. I fused the passenger strand of miR-34c and 
the aptamer GL21.T, that selectively recognizes the AXL receptor, by the mean 
of complementary sticky ends elongated at the 3’ end of the aptamer and at the 
5’ end of the miRNA single chain, respectively. Finally, I annealed the guide 
strand of miRNA to the template (Figure 23). 
 
 
 
Figure 23. GL21.T/miR-34c design. Secondary structure prediction of GL21.T/miR-
34c conjugate, using RNA structure 5.3 program. 
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I verified the correct annealing of the conjugate by a non-denaturating gel 
electrophoresis analysis. In Figure 24, the annealed GL21.T/miR-34c conjugate 
is clearly visible as a shift of band migration (lane 4). 
 
 
 
Figure 24. GL21.T/miR-34c conjugate folding. To confirm the annealing efficiency, 
all RNA sequences and annealed GL21.T/miR-34c conjugate were loaded on a 10% 
non denaturing polyacrilamide gel visualized after staining with ethidium bromide. 
  
 
To test whether the miR-34c, when conjugated to the aptamer, is still 
recognized as a Dicer substrate, I incubated GL21.T/miR-34c in the presence 
or absence of recombinant human Dicer enzyme, for 1 hour at 37°C. As 
showed in Figure 25, the conjugate, but not the GL21.T aptamer, was digested 
by Dicer enzyme, resulting in three cleaved products corresponding to the 
bands of the expected size. I observed the Dicer cleavage products by a non-
denaturating gel electrophoresis analysis. 
 
 
 
Figure 25. GL21.T/miR-34c conjugate processing. The indicated RNA sequences, 
treated or untreated with recombinant Dicer, were loaded on a 12% non-denaturing 
polyacrilamide gel and visualized after staining with ethidium bromide. The arrows 
indicate bands corresponding to the Dicer cleavage products. 
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An important feature for the potential clinical translation of new 
therapeutics is represented by their in vivo stability. Therefore, to evaluate the 
GL21.T/34c stability, I incubated the conjugate in human serum for increasing 
times up to one week. Serum-RNA samples were recovered at the indicated 
time-points (0, 1, 2, 4, 8 hrs) and analyzed by non-denaturing polyacrylamide 
gel electrophoresis (Figure 26). As shown, the conjugate was stable up to 
approximately 2 hrs and then gradually degraded. 
The multiple RNA bands observed at longer times likely reflect different 
stabilities of the two components of the conjugate. 
  
 
Figure 26. GL21.T/miR-34c serum stability. GL21.T/34c chimera was incubated 4 
µM in 80% human serum for indicated times. Loss of correct folding and RNA 
degradation was evaluated by electrophoresis into 12% non-denaturing 
polyacrylamide gel stained with ethidium bromide. 
 
 
4.5 GL21.T as selective delivery of functional miR-34c  
 
In order to understand whether GL21.T aptamer may act as a selective 
carrier for delivering the conjugated miRNA, I performed in vitro experiments 
in two different cell lines, expressing different AXL levels, Calu-1 and MCF7. 
In fact, by a preliminary analysis of AXL protein levels in different cell lines, 
Calu-1 and MCF7 express high and low levels of AXL protein, respectively 
(Figure 27). 
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Figure 27. Differential expression of AXL. AXL protein expression in different 
cell lines (Calu-1, A549, Calu-3, H460, MRC-5, and MCF-7) was evaluated by 
Western blot analysis. β-Actin was used as internal control. 
 
 
 I treated Calu-1 and MCF-7 cells with GL21.T/miR-34c for 72 hours and 
then I evaluated miR-34c levels by RT-PCR. As shown, GL21.T/miR-34c 
conjugate increased miR-34c level in Calu-1 cells (AXL+), compared to the 
GL21.T aptamer alone (Figure 28; left panel). 
On the contrary, the treatment of MCF-7 cells (AXL-) with the conjugate 
did not result in alterations of miR-34c levels (Figure 28; right panel). 
 
 
 
Figure 28. GL21.T aptamer-mediated delivery of miR-34c. Calu-1 and MRC-5 
cells were treated with GL21.T or GL21.T/miR-34c 400nM. After 72 hrs, miR-34c 
was quantified by RT-PCR (** P-value<0.01). 
  
 
To confirm the receptor-dependent delivering of miR34c, I silenced AXL 
levels in Calu-1 cells (AXL+), and, 48 hours after si-AXL transfection, I treated 
cells with GL21.T/miR-34c for 72 hours. I evaluated the miR-34c levels by 
RT-PCR. As expected, I did not observe an increase of miR-34c levels in Calu-
1 (siAXL)-treated cells (Figure 29). The efficiency of si-AXL transfection was 
determined by immunoblotting (data not shown). 
 
47 
 
 
 
Figure 29. Receptor-dependent internalization of GL21.T-miR34c chimera. Calu-
1 cells were transfected with si-AXL or siRNA control (si-NC) for 48 hrs and treated 
with GL21.T/miR-34c for 72 hrs. miR-34c levels were quantified by RT-PCR (* P-
value<0.05). 
 
 
Otherwise, I transiently upregulated AXL in MCF7 cells (AXL-), 
transfecting AXL cDNA. Following treatment with the conjugate, I assessed 
miR-34c levels by RT-PCR. Interestingly, the forced expression of AXL in 
AXL- cells induced an increase of miR-34c level mediated by the chimera 
(Figure 30). 
 
 
  
Figure 30. Receptor-dependent internalization of GL21.T-miR34c chimera. 
MCF7 cells were transfected with AXL or control vector (VV) for 24 hrs and treated 
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with GL21.T/miR-34c for 72 hrs. miR-34c levels were quantified by RT-PCR (* P-
value<0.05). 
 
 
These results indicate that GL21.T is able to deliver miR-34c inside the 
cells, in a specific way mediated by AXL receptor. 
As previously demonstrated, miR-34c targets the AXL 3’-UTR. 
Accordingly, I observed that GL21.T/miR-34c treatment, but not the aptamer 
alone, was able to suppress the expression of AXL protein (Figure 31). 
 
 
 
Figure 31. GL21.T/miR-34c treatment decreased AXL protein levels. Calu-1 cells 
were transfected or treated as indicated, and AXL protein expression was analyzed by 
Western blot after 72 hrs. β-Actin was used as internal control. 
 
 
4.6 Functional aspects of GL21.T/miR-34c chimera  
 
4.6.1 GL21.T/miR-34c effects on cell proliferation 
 
To further support the efficacy of the conjugate treatment I investigated 
whether, in the GL21.T/miR-34c conjugate contest, miR-34c and the AXL 
inhibitor aptamer cooperate to produce synergistic effects on cell growth. To 
this aim, I treated Calu-1 cells with GL21.T/miR-34c conjugate and then 
analyzed antiproliferative effects by the MTS assay, and colony formation 
assay. 
MTS assay showed that cell proliferation of Calu-1 cells was inhibited by 
GL21.T/miR-34c treatment to almost the same extent as observed with miR-
34c transfection (Figure 32A).  
Furthermore, I observed in Calu-1 cells treated with GL21.T/miR-34c a 
decreased ability to form colonies (Figure 32B). 
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Figure 32. Antiproliferative effects of GL21.T/miR-34c in NSCLC cells. (A) Calu-
1 cells were transfected with miR-34c or treated with GL21.T/miR-34c and GL21.T 
aptamer alone. Cell proliferation was analyzed by MTS assay 3, 4, 5 and 6 days upon 
transfection. P-value<0.0001, compared with the non-transfected cells (Unt). (B) 
Colony formation of Calu-1 cells. Cells were transfected with miR-NC and miR-34c 
or treated with GL21.T/miR-34c and GL21.T aptamer alone. 
 
 
I also determined the effects of GL21.T/miR-34c conjugate on cell growth 
in primary cells obtained by surgical specimens of lung cancer patients. 
Preliminarily, I analyzed AXL protein levels in different primary lung cancer 
cells, to discriminate patients with high and low levels of AXL (Figure 33A). 
Then, I performed preliminary proliferation assays on #5T and #9T patients 
cells, with high and low AXL levels, respectively. As shown, #5T cells treated 
with the conjugate have reduced viability, compared to control cells (Figure 
Calu-1 
 untreated  miR-NC  miR-34c GL21.T  GL21.T/ miR-34c 
B 
p<0.0001 
A 
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33B). While, treatment of #9T cells did not display a reduction in cell growth 
(Figure 33C).  
 
 
 
 
 
 
 
Figure 33. Antiproliferative effects of GL21.T/miR-34c in primary lung cancer 
cells. (A) AXL protein expression in different primary lung cancer cells was evaluated 
by Western blot analysis. β-Actin was used as internal control. (B) #5T cells (AXL+) 
51 
 
were transfected with miR-34c or treated with GL21.T/miR-34c and GL21.T aptamer 
alone. Cell proliferation was analyzed by MTS assay 3, 4, 5 and 6 days upon 
transfection. P-value<0.001, compared with the non-transfected cells (Unt). (C) #9T 
cells (AXL-) were transfected with miR-34c or treated with GL21.T/miR-34c and 
GL21.T aptamer alone. Cell proliferation was analyzed by MTS assay 3, 5 and 6 days 
upon transfection. P-value<0.0001, compared with the non-transfected cells (Unt).  
 
 
4.6.2 GL21.T/miR-34c effects on cell migration 
 
Then, I assessed the ability of the conjugate to affect cell migration. 
As shown in Figure 34, the migration of Calu-1 cells treated with aptamer 
alone was similar to that of untreated cells. However, miR-34c transfection and 
GL21.T/miR-34c treatment inhibited Calu-1 migration to approximately 40% 
and 20%, respectively, compared to untreated cells. 
The results of transwell migration assay showed that high levels of miR-34c 
could significantly suppress the migration abilities of Calu-1 cells, as a 
consequence of its inhibitory activity on AXL gene expression, also when 
delivered by GL21.T aptamer. 
 
 
 
Figure 34. GL21.T/miR-34c reduce cell migration motility. Calu-1 cells were 
transfected with miR-34c or treated with GL21.T aptamer or GL21.T/miR-34c 
conjugate. The cell migration capability was analyzed by Transwell Migration Assay 
using 10% FBS as migration inducer. Migrated cells were stained with crystal violet 
Calu-1 
52 
 
and photographed. **** P-value<0.0001, compared with the non-transfected cells 
(Unt). 
 
 
4.6.3 GL21.T/miR-34c effects on cell sensitivity to ionizing 
radiation 
 
Finally, I evaluated the long-term irradiation effects on cell survival. In the 
Calu-1 cell line, overexpression of miR-34c increased the sensitivity of cells to 
all ionizing radiation doses, when compared to control cells. Moreover, 
GL21.T/miR-34c conjugate was able to increase this sensitivity to low 
exposure doses (Figure 35). 
 
 
 
 
Figure 35. GL21.T/miR-34c enhances cell sensitivity to ionizing radiation. Effect 
of GL21.T/miR-34c conjugate on Calu-1 long-term cell survival after irradiation at 
different doses. 
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5. DISCUSSION 
 
 
According to the World Health Organization, lung cancer is the leading 
cause of cancer death in both men and women worldwide, accounting around 
19% of all deaths and this percentage is expected to further increase in the next 
years. Thus, the high mortality rate associated with lung cancer has encouraged 
numerous efforts to identify novel therapeutic targets and treatment [Travis et 
al. 2015]. 
For the identification of new therapies it is critical to specifically target 
cancer cells with the aim to reduce the frequency of side effects.  
Non-coding RNAs (ncRNAs) represent a structurally and functionally 
heterogeneous class of molecules recently implicated in multiple biological 
processes. Due to their altered expression in many tumors, ncRNAs have 
attracted increasing attention as highly promising therapeutics in cancer. 
As discussed, among the most promising ncRNAs in cancer treatment are 
miRNAs. MicroRNAs have been frequently indicated to be deregulated in 
different human cancers, acting both as oncogenes or tumor-suppressors. There 
is growing evidence that they play substantial roles in basic cellular functions. 
In addition, they have the capacity to target tens to hundreds of genes 
simultaneously. Thus, they are attractive candidates as prognostic biomarkers 
and therapeutic targets in cancer.  
Accumulating evidences have demonstrated direct connections between 
deregulation of microRNAs and NSCLC carcinogenesis and prognosis. One of 
the first miRNAs to be associated with lung cancer pathogenesis was let-7.  
Takamizawa et al. found that reduced let-7 expression is significantly 
associated with the short survival of lung cancer patients [Takamizawa et al. 
2004].  
Furthermore, it appears that miRNAs can be used to differentiate 
histological subtypes and predict survival of cancer patients. For example, it 
has been shown that expression levels of miR-34 is strongly correlated with 
squamous cell carcinomas (SQ) and adenocarcinomas (AD) differentiation 
[Landi et al. 2010]. This difference in miRNA levels is most significant in the 
earlier stages of disease. 
It has been shown that NSCLC presents a distinctive miRNA expression 
profile and recent studies have linked some microRNAs alterations to key 
hallmarks of cancer, including proliferation, survival, invasion, and 
angiogenesis. Among these studies, Võsa et al. analyzed the expression profile 
of 858 miRNAs in 38 early-stage NSCLC and 27 adjacent normal lung tissue 
samples. Their findings revealed a large list of altered miRNAs involved in 
tumor gene expression. Among the deregulated miRNAs, there are miR-126, 
crucial for angiogenesis and vascular maintenance, and miR-21, implicated in 
modulation of the K-Ras pathway. Other significantly deregulated miRNAs are 
miR-9, miR-30d, miR-106a, and miR-451. Moreover, they reported that low 
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expression of miR-374a is associated with a poor survival prognosis, but its 
function is currently unknown [Võsa et al. 2012] 
Yu et al. conducted another interesting analysis about miRNAs that predicts 
cancer relapse and survival of patients with lung cancer. They reported a five-
miRNA signature, identifying two miRs that correlate with survival (miR-221 
and let-7a), and three miRs associated with poor clinical outcome (miR-137, 
miR-372, and miR-182*) [Yu et al. 2008]. Also Landi et al. performed an 
interesting study on 440 miRNAs in 107 male smokers obtaining a different 
signature. They found that a decreased expression of miR-25, miR-34, miR-
191, and let-7 was associated with significantly poorer survival in SCC patients 
[Landi et al. 2010]. 
Because of the lack of a robust moiety to selectively drive miRNAs to 
malignant tumor cells, the main problem remains their translation to the clinic. 
In this regards, nucleic acid-based aptamers represent a very promising 
approach for delivering of therapeutic cargos in diseased cells. 
Several studies have demonstrated new applications for aptamers in anti-
cancer targeted therapies, both as tools for cancer cell-targeted therapy and as 
possible molecular vehicles [Dassie et al. 2009; Zhou and Rossi 2010; Wu et 
al. 2011; Liu et al. 2012]. Aptamers have been successfully used for the 
delivery of active molecules, both in vitro and in vivo, including anticancer 
drugs, toxins, siRNAs, and, more recently, miRNAs. In fact, some evidences 
confirm that either siRNAs or miRNAs, appropriately conjugated to aptamers, 
are functionally delivered and processed into target cells in a receptor 
dependent manner [Esposito et al. 2014; Catuogno et al. 2015; Iaboni et al. 
2016]. 
Also in this study, I demonstrate that cell-targeted aptamers can be used to 
deliver a miRNA into specific NSCLC cell types. I designed and characterized 
an aptamer-miRNA conjugate (GL21.T/miR-34c), covalently joining GL21.T, 
an anti-AXL aptamer, to the tumor suppressor miRNA, miR-34c.  
Among all down-regulated miRNAs reported for NSCLC, I focused my 
attention on miR-34c, a tumor suppressor miRNA largely investigated in 
cancers. Its oncosuppressive role has been well defined in various tumor types, 
including lung cancer [Gallardo et al. 2009; Cai et al. 2010; Ji et al. 2009; 
Corney et al. 2010; Hagman et al. 2013]. 
This miRNA was first reported to play an oncosuppressive role by Corney 
et al. They found that miR-34c is a transcriptional target of p53 and represents 
a novel effector mediating its suppression of neoplastic growth. It was able to 
inhibit proliferation and adhesion-independent growth by targeting different 
genes, such as Cyclin D1, Notch1, Met, and Ezh2 [Corney et al. 2007]. 
Another work reported mechanisms and implications of miR-34c 
deregulation in prostate cancer. In a prostate cohort of 47 patients with PCa, 
miR-34c was found down-regulated compared to adjacent prostate tissue, and 
MET was identified as its target gene. miR-34c overexpression was correlated 
with MET down-regulation, leading to the inhibition of cell migration 
[Hagman et al. 2013]. Further, it was reported that miR-34c and MET are 
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connected by a positive feedback loop. MET triggers the activation of 
PI3K/AKT pathway, that inhibits p53, which in turn activates the expression of 
miR-34c. 
Recently, Garofalo et al. demonstrated that miR-34a and miR-34c are 
downregulated in NSCLC cell lines and described as the miR-34a/c 
replacement antagonizes tumorigenicity and increases sensitivity to TRAIL-
induced cell death, suggesting an important therapeutic application for lung 
cancer [Garofalo et al. 2013]. The therapeutic utility of miR-34 is further 
confirmed by Kasinski et al., who investigated the effects of miR-34 re-
expression on tumor formation and progression in a mouse lung cancer model 
[Kasinski et al. 2012]. In fact, they found that, using a systemic nano-delivery, 
the combination of two tumor-suppressive miRNAs, miR-34 and let-7, controls 
tumor growth leading to a survival advantage. 
 In this study, I investigated miR-34c expression and functional role in vitro. 
Firstly, I evaluated miR-34c expression in NSCLC tissues compared with non-
tumor lung tissues, in data collected from “The Cancer Genome Atlas” 
(TCGA) database. MiR-34c resulted significantly lower in NSCLC samples 
compared to normal lung. More importantly, in a cohort of NSCLC patients 
(64 primary specimens from TCGA), statistical analysis revealed that patients 
with higher expression of miR-34c showed a significant longer survival and a 
better prognosis. Taken together, these data confirm that miR-34c down-
regulation is implicated in cancer processes that disclose a worse outcome. 
Zhou et al. and Liu et al. showed that the over expression of miR-34c 
suppressed proliferation of NSCLC cells, partially by inhibiting PAC1/MAPK 
pathway and eIF4E [Zhou et al. 2015; Liu et al. 2015]. Also my in vitro 
functional studies prove that the increase of miR-34c in NSCLC cells 
determined a long-term inhibition of cell proliferation. In fact, the analysis of 
cell proliferation in Calu-1 cells transiently transfected with miR-34c 
demonstrated that this miRNA up-regulation reduces cell growth. The same 
result was obtained performing a colony formation assay in the same cells. 
Conversely, the expression of anti-miR-34c was able to induce cell 
proliferation of MRC-5 normal lung cells. 
Further, I provide evidence for the first time that miR-34c is able to directly 
bind a 3’UTR region of AXL, thus strongly inhibiting AXL at protein level. By 
luciferase assay, I also identified the 3‘UTR region of the AXL gene that 
represents the miRNA binding site. AXL is a member of TAM receptors, a 
receptor tyrosine kinase (RTK) family, comprising Tyro3, AXL, and MerTK. 
These receptors have attracted great interest as potential therapeutic targets in a 
wide range of cancers, since they are important in many physiological 
processes. Particularly, AXL overexpression has been reported in a number of 
solid tumors as strongly associated with metastatic capacity, invasiveness in 
vitro, and resistance to targeted therapies [Gjerdrum et al. 2010; Holland et al. 
2010; Hutterer et al. 2008; Thomson et al. 2011; Zhang et al. 2008; Zhang et al. 
2012]. 
The development of my aptamer-miRNA conjugate is an important example 
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of targeted miRNA delivery, using an RNA aptamer. Indeed, the aptamer-
miRNA conjugate generated combines the multifunctional properties of the 
miRNA moiety with those of the GL21.T aptamer, producing a multifunctional 
molecule. 
Because the major restriction to the use of RNA-based drugs in vivo is the 
rapid degradation of natural RNAs in serum, in order to protect the 
GL21.T/miR-34c molecule from this degradation the pyrimidines at all 
positions of aptamer and miRNA sequences were substituted with 2′-
fluoropyrimidines. This modification is well characterized and well tolerated in 
humans, with low toxicity [Behlke 2008]. RNA oligonucleotides with this 
modification have already been approved for use in humans (Macugen), with 
many more quickly moving through the clinical pipeline [Katz and Goldbaum 
2006]. 
The GL21.T/miR-34c chimera was further characterized, demonstrating its 
in vitro targeting and processing. GL21.T/miR-34c conjugate was efficiently 
processed, once delivered into target cells, to produce the mature miR-34c 
duplex, indicating the effective functionality of the miRNA moiety. 
Given that an essential property to clinical translation of new therapeutics is 
related to their ability to resist degradation in human serum due to endogenous 
ribonucleases, I evaluated the serum stability of my chimera. Results revealed 
that GL21.T/miR-34c conjugate was stable up to approximately 8hrs, but its 
slow degradation seemed to start after an incubation for 2hrs.  
Following treatment with GL21.T/miR-34c conjugate, I observed miRNA 
uptake into target tumor cells (Calu-1) but not in cells that do not express AXL 
(MCF-7). Furthermore, miRNA enhance, resulted in the downregulation of 
AXL target gene and in decreased cell proliferation, almost comparable to 
miRNA transfected effects. Same results on cell proliferation, were observed in 
preliminary experiments performed in primary lung cancer cells, obtained from 
human lung specimens.  
I also demonstrated that the conjugate acts in a cell-specific manner. Indeed, 
I show that both the amounts of intracellular miR-34c and the extent of target 
downregulation depend on the level of expression of AXL on the cell surface. 
Previous studies have showed that miR-34c is also involved in NSCLC 
migration and invasion, through targeting multiple signaling pathway [Zhou et 
al. 2015; Liu et al. 2015]. For this reason I performed an in vitro migration 
assay which confirm that the over-expression of miR-34c, even mediated to 
GL21.T aptamer, inhibited the migration ability of NSCLC cells. 
Since the radiation resistance is a common phenomenon in NSCLC patients, 
it is crucial to identify molecules capable of increasing the radiosensitivity, for 
a better prognosis of such patients. Because there is already evidence in the 
literature on the involvement of the miR-34b as radiosensitizers, I studied a 
possible effect of miR-34c in promoting cancer cell death as a result of 
radiotherapy [Balça-Silva et al. 2012]. Interestingly, my data illustrated that 
miR-34c, even in the contest of chimera, is able of increasing the sensitivity of 
NSCLC to ionizing radiation, even at low exposure doses. This is extremely 
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important because the dosage diminution, results in an increase of treatment 
efficiency and in a reduction of side effects.  
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6. CONCLUSIONS 
 
In conclusion, I observed a direct correlation between miR-34c expression and 
survival in NSCLC patients, and demonstrated that miR-34c has a powerful 
oncosuppressive role in this tumor. Moreover, I found AXL receptor as a new 
target of this miRNA. Taken together, these results may suggest the use of 
miR-34c as a novel potential therapeutic tool for NSCLC treatment. 
More important, I explored the new applications of aptamers in targeted anti-
cancer therapies, as means for the selective delivery of miRNAs. Obtained 
results reveal that GL21.T/miR-34c is a multifunctional molecule. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
59 
 
7. AKNOWLEDGEMENT 
 
 
First, I would like to express my special thanks to my supervisor Professor 
Dr. Gerolama Condorelli, for supporting my PhD study and for allowing me to 
grow as a research scientist. Many thanks for the opportunity of this 
experience, for your encouragement and assistance during these pleasant three 
years. 
I thank Dr. Vittorio de Franciscis and all his lab members for the continuous 
suggestions and scientific assistances. 
I wish to thank my desk mates, Giusy and Alessandra, and all my lab 
colleagues, Elvira, Assunta, Ilaria, Fabio, Claudia and Susy, because I gained a 
lot from all of them, through personal and academic interactions, and their 
advices. 
A special acknowledgement goes to my students, Alessia and Francesco, for 
all the help given. Thanks to you I grew up and I hope to have provided to your 
scientific growth, at least a little bit. 
Special thank are also given to Dr. Margherita Iaboni, for her scientific 
guidance and knowledge, and many stimulating discussions. She is my primary 
resource for answering my scientific (and not) questions and contributed to my 
research project. But above all, she is a true friend. 
I am also grateful to my “companion in adventure”, Raffaela Fontanella, for 
all the fun we have had in the last three years, for having often worked 
together, and because she was able to be more anxious than me in many 
situations.  
No acknowledgments would be complete without giving thanks to my 
family. Words cannot express my grateful to my parents for supporting me 
throughout my life and for all of the sacrifices that they have made on my 
behalf, and to my sister for always believing in me and encouraging me to 
follow my dreams. 
Last, but certainly not least, I would like to thank Antonio, who is 
constantly by my side, in my greatest moments, but even in the worst. Through 
his love, support and belief in me, he encourages me to achieve always my 
goals. He is really a treasure for me. 
Finally, I would like to thank the Department of Molecular Medicine and 
Medical Biotechnology. It has provided the support and equipment I have 
needed to produce and complete my PhD thesis. 
 
 
  
60 
 
8. REFERENCES 
 
Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5. 
 
Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamer-doxorubicin physical 
conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 
2006;45:8149-52. 
 
Balca-Silva J, Sousa Neves S, Goncalves AC et al. Effect of miR-34b 
overexpression on the radiosensitivity of non-small cell lung cancer cell lines. 
Anticancer research 2012;32:1603-9. 
 
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 
2004;116:281-97. 
 
Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and 
development of the G-rich oligonucleotide AS1411 as a novel treatment for 
cancer. Exp Mol Pathol 2009;86:151-64. 
 
Behlke MA. Chemical modification of siRNAs for in vivo use. 
Oligonucleotides 2008;18:305-19. 
 
Cai KM, Bao XL, Kong XH et al. Hsa-miR-34c suppresses growth and 
invasion of human laryngeal carcinoma cells via targeting c-Met. International 
journal of molecular medicine 2010;25:565-71. 
 
Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-
regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic 
lymphocytic leukemia. Proceedings of the National Academy of Sciences of 
the United States of America 2002;99:15524-9. 
 
Calin GA, Ferracin M, Cimmino A et al. A MicroRNA signature associated 
with prognosis and progression in chronic lymphocytic leukemia. N Engl J 
Med 2005;353:1793-801. 
 
Catuogno S, Rienzo A, Di Vito A, Esposito CL, de Franciscis V. Selective 
delivery of therapeutic single strand antimiRs by aptamer-based conjugates. 
Journal of controlled release : official journal of the Controlled Release Society 
2015;210:147-59. 
 
Cerchia L, De Franciscis V. Noncoding RNAs in cancer medicine. J Biomed 
Biotechnol 2006;2006:73104. 
 
61 
 
Cerchia L, Esposito CL, Camorani S et al. Targeting AXL with an high-affinity 
inhibitory aptamer. Molecular therapy : the journal of the American Society of 
Gene Therapy 2012;20:2291-303. 
 
Cerchia L, Esposito CL, Jacobs AH, Tavitian B, de Franciscis V. Differential 
SELEX in human glioma cell lines. PloS one 2009;4:e7971. 
 
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current 
standards and the promise of the future. Transl Lung Cancer Res 2015;4:36-54. 
 
Chen CH, Dellamaggiore KR, Ouellette CP et al. Aptamer-based endocytosis 
of a lysosomal enzyme. Proceedings of the National Academy of Sciences of 
the United States of America 2008;105:15908-13. 
 
Chu TC, Marks JW, 3rd, Lavery LA et al. Aptamer:toxin conjugates that 
specifically target prostate tumor cells. Cancer research 2006;66:5989-92. 
 
Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. 
Nucleic Acids Res 2006;34:e73. 
 
Ciafre SA, Galardi S, Mangiola A et al. Extensive modulation of a set of 
microRNAs in primary glioblastoma. Biochem Biophys Res Commun 
2005;334:1351-8. 
 
Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. 
MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control 
of cell proliferation and adhesion-independent growth. Cancer research 
2007;67:8433-8. 
 
Corney DC, Hwang CI, Matoso A et al. Frequent downregulation of miR-34 
family in human ovarian cancers. Clinical cancer research : an official journal 
of the American Association for Cancer Research 2010;16:1119-28. 
 
Costinean S, Zanesi N, Pekarsky Y et al. Pre-B cell proliferation and 
lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic 
mice. Proceedings of the National Academy of Sciences of the United States of 
America 2006;103:7024-9. 
 
Dassie JP, Liu XY, Thomas GS et al. Systemic administration of optimized 
aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. 
Nature biotechnology 2009;27:839-49. 
 
Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, 
and prevention. Clin Chest Med 2011;32:605-44. 
 
62 
 
Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ. Targeted delivery of 
cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-
PLGA-PEG nanoparticles. Proceedings of the National Academy of Sciences 
of the United States of America 2008;105:17356-61. 
 
Dua P, Kim S, Lee DK. Nucleic acid aptamers targeting cell-surface proteins. 
Methods 2011;54:215-25. 
 
Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind 
specific ligands. Nature 1990;346:818-22. 
 
Esposito CL, Cerchia L, Catuogno S et al. Multifunctional aptamer-miRNA 
conjugates for targeted cancer therapy. Molecular therapy : the journal of the 
American Society of Gene Therapy 2014;22:1151-63. 
 
Eulberg D, Buchner K, Maasch C, Klussmann S. Development of an 
automated in vitro selection protocol to obtain RNA-based aptamers: 
identification of a biostable substance P antagonist. Nucleic Acids Res 
2005;33:e45. 
 
Farokhzad OC, Cheng J, Teply BA et al. Targeted nanoparticle-aptamer 
bioconjugates for cancer chemotherapy in vivo. Proceedings of the National 
Academy of Sciences of the United States of America 2006;103:6315-20. 
 
Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. 
Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate 
cancer cells. Cancer research 2004;64:7668-72. 
 
Field RW, Withers BL. Occupational and environmental causes of lung cancer. 
Clin Chest Med 2012;33:681-703. 
 
Gallardo E, Navarro A, Vinolas N et al. miR-34a as a prognostic marker of 
relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 
2009;30:1903-9. 
 
Garofalo M, Jeon YJ, Nuovo GJ et al. MiR-34a/c-Dependent PDGFR-
alpha/beta Downregulation Inhibits Tumorigenesis and Enhances TRAIL-
Induced Apoptosis in Lung Cancer. PloS one 2013;8:e67581. 
 
Gee HE, Camps C, Buffa FM et al. MicroRNA-10b and breast cancer 
metastasis. Nature 2008;455:E8-9; author reply E9. 
 
Girvan AC, Teng Y, Casson LK et al. AGRO100 inhibits activation of nuclear 
factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential 
modulator (NEMO) and nucleolin. Mol Cancer Ther 2006;5:1790-9. 
63 
 
 
Gjerdrum C, Tiron C, Hoiby T et al. AXL is an essential epithelial-to-
mesenchymal transition-induced regulator of breast cancer metastasis and 
patient survival. Proceedings of the National Academy of Sciences of the 
United States of America 2010;107:1124-9. 
 
Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer research 
2005;65:3509-12. 
 
Griffiths-Jones S. miRBase: the microRNA sequence database. Methods Mol 
Biol 2006;342:129-38. 
 
Guo K, Wendel HP, Scheideler L, Ziemer G, Scheule AM. Aptamer-based 
capture molecules as a novel coating strategy to promote cell adhesion. J Cell 
Mol Med 2005;9:731-6. 
 
Hagman Z, Haflidadottir BS, Ansari M et al. The tumour suppressor miR-34c 
targets MET in prostate cancer cells. British journal of cancer 2013;109:1271-
8. 
 
Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science 
2000;287:820-5. 
 
Hicke BJ, Stephens AW, Gould T et al. Tumor targeting by an aptamer. J Nucl 
Med 2006;47:668-78. 
 
Holland SJ, Pan A, Franci C et al. R428, a selective small molecule inhibitor of 
AXL kinase, blocks tumor spread and prolongs survival in models of 
metastatic breast cancer. Cancer research 2010;70:1544-54. 
 
Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. Novel MUC1 aptamer 
selectively delivers cytotoxic agent to cancer cells in vitro. PloS one 
2012;7:e31970. 
 
Hutterer M, Knyazev P, Abate A et al. AXL and growth arrest-specific gene 6 
are frequently overexpressed in human gliomas and predict poor prognosis in 
patients with glioblastoma multiforme. Clinical cancer research : an official 
journal of the American Association for Cancer Research 2008;14:130-8. 
 
Iaboni M, Russo V, Fontanella R, Roscigno G, Fiore D, Donnarumma E, 
Esposito CL, Quintavalle C, Giangrande P, de Franciscis V, Condorelli G. 
Aptamer-miRNA-212 conjugate sensitizes NSCLC cells to TRAIL. Molecular 
Therapy - Nucleic Acids 2016. (in press)  
 
64 
 
Ji Q, Hao X, Zhang M et al. MicroRNA miR-34 inhibits human pancreatic 
cancer tumor-initiating cells. PloS one 2009;4:e6816. 
 
Johnson SM, Grosshans H, Shingara J et al. RAS is regulated by the let-7 
microRNA family. Cell 2005;120:635-47. 
Kasinski AL, Slack FJ. miRNA-34 prevents cancer initiation and progression 
in a therapeutically resistant K-ras and p53-induced mouse model of lung 
adenocarcinoma. Cancer research 2012;72:5576-87. 
 
Katz B, Goldbaum M. Macugen (pegaptanib sodium), a novel ocular 
therapeutic that targets vascular endothelial growth factor (VEGF). 
International ophthalmology clinics 2006;46:141-54. 
 
Klein R, Conway D, Parada LF, Barbacid M. The trkB tyrosine protein kinase 
gene codes for a second neurogenic receptor that lacks the catalytic kinase 
domain. Cell 1990;61:647-56. 
 
Koorstra JB, Karikari CA, Feldmann G et al. The AXL receptor tyrosine kinase 
confers an adverse prognostic influence in pancreatic cancer and represents a 
new therapeutic target. Cancer Biol Ther 2009;8:618-26. 
 
Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new 
potential biomarker for cancer diagnosis and prognosis. Cancer Sci 
2010;101:2087-92. 
 
Landi MT, Zhao Y, Rotunno M et al. MicroRNA expression differentiates 
histology and predicts survival of lung cancer. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2010;16:430-
41. 
 
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 
encodes small RNAs with antisense complementarity to lin-14. Cell 
1993;75:843-54. 
 
Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise 
processing and subcellular localization. EMBO J 2002;21:4663-70. 
 
Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad 
OC. Nanotechnology and aptamers: applications in drug delivery. Trends 
Biotechnol 2008;26:442-9. 
 
Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. British journal of cancer 
2010;103:1144-8. 
 
65 
 
Liu F, Wang X, Li J et al. miR-34c-3p functions as a tumour suppressor by 
inhibiting eIF4E expression in non-small cell lung cancer. Cell proliferation 
2015;48:582-92. 
 
Liu N, Zhou C, Zhao J, Chen Y. Reversal of paclitaxel resistance in epithelial 
ovarian carcinoma cells by a MUC1 aptamer-let-7i chimera. Cancer 
investigation 2012;30:577-82. 
 
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 
2001;25:402-8. 
 
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis 
initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8. 
 
Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical 
evaluation of microRNA expression profiling in non small cell lung cancer. 
Lung Cancer 2013;81:388-96. 
 
McNamara JO, 2nd, Andrechek ER, Wang Y et al. Cell type-specific delivery 
of siRNAs with aptamer-siRNA chimeras. Nature biotechnology 
2006;24:1005-15. 
 
Nana-Sinkam SP, Croce CM. Clinical applications for microRNAs in cancer. 
Clin Pharmacol Ther 2013;93:98-104. 
 
Ng EW, Shima DT, Calias P, Cunningham ET, Jr., Guyer DR, Adamis AP. 
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev 
Drug Discov 2006;5:123-32. 
 
Pallante P, Visone R, Ferracin M et al. MicroRNA deregulation in human 
thyroid papillary carcinomas. Endocr Relat Cancer 2006;13:497-508. 
 
Pasquinelli AE, Reinhart BJ, Slack F et al. Conservation of the sequence and 
temporal expression of let-7 heterochronic regulatory RNA. Nature 
2000;408:86-9. 
 
Patil SD, Rhodes DG, Burgess DJ. DNA-based therapeutics and DNA delivery 
systems: a comprehensive review. AAPS J 2005;7:E61-77. 
 
Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for 
in vivo applications. Biochimie 2005;87:921-30. 
 
Rikova K, Guo A, Zeng Q et al. Global survey of phosphotyrosine signaling 
identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-203. 
66 
 
 
Rusconi CP, Scardino E, Layzer J et al. RNA aptamers as reversible 
antagonists of coagulation factor IXa. Nature 2002;419:90-4. 
 
Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. 
Gas6 induces proliferation in prostate carcinoma cell lines expressing the AXL 
receptor. J Cell Physiol 2005;204:36-44. 
 
Schuchert MJ, Luketich JD. Solitary sites of metastatic disease in non-small 
cell lung cancer. Curr Treat Options Oncol 2003;4:65-79. 
 
Shieh YS, Lai CY, Kao YR et al. Expression of AXL in lung adenocarcinoma 
and correlation with tumor progression. Neoplasia 2005;7:1058-64. 
 
Shilnikova NS, Preston DL, Ron E et al. Cancer mortality risk among workers 
at the Mayak nuclear complex. Radiat Res 2003;159:787-98. 
 
Siegel RL, Sahar L, Portier KM, Ward EM, Jemal A. Cancer death rates in US 
congressional districts. CA Cancer J Clin 2015;65:339-44. 
 
Soontornworajit B, Wang Y. Nucleic acid aptamers for clinical diagnosis: cell 
detection and molecular imaging. Anal Bioanal Chem 2011;399:1591-9. 
 
Soundararajan S, Chen W, Spicer EK, Courtenay-Luck N, Fernandes DJ. The 
nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in 
human breast cancer cells. Cancer research 2008;68:2358-65. 
 
Stitt TN, Conn G, Gore M et al. The anticoagulation factor protein S and its 
relative, Gas6, are ligands for the Tyro 3/AXL family of receptor tyrosine 
kinases. Cell 1995;80:661-70. 
 
Takamizawa J, Konishi H, Yanagisawa K et al. Reduced expression of the let-7 
microRNAs in human lung cancers in association with shortened postoperative 
survival. Cancer research 2004;64:3753-6. 
 
Tavazoie SF, Alarcon C, Oskarsson T et al. Endogenous human microRNAs 
that suppress breast cancer metastasis. Nature 2008;451:147-52. 
 
Thomson S, Petti F, Sujka-Kwok I et al. A systems view of epithelial-
mesenchymal transition signaling states. Clinical & experimental metastasis 
2011;28:137-55. 
 
Tong GJ, Hsiao SC, Carrico ZM, Francis MB. Viral capsid DNA aptamer 
conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 
2009;131:11174-8. 
67 
 
 
Travis WD. Classification of lung cancer. Semin Roentgenol 2011;46:178-86. 
 
Travis WD, Brambilla E, Nicholson AG et al. The 2015 World Health 
Organization Classification of Lung Tumors: Impact of Genetic, Clinical and 
Radiologic Advances Since the 2004 Classification. J Thorac Oncol 
2015;10:1243-60. 
 
Vosa U, Vooder T, Kolde R, Vilo J, Metspalu A, Annilo T. Meta-analysis of 
microRNA expression in lung cancer. International journal of cancer 
2013;132:2884-93. 
 
Wan Y, Kim YT, Li N et al. Surface-immobilized aptamers for cancer cell 
isolation and microscopic cytology. Cancer research 2010;70:9371-80. 
 
Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human 
MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol 
Metab 2006;91:3584-91. 
 
Willis MC, Collins BD, Zhang T et al. Liposome-anchored vascular 
endothelial growth factor aptamers. Bioconjug Chem 1998;9:573-82. 
 
Wu CW, Li AF, Chi CW et al. Clinical significance of AXL kinase family in 
gastric cancer. Anticancer research 2002;22:1071-8. 
 
Wu X, Ding B, Gao J et al. Second-generation aptamer-conjugated PSMA-
targeted delivery system for prostate cancer therapy. Int J Nanomedicine 
2011;6:1747-56. 
 
Wu Y, Crawford M, Yu B, Mao Y, Nana-Sinkam SP, Lee LJ. MicroRNA 
delivery by cationic lipoplexes for lung cancer therapy. Molecular 
pharmaceutics 2011;8:1381-9. 
 
Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific 
induction of apoptosis by rationally designed bivalent aptamer-siRNA 
transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 
2008;8:554-65. 
 
Xiao Z, Shangguan D, Cao Z, Fang X, Tan W. Cell-specific internalization 
study of an aptamer from whole cell selection. Chemistry 2008;14:1769-75. 
 
Yu SL, Chen HY, Chang GC et al. MicroRNA signature predicts survival and 
relapse in lung cancer. Cancer cell 2008;13:48-57. 
 
68 
 
Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor 
suppressors. Dev Biol 2007;302:1-12. 
 
Zhang YX, Knyazev PG, Cheburkin YV et al. AXL is a potential target for 
therapeutic intervention in breast cancer progression. Cancer research 
2008;68:1905-15. 
 
Zhang Z, Lee JC, Lin L et al. Activation of the AXL kinase causes resistance to 
EGFR-targeted therapy in lung cancer. Nature genetics 2012;44:852-60. 
 
Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence 
2010;1:4. 
 
Zhou J, Satheesan S, Li H et al. Cell-specific RNA aptamer against human 
CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 
infectivity. Chem Biol 2015;22:379-90. 
 
Zhou YL, Xu YJ, Qiao CW. MiR-34c-3p suppresses the proliferation and 
invasion of non-small cell lung cancer (NSCLC) by inhibiting PAC1/MAPK 
pathway. International journal of clinical and experimental pathology 
2015;8:6312-22. 
 
 
 
 
 
 
 
 
 
 
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2015
MiR-221 promotes stemness of breast cancer cells by targeting 
DNMT3b
Giuseppina Roscigno1,2, Cristina Quintavalle1,2, Elvira Donnarumma3, Ilaria Puoti1, 
Angel Diaz-Lagares4, Margherita Iaboni1, Danilo Fiore1, Valentina Russo1, Matilde 
Todaro5, Giulia Romano6, Renato Thomas7, Giuseppina Cortino7, Miriam Gaggianesi5, 
Manel Esteller4, Carlo M. Croce6, Gerolama Condorelli1,2
1Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy
2IEOS-CNR, Naples, Italy
3IRCCS-SDN, Naples, Italy
4Epigenetic and Cancer Biology Program (PEBC) IDIBELL, Hospital Duran I Reynals, Barcelona, Spain
5 Department of Surgical and Oncological Sciences, Cellular and Molecular Pathophysiology Laboratory, University of Palermo, 
Palermo, Italy
6 Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive 
Cancer Center, The Ohio State University, Columbus, OH, USA
7Department of Surgical and Oncology, Clinica Mediterranea, Naples, Italy
Correspondence to:
Gerolama Condorelli, e-mail: gecondor@unina.it
Keywords: microRNAs, breast cancer, cancer stem cells, DNMT
Received: June 15, 2015     Accepted: October 09, 2015     Published: October 19, 2015
ABSTRACT
Cancer stem cells (CSCs) are a small part of the heterogeneous tumor cell 
population possessing self-renewal and multilineage differentiation potential as well 
as a great ability to sustain tumorigenesis. The molecular pathways underlying CSC 
phenotype are not yet well characterized. MicroRNAs (miRs) are small noncoding 
RNAs that play a powerful role in biological processes. Early studies have linked 
miRs to the control of self-renewal and differentiation in normal and cancer stem 
cells. We aimed to study the functional role of miRs in human breast cancer stem 
cells (BCSCs), also named mammospheres. We found that miR-221 was upregulated 
in BCSCs compared to their differentiated counterpart. Similarly, mammospheres 
from T47D cells had an increased level of miR-221 compared to differentiated cells. 
Transfection of miR-221 in T47D cells increased the number of mammospheres and 
the expression of stem cell markers. Among miR-221’s targets, we identified DNMT3b. 
Furthermore, in BCSCs we found that DNMT3b repressed the expression of various 
stemness genes, such as Nanog and Oct 3/4, acting on the methylation of their 
promoters, partially reverting the effect of miR-221 on stemness. We hypothesize 
that miR-221 contributes to breast cancer tumorigenicity by regulating stemness, at 
least in part through the control of DNMT3b expression.
INTRODUCTION
Over the last years, evidence has accumulated on a 
small subclass of cancer cells with tumorigenic potential 
and stemness properties [1]. These so-called cancer stem 
cells (CSCs) have been isolated from a variety of tumor 
types, including those of the breast [2]. CSCs have two 
important characteristics: self-renewal and multipotency. 
These properties make CSCs able to generate new CSCs 
and simultaneously to produce differentiated mature cells 
responsible for the cellular heterogeneity of the tumor. 
CSCs are now considered the driving force of the tumor. In 
fact, they are the only cells able to regenerate a new tumor 
when xenografted in to mice, even when only very few 
cells are injected [2]. Furthermore, CSCs are resistant to 
conventional chemotherapy and are considered responsible 
for tumor recurrence [3]. Breast cancer stem cells (BCSCs) 
are characterized by high CD44 and low CD24 expression, 
Oncotarget2www.impactjournals.com/oncotarget
and can be identified as cells able to grow in suspension as 
spherical structures called mammospheres. Mammospheres 
derived from tissue specimens survive in non-adherent 
conditions and differentiate along different mammary 
epithelial lineages [4]. Within a tumor, CSC enrichment 
correlates with the grade of the tumor [5].
MicroRNAs (miRs) belong to the non-coding 
RNA family. They have a size ranging from 20 to 25 
nucleotides, and function as endogenous regulators of gene 
expression. MiRs impair mRNA translation or negatively 
regulate mRNA stability by recognizing complementary 
target sites in their 3′ untranslated region (UTR). MiRs 
are involved in the regulation of many physiological 
processes, including development, proliferation, and 
apoptosis, as well as of pathological processes such as 
cancerogenesis. In breast cancer, miR-21, -155, -96, and 
-182 have been identified as oncogenes [6–9], whereas 
miR-125, -205, and -206 have been identified as tumor 
suppressors [10–12]. MiRs play an essential role also in 
self-renewal of CSCs. For instance, miR-100 inhibited 
the maintenance and expansion of CSCs in basal-like 
breast cancer, and its ectopic expression enhanced BCSC 
differentiation, controlling the balance between self-
renewal and differentiation [13].
In the present study, we investigated whether other 
miRs are involved in the regulation of stemness in breast 
cancer. To this end, we isolated BCSCs from patients 
and analyzed their miR expression profile. We found 
that miR-221 was significantly up-regulated in BCSCs 
and was involved in stemness phenotyping through post-
transcriptional regulation of DNMT3b, a methyltransferase 
involved in epigenetic regulation of gene expression.
RESULTS
MiRs involved in stemness
To identify miRs differentially expressed in BCSCs 
and involved in stemness maintenance, we performed a 
microarray analysis. The array was performed analyzing 
the miR expression profile of BCSCs, collected from three 
patients, compared to that of breast cancer cells growing 
in adherence (differentiated cells). BCSCs obtained by 
biopsy digestion were characterized by real time PCR 
for the expression of the stem cells markers Nanog and 
Sox2 (Figure 1A) and by their ability to give rise tumors 
when injected into the flank of nude mice at low number 
(Supplementary Table S1). The microarray analysis revealed 
that there was a significant upregulation of miR-221, 
miR-24, and miR-29a in BCSCs and a down-regulation of 
miR-216a, miR-25, and let-7d compared to differentiated 
cells (Table 1). We focused our attention on miR-221, since 
its role in tumorigenesis has already been reported in several 
tumor types [14–16]. Microarray results for miR-221 were 
validated by real time PCR on the same samples and in one 
additional patient (patient #4) (Figure 1B).
T47D mammospheres are enriched in stem 
progenitors and expresses high levels of miR-221
We then studied in vitro enrichment and propagation 
of mammary stem cells with the T47D breast cancer cell 
line. 1 × 104 T47D cells were grown in DMEM-F12 
supplemented with EGF, b-FGF, and B27. After 7 
days of culture, we evaluated the stemness markers 
through real-time PCR and Western blot analysis, and 
the differentiation markers only through Western blot 
analysis. The stemness markers Nanog, Oct 3/4, Slug, 
and Zeb 1 were found upregulated in the suspension 
cultures, whereas the differentiation markers E-Cadherin, 
cytokeratin 18, and cytokeratin 8 were upregulated in 
adherence cultures (Figure 1C and 1D). Moreover, miR-
221 expression was increased in T47D mammospheres 
compared to differentiated cells (Figure 1E), highlighting 
the correlation of this miR with the stem cell state. Similar 
results were obtained in additional breast cancer cell lines 
(MCF-7, MDA-MB-231, and BT-549) (Supplementary 
Figure S1).
MiR-221 and stemness phenotype
To analyze the biological role of miR-221 for the 
stem cell phenotype, we overexpressed miR-221 in 
differentiated T47D cells and analyzed different stem 
cells markers. In order to obtain mammospheres, the cells 
were kept in stem medium for 6 days. We found that, 
compared to control, miR-221 overexpression induced 
a significant increase in the number of mammospheres 
(Figure 2A) and expression of stem cells markers Nanog, 
Oct 3/4, and β-Catenin (Figure 2B, 2C). Expression of 
anti-miR-221 induced an opposite effect (Figure 2D, 2E, 
2F). Similar results were obtained in the MCF-7 cell line 
(Supplementary Figure S2). To further investigate the 
effect of miR-221 on stem cell properties, we transduced 
T47D cells with a lentiviral construct encoding miR-
221. These stably overexpressing miR-221 cells showed 
enrichment of the CD44+/CD24− population thanks to an 
increase of CD44 (17% versus 43.7%) and to a decrease 
of CD24 (62.5% versus 33.8%), as assessed by FACS 
analysis (Figure 3A). The stable expression of miR-221 
in T47D cells induced also an increase in mammosphere 
number. This ability was enhanced after the first and 
second replanting, suggesting an expansion of the stem 
cell compartment (Figure 3B). The increase in sphere 
number and the upregulation of stemness markers upon 
miR-221 overexpression indicated an expansion of the 
stemness pool. In the same manner, the stable expression 
of miR-221, assessed by qRT-PCR in a breast primary cell 
line (patient #5), was able to increase sphere formation 
capacity and Nanog expression also in a primary context 
(Supplementary Figure S3A, S3B, S3C).
To further verify this phenotype, we assessed 
the shift from asymmetric to symmetric cell division 
with PKH26 staining. Fast and symmetrically dividing 
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Figure 1: MiR-221 expression in BCSCs and in T47D cell mammospheres. A. qRT-PCR validated the increase of stem markers 
Nanog and Sox 2 and B. of miR-221 in BCSCs. C, D. Nanog, Oct 3/4, Sox 2, Zeb 1, cytokeratin (Ck) 8 and cytokeratin (Ck) 18 were 
analyzed by qRT-PCR and Western blot and were found up-regulated in T47D stem cells compared to the differentiated counterpart. 
E. qRT-PCR revealed the upregulation of miR-221 in T47D mammospheres with respect to differentiated T47D cells. In C and E, data are 
mean values ± SD of three independent experiments. Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01. Western 
blots are from representative experiments.
Table 1: MiR expression in breast cancer stem cells
Unique ID Parametric p-value Fold Change (stem vs diff)
hsa- miR-221 0.013 1.8
hsa-miR-24 0.003 2.4
hsa-miR-29a 0.012 1.4
hsa-miR-216a 0.004 2.5
hsa-miR-25 0.042 2.2
let-7d 0.034 1.3
Up- and down-regulation of miRs in breast cancer stem cells vs differentiated cells. miR screening was performed in 
triplicate. A two-tailed, two sample t-test was used (p < 0.05). Four miRs were found significantly upregulated in breast 
cancer stem cells, and three were found downregulated.
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CSCs tend to rapidly lose PKH26, which then results 
equally distributed among the daughter cells during 
each cell division [5, 17]. Mammospheres from T47D 
cells stably transduced with a Tween control or with 
miR-221 were labeled with PKH26 and then analyzed 
by fluorescence microscopy and FACS after 7 days. 
As shown in Figure 3C, miR-221 overexpression 
induced a strong decrease of PKH26 (8.6% in Tween 
cells versus 1.5% in miR-221 cells), suggesting that 
miR-221 led to an expansion in stem cell number 
through symmetric division. Asymmetric division 
was evaluated by the distribution of the cell fate 
determinant Numb, known to be highly present upon 
differentiation, and of p53, whose expression is lost 
in stem cells [17, 18]. Western blotting revealed 
lower protein expression of both markers in miR-221-
overexpressing cells with respect to the Tween control 
(Figure 3D).
Stemness gene expression is mainly regulated by DNA 
methylation [19]. For this reason, we decided to evaluate the 
effect of miR-221 expression on DNA methylation levels of 
Nanog and Oct3/4 promoters and consequently the regulation 
of their expression profile. We assessed CpG dinucleotides, 
which are known to be methylated during differentiation 
[20, 21]. The 2 CpGs analyzed of Nanog promoter 
region were −83, −36 from to the Transcription Start Site 
(TSS); whereas the 3 CpGs analyzed of Oct 3/4 promoter 
region were +319, +346, +358 from the TSS. Through 
pyrosequencing analysis, we found that methylation levels 
at CpGs analyzed on Nanog and Oct 3/4 promoters were 
significant decreased (17% and 8% respectively) in cells 
transfected with miR-221 compared to the scrambled control 
(Figure 3E). Similar results were obtained in additional GpGs 
analyzed of both promoter regions (10% for CpG at −302, 
−300, −296 from TSS of Nanog and 10% for CpG + 250, 
+253, +277 of Oct 3/4.) (Supplementary Figure S4A).
Figure 2: MiR-221 effects on mammospheres and stemness genes expression. A. T47D cells were transfected with a pre-miR, 
and mammospheres counted after 6 days. miR-221 induced an increase in the number of mammospheres (140 ± SD versus 76 ± SD). 
B, C. Western blot and qRT-PCR showing that pre-miR-221 transfected in T47D cells upregulates stem cell marker expression. Anti-
miR-221 transfection induced a reduction of mammospheres (48 ± SD versus 60 ± SD) D. and of stem cell markers E, F. Western blots 
are representative experiments. Data are mean values ± SD of three independent experiments. In A, D, significance was calculated using 
Student’s t-test. *, p < 0.05.
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MiR-221 specifically represses DNMT3b 
expression
Thereafter, we investigated miR-221 targets 
possibly involved in stemness. Among the potential targets 
predicted by bioinformatics (RNA hybrid- http://www.
microRNA.org/, Miranda- http://www.microRNA.org/), 
we focus our attention on DNMT3b, which encodes a DNA 
methyltransferase involved in de novo DNA methylation 
[22–24]. To examine whether miR-221 interfered with 
DNMT3b expression by directly targeting the predicted 
3′UTR region, we cloned this region downstream of a 
luciferase reporter gene in the pGL3 vector. HEK-293 
cells are an easy model to use for the luciferase assay 
thanks to their transfection efficiency. HEK-293 cells were 
transfected with the reporter plasmid in the presence of 
a negative control miR (scrambled miR) or miR-221. As 
shown in Figure 4A, DNMT3b 3′UTR luciferase reporter 
activity was significantly repressed by the addition of miR-
221 compared to the scrambled sequence. This luciferase 
activity was not affected by miR-221 overexpression 
in the presence of a mutant construct in which the seed 
sequence was cloned inversely (Figure 4A). In order to 
find a causative effect between miR-221 and DNMT3b 
expression, we transfected T47D cells with a pre-miR-221 
for 48 h and then analyzed DNMT3b levels by Western 
blot and qRT-PCR. We found that DNMT3b protein 
and mRNA levels were downregulated after miR-221 
overexpression (Figure 4B). Similar results were obtained 
when we transfected miR-222, which shares a similar seed 
Figure 3: MiR-221 overexpression regulates stemness properties in BCSCs. A. FACS analysis of CD24/CD44 expression 
in T47D cells infected with miR-221 lentivirus and control Tween virus (Tw). MiR-221 stable expression induced an increase of CD44 
(17% versus 43.7%) and a decrease of CD24 (62.5% versus 33.8%). B. Effect of lentivirally mediated overexpression of miR-221 on 
mammosphere number at the first plating and after dissociation and replating. The data represent the mean value ± SD of two independent 
experiments. C. T47D mammospheres stably infected with the empty vector or miR-221 were evaluated by FACS for PKH26 staining. 
miR-221 infection induced a decrease of PKH26 in cells (8.6% versus 1.5%). The staining of the two populations was verified at day 0 or 
after 6 days, as indicated in C. D. Asymmetric division was evaluated by Western blotting for Numb and p53. Western blots is representative 
experiment. E. Analysis of methylation change of two consecutive CpGs of Nanog and 3 CpGs of Oct 3/4 promoters (17% and 8% 
respectively). Methylation values: mean of consecutive CpGs. Significance was calculated using U-Mann Whitney test. *, p < 0.05.
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sequence with miR-221 (Supplementary Figure S5). In 
contrast, anti-miR-221 induced an increase of DNMT3b 
levels (Figure 4C). Then, we verified DNMT3b expression 
in stem and differentiated T47D cells. As shown in Figure 
4D, DNMT3b expression was lower in stem cells and 
inversely correlated with miR-221 levels. Furthermore, 
DNMT3b expression was reduced in T47D cells 
transfected with miR-221 lentiviral vectors (Figure 4E). 
We also observed a reduction of DNMT3b levels by qRT-
PCR and immunofluorescence in stem cells compared to 
differentiated primary cells (Figure 5A, 5C), as well as in 
MCF7 cells and MDA-MB-231 cells (Figure 5B).
miR-221 controls stemness by inhibiting 
DNMT3b expression
DNMT3b is a master regulator of Nanog and Oct 3/4 
expression and, through its methylation activity, represses 
their expression during embryogenesis [25]. Therefore, 
we wondered whether the stemness features observed 
upon expression of miR-221 were related to DNMT3b 
downregulation and, consequently, to a reduced methylation 
activity. We transfected T47D cells with a DNMT3b cDNA 
and investigated the effect on stem marker expression and 
mammosphere formation. As shown in Figure 6A–6B 
DNMT3b inhibited mammosphere formation (63 versus 80) 
and Nanog, and Oct 3/4 expression. In contrast, treatment 
with a specific si-DNMT3b-mRNA induced an increase in 
mammosphere number (Figure 6D) and upregulated Nanog 
and Oct 3/4 protein levels (Figure 6E). Furthermore, to 
establish a causal link between miR-221-mediated DNMT3b 
downregulation and stem cell phenotype, we performed a 
rescue experiment by transfecting T47D cells simultaneously 
with pre-miR-221 and a DNMT3b cDNA lacking the 3′UTR. 
We found that the effect of miR-221 on Nanog and Oct 3/4 
expression was abolished by DNMT3b cDNA overexpression 
Figure 4: DNMT3b is a direct target of miR-221. A. Predicted alignment between the miR-221 sequence and the 3′UTR of DNMT3b. 
Luciferase assay showed that reporter activity was inhibited in T47D cells only in the presence of wild type DNMT3b and not with a mutated 
3′UTR. The data represent the results of two independent experiments. B. MiR-221 transfection downregulated DNMT3b mRNA and protein 
levels, as assessed by qRT-PCR and Western blotting. C. Anti-miR-221 transfection upregulated the levels of DNMT3b. D. DNMT3b mRNA 
and protein were downregulated in T47D stem cells compared to differentiated cells. E. DNMT3b mRNA and protein were downregulated 
in T47D cells stably infected with a miR-221 lentivirus. In B, C, D, E data are mean values ± SD from three independent experiments. 
Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01. Western blot analyses are from representative experiments.
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(Figure 6B). Its effect on the number of mammospheres (114 
versus 93) (Figure 6A) and on growth in soft agar was also 
partially reverted (Figure 6C). To further asses the role of 
DNMT3b, we evaluated mammosphere number in T47D 
cells stably transfected with a shRNA targeting DNMT3b. 
The expression of a DNMT3b short hairpin increased the 
number of mammospheres in DNMT3b-silenced T47D cells, 
an effect enhanced after the first replating (Figure 6F).
We then hypothesized that DNMT3b affects the 
methylation pattern of Nanog and Oct 3/4 promoter 
regions, influencing their expression. Pyrosequencing 
analysis revealed that cells transfected with a DNMT3b 
siRNA showed a significant decrease (23% and 11%, 
respectively) in methylation levels at CpGs analyzed on 
Nanog and Oct 3/4 promoters compared to the scrambled 
control cells (Figure 6G). Similar results were obtained in 
additional GpGs analyzed of both promoter regions (20% 
and 5% respectively) (Supplementary Figure S4B).
DISCUSSION
Breast cancer is the leading cause of death in woman 
and is characterized by an elevated heterogeneity, different 
responses to therapy, and metastatic variability among 
patients [26]. It represents the first human carcinoma 
for which a putative cancer stem cell subpopulation 
has been isolated on the basis of its CD44+/CD24−/low 
antigenic phenotype [2]. However, little is known on the 
mechanisms regulating the ability of BCSCs for self-
renewal and to initiate tumors.
Recently, miRs have been found to be critical 
regulators of several cellular events [27]. By their 
ability to target hundreds of mRNAs, they can induce a 
rapid switch in cell fate and a fine exchange in genome 
expression; they are now accepted as major post-
transcriptional regulators. The importance of miRs in 
gene expression regulation is emphasized by the finding 
that they are often deregulated in cancer [28]. MiRs may 
affect cancer development, progression, and response to 
therapy. Interestingly, some miRs have been reported to 
regulate CSC phenotype, since their modulation has been 
shown to contribute to the maintenance or triggering of the 
phenotype in different cancer models. For instance, it was 
found that miR-22 induces an expansion of the breast CSC 
compartment and induces metastasis by downregulating a 
member of the TET family [29]. Different members of the 
Figure 5: DNMT3b expression in stem and differentiated breast cancer cells. A. DNMT3b levels were analyzed by qRT-PCR 
in stem and differentiated breast cancer primary cells or B. in MCF7 cells and MDA-231 cells. C. Immunofluorecence analysis of DNMT3b 
expression in stem and differentiated breast cancer primary cells from 4 patients. In B, data are mean values ± SD from three independent 
experiments. Significance was calculated using Student’s t-test. *, p < 0.05; **, p < 0.01.
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miR-200 family were found downregulated in CSCs 
isolated from colorectal, head and neck, prostate, and 
breast cancer compared to their non-CSC counterparts 
[30–33]. Expression of miR-200 represses EMT, contri-
buting thus to the progression of cancer by promoting 
invasion, metastasis [34], and stemness phenotype.
In the present study, we identify miR-221 as an 
important player in the control of the CSC homeostasis. 
We provide evidence that miR-221 is expressed at higher 
levels in the stem cell population of primary and T47D 
cells compared to differentiated cells. MiR-221 has been 
found overexpressed in a number of human tumors by us 
and others [14, 35–38]. The relevance of this miR as an 
oncogene in breast cancer is reported by several papers, 
demonstrating the broad spectrum of action miR-221 and 
its regulation of several features of tumorigenesis [35, 39]. 
MiR-221 is found often abnormally expressed in breast 
cancer [40] and recent studies have found that it may be 
responsible for resistance to tamoxifene [41]. MiR-221 
promotes tumorigenesis of triple negative breast cancer 
through the alteration of key genes of the EMT process, 
such as E-cadherin, Slug, and Snail [42]; its expression is 
under the direct control of Slug, suggesting the existence 
of a miR-221–EMT regulatory loop [43]. In addition, it 
was reported that miR-221 is upregulated in prolonged 
mammosphere cultures of MCF7 cells undergoing EMT 
and with downregulated ER-alpha [44], and that it is able 
to sustain breast cell hierarchy in normal and malignant 
breast cells, probably via EMT [45].
Here we demonstrate that miR-221 induces 
expression of pluripotency-associated genes, such as 
Nanog, Oct 3/4, and β—Catenin, enforcing stemness 
and mammosphere formation. miR-221 downregulates 
DNMT3b expression, modifying BCSC phenotype. 
Figure 6: MiR-221 regulates stemness by targeting DNMT3b. A. DNMT3b represses mammosphere formation, as assessed 
with a mammosphere counting assay. Data are mean values ± SD from three independent experiments. Significance was calculated using 
Student’s t-test. *, p < 0.05. B. Stem cell markers assessed by Western blotting. C. MiR-221 transfection in T47 stem cells induced an 
increase in the number of colonies, as assessed by a soft agar assay. Co-transfection of DNMT3b and miR-221 rescued this effect. Data are 
mean values ± SD from two independent experiments. Significance was calculated using Student’s t-test.**, p < 0.01; Transient DNMT3 
silencing mimicked the effect of miR-221 on D. sphere formation and E. stem markers, whereas stable silencing mimicked miR-221 
behavior F. on sphere number in a plating assay. In D, data are mean values ± SD of three independent experiments. Significance was 
calculated using Student’s t-test. *, p < 0.05. In G. Pyrosequencing analysis of cells transfected with a DNMT3b siRNA showed a significant 
decrease in methylation levels at CpGs analyzed on Nanog and Oct 3/4 promoters compared to the scrambled control cells (23% and 11% 
respectively). Significance was calculated using U-Mann Whitney test. *, p < 0.05. Western blot analyses are representative experiments.
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DNMT3a, DNMT3b, and DNMT1 are members of the 
DNA methylation machinery. During DNA replication, 
DNMT1 recognizes the CpGs present on the parent strand 
and methylates the corresponding CpG sites of the newly 
synthesized strand [46, 47]. In contrast, DNMT3a and 
DNMT3b are responsible for de novo DNA methylation 
predominantly during early development [48, 49]; in 
addition, they are important for stable inheritance of some 
DNA methylation, and the silencing of both enzymes in 
embryonic stem cells (ESCs) determines a progressive loss 
of DNA methylation at critical sites of the genome, such as 
repetitive and single copy elements [50]. Moreover, ESCs 
lacking both DNMT3a and DNMT3b progressively lose 
differentiation potential after several cell passages, but are 
able to maintain self-renewal [25, 50, 51]. Interestingly, 
it has been demonstrated that DNMT3a and DNMT3b 
ablation induces aberrant expression of Nanog and 
Oct 3/4 in ESCs [52]. The role of DNMT3b in cancer 
development is not still clear. Although DNMT3b was 
classically considered an oncogene, due to its role in the 
hypermethylation of tumor suppressor genes during tumor 
progression in lung, breast, colon, and bladder cancers 
[53, 54], several reports also indicate a tumor suppressor 
behavior at an advanced tumor stage [55, 56]. Therefore, 
DNMT3b may act as a tumor suppressor or an oncogene 
depending on tumor stage or on the type of tumor cell 
population. In the present study, we demonstrate that 
DNMT3b represses the expression of Nanog and Oct 3/4 
and increases the number of breast cancer cell spheres. 
Thus, DNMT3b downregulation may represent an 
advantage for cancer development, driving the expansion 
of the stem cell compartment. Further experiments are 
necessary to elucidate the mechanism through which 
DNMT3b regulates stemness, other than acting directly 
on Nanog and Oct 3/4 promoters.
In conclusion, we have identified a new mechanism 
by which miR-221 affects the tumor stemness phenotype 
of breast cancer cells, providing more information on the 
oncogenic role of miR-221 in breast cancer.
MATERIALS AND METHODS
Cell and mammosphere culture
Differentiated breast tumor cells from three patients 
(#1, #2, #3) and BTSCs (breast tumor stem cells) were 
obtained as previously described [57] and were used for 
microRNA array. T47D cells were grown in RPMI 1640 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS), 2 mM L-glutamine, and 100 U/ml penicillin/
streptomycin. For mammosphere culture, single cells 
were plated at a density of 1,000 cells/ml. Cells were 
grown in serum-free DMEM-F12 (Sigma, Milan, Italy) 
supplemented with B27 (Life technologies Milan Italy), 
10 ng/ml EGF (Sigma, Milan, Italy), 20 ng/ml βFGF (BD 
Biosciences, Milan, Italy), and 1X antibiotic–antimycotics 
(Life technologies, Milan, Italy). After 5–7 days, 
mammospheres, which appeared as spheres of floating 
viable cells, were collected by gentle centrifugation 
(800 rpm) and dissociated with 0.25% trypsin for 5 min. 
HEK-293 cells were grown in DMEM supplemented 
with 10% heat-inactivated FBS and 100 U/ml penicillin/
streptomycin.
Cell and sphere transfection
For transient transfection with miRs, cells at 50% 
confluence were transfected using Oligofectamine (Life 
Technologies Milan Italy) with 100 nM of pre-miR-221, 
scrambled, or anti miR-221 (Ambion, Life Technologies 
Milan Italy). In order to overexpress DNMT3b, cells 
were transfected with Lipofectamine 2000 and 3 μg of 
DNMT3b cDNA, a kind gift of Ana Portela (IDIBELL, 
Barcelona, Spain). To transiently knockdown DNMT3b 
gene expression, a pool of DNMT3b siRNAs is transfected 
using Lipopfectamine 2000 at a final concentration of 
100 nM (Santa Cruz Biotechnology, MA, USA). To 
stably knockdown DNMT3b, cells were infected with a 
shDNMT3b (Santa Cruz Biotechnology, MA, USA) and 
the expression of DNMT3b studied by qRT-PCR in pooled 
cell populations (data not shown).
Transduction with viral vectors
T47D cells and a primary breast cell line obtained 
from patient #5 were infected using Tween miR-221 or 
Tween control vector, as already described by Quintavalle 
et al. [14]. Briefly, on the day of infection, the medium 
was removed and replaced with viral supernatant with the 
addition of 4 mg/ml of polybrene (Sigma Aldrich, Milan 
Italy). Cells were then centrifuged in their plate for 45 
min in a Beckman GS-6KR centrifuge, at 1800 rpm and 
32°C. After centrifugation, cells were kept overnight in 
a 5% CO2 incubator at 37°C. After exposure, cells were 
washed twice with cold PBS and fresh medium added. 
48 h after the transduction, cells were washed with PBS, 
harvested with trypsin/EDTA, and analyzed by FACS for 
GFP expression.
Protein isolation and western blotting
Cells were washed twice in ice-cold PBS, and lysed 
in JS buffer (50 mM HEPES pH 7.5 containing 150 mM 
NaCl, 1% Glycerol, 1% Triton X100, 1.5 mM MgCl2, 
5 mM EGTA, 1 mM Na3VO4, and 1X protease inhibitor 
cocktail). Protein concentration was determined by the 
Bradford assay (BioRad, Milan, Italy) using bovine serum 
albumin as the standard, and equal amounts of proteins 
were analyzed by SDS-PAGE (12.5% acrylamide). Gels 
were electroblotted onto nitrocellulose membranes (G&E 
Healthcare, Milan, Italy). Membranes were blocked for 
1 h with 5% non-fat dry milk in Tris Buffered Saline 
(TBS) containing 0.1% Tween-20, and incubated at 
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4°C overnight with the primary antibody. Detection 
was performed with peroxidase-conjugated secondary 
antibodies using an enhanced chemiluminescence system 
(ThermoEuroclone, Milan, Italy). Primary antibodies used 
were: anti-Zeb-1, -Oct 3/4, -Nanog, -cytokeratin 18, and 
-cytokeratin 8 (Santa Cruz Biotechnologies, MA, USA), 
anti-DNMT3b (Abcam, MA, USA), and anti-β-actin 
(Sigma Aldrich, Milan, Italy).
miRNA microarray
5 μg of total RNA from each sample was reverse 
transcribed using biotin end-labeled random-Octamer 
oligonucleotide primer. Hybridization of biotin-labeled 
complementary DNA was performed on Ohio State 
University custom miRNA microarray chips (OSU_
CCC version 3.0), which contain 1150 miR probes, 
including 326 human and 249 mouse miR genes, spotted 
in duplicate. The hybridized chips were washed and 
processed to detect biotin-containing transcripts by 
streptavidin-Alexa647 conjugate and scanned on an Axon 
4000B microarray scanner (Axon Instruments, Sunnyvale, 
California, USA).
Raw data were normalized and analyzed with 
GENESPRING 7.2 software (zcomSilicon Genetics, 
Redwood City, CA, USA). Expression data were median-
centered with the GENESPRING normalization option and 
the global median normalization of the BIOCONDUCTOR 
package (http://www.bioconductor.org), which produced 
similar results. Statistical comparisons were done with 
the GENESPRING ANOVA tool, predictive analysis 
of microarray (PAM), and the Significance Analysis of 
Microarray (SAM) software (http://www-stat.stanford.
edu/~tibs/SAM/index.html).
Mammosphere forming assay
Mammospheres were resuspended in 0.5% agar 
(Bacto-Agar, Difco Laboratories) and layered on a 
preformed 0.8% agar layer using 60 mm Petri dishes (BD). 
Colonies were counted under an inverted microscope 
(Nikon, Milan, Italy) and then photographed.
RNA extraction and real-time PCR
Total RNAs (miR and mRNA) were extracted 
using Trizol (LifeTechnologies, Milan, Italy) according 
to the manufacturer’s protocol. Reverse transcription 
of total miRNA was performed using miScript reverse 
Transcription Kit (Qiagen, Milan Italy), for mRNA 
we used SuperScript® III Reverse Transcriptase (Life 
Technologies, Milan, Italy). Quantitative analysis of 
Nanog, Oct 3/4, Sox2, β-Actin (as an internal reference), 
miR-221, and RNU6B (as an internal reference) was 
performed by real time PCR using specific primers 
(Qiagen, Milan, Italy), miScript SYBR Green PCR Kit 
(Qiagen, Milan Italy), and iQ™ SYBR Green Supermix 
(Bio-Rad, Milan, Italy), respectively. Experiments were 
carried out in triplicate for each data point, and data 
analysis was performed with software (Bio-Rad, Milan 
Italy).
Luciferase assay
The 3′ UTR of the human DNMT3b gene was PCR-
amplified using the following primers: DNMT3b-Fw:5′G
CTCTAGACAGCCAGGCCCCAAGCCC3′; DNMT3b-
Rv: 5′GCTCTAGAACCTCAGGCTACCCCTGC3′, 
and cloned downstream of the Renilla luciferase stop 
codon in pGL3 control vector (Promega, Milan, Italy). 
An inverted sequence of the miR-binding sites was used 
as negative control. HEK-293 cells were co-transfected 
with 1.2 μg of plasmid and 400 μg of a Renilla luciferase 
expression construct, pRL-TK (Promega, Milan, Italy), 
with Lipofectamine 2000 (Life Technologies, Milan, 
Italy). Cells were harvested 24 h post-transfection and 
assayed with Dual Luciferase Assay (Promega, Milan, 
Italy) according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate.
DNA methylation analysis by pyrosequencing
Bisulphite conversion of 500 ng of each DNA 
sample was performed with EZ DNA Methylation-
Gold Kit (Zymo Research, Milan Italy) according to 
the manufacturer’s recommendations. PCR for Nanog 
and Oct 3/4 promoters was performed with 1 μl of 
bisulphite converted DNA under standard conditions 
with biotinylated primers using an annealing temperature 
of 60°C. Primer sequences are given in Supplementary 
Table S2 and were designed with PyroMark Assay Design 
2.0. PCR products were observed on 2% agarose gels 
before pyrosequencing analysis. Reactions were performed 
in a PyroMark Q96 System version 2.0.6 (Qiagen, Milan, 
Italy) and the methylation values of the CpG dinucleotides 
were obtained using Pyro Q-CpG 1.0.9 (Qiagen, Milan, 
Italy). The 2 CpGs analyzed of Nanog promoter region 
were −83, −36, from to the Transcription Start Site (TSS); 
whereas the 3 CpGs analyzed of Oct3/4 promoter region 
were +319, +346, +358 from the TSS. Additional GpGs 
analyzed of both promoter regions were −302, −300, −296 
from TSS of Nanog and + 250, +253, +277 from TSS 
of Oct 3/4.
Immunofluorescence
Immunofluorescence was performed on cultured 
BCSC cytospins fixed with 2% paraformaldehyde for 20 
minutes at 37°C, washed and permeabilized with PBS plus 
0.1% Triton X-100 for 10 min on ice. After washing, cells 
were stained overnight at 4°C using antibodies against 
DNMT3b (Abcam- ab13604) or isotype-matched controls 
at appropriate dilutions. Then cells were labeled with 
FITC-conjugated secondary antibodies for 1 h at 37°C. 
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Nucleus counterstaining was performed using Toto-3 
iodide. Samples were analyzed by confocal microscope.
Statistical analysis
All experiments were repeated at least twice. 
Continuous variables are given as mean ± 1 standard 
deviation (SD). For two-group comparison, Student’s 
t-test was used to determine differences between mean 
values for normal distribution. All data were analyzed for 
significance using GraphPadPrism 6 software (San Diego, 
CA, USA); a probability level <0.05 was considered 
significant throughout the analysis.
ACKNOWLEDGMENTS AND FUNDING
This work was partially supported by funds from 
Associazione Italiana Ricerca sul Cancro, AIRC (grant 
no.10620 to G.C., and no. 10254 to M.T.).
MERIT (RBNE08E8CZ_002) to G.C., and 
Fondazione Berlucchi to G.C.
Angel Diaz-Lagares was supported by a Río Hortega 
(CM14/00067) from the “Instituto de Salud Carlos III”. 
Manel Esteller is an ICREA Research Professor.
CONFLICTS OF INTEREST
The authors declare to have no conflict of interests.
REFERENCES
1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem 
cells, cancer, and cancer stem cells. Nature. 2001; 
4146859:105–111.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, 
Clarke MF. Prospective identification of tumorigenic 
breast cancer cells. Proceedings of the National Academy 
of Sciences of the United States of America. 2003; 
1007:3983–3988.
3. Visvader JE, Lindeman GJ. Cancer stem cells in solid 
tumours: accumulating evidence and unresolved questions. 
Nature reviews Cancer. 2008; 810:755–768.
4. Dontu G, Liu S, Wicha MS. Stem cells in mammary devel-
opment and carcinogenesis: implications for prevention and 
treatment. Stem cell reviews. 2005; 13:207–213.
5. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, 
Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP. 
Biological and molecular heterogeneity of breast cancers corre-
lates with their cancer stem cell content. Cell. 2010; 1401:62–73.
6. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, 
Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, 
Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, 
Nenci I, et al. MicroRNA gene expression deregula-
tion in human breast cancer. Cancer research. 2005; 
6516:7065–7070.
7. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, 
Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, 
Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, 
Negrini M, et al. A microRNA expression signature 
of human solid tumors defines cancer gene targets. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2006; 1037:2257–2261.
8. Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The 
oncogenic role of miR-155 in breast cancer. Cancer 
 epidemiology, biomarkers & prevention : a publication of 
the American Association for Cancer Research, cospon-
sored by the American Society of Preventive Oncology. 
2012; 218:1236–1243.
9. Li P, Sheng C, Huang L, Zhang H, Huang L, Cheng Z, 
Zhu Q. MiR-183/-96/-182 cluster is up-regulated in most 
breast cancers and increases cell proliferation and migra-
tion. Breast cancer research. 2014; 166:473.
10. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, 
Li G, Lu J, Fodstad O, Riker AI, Tan M. MicroRNA-125b 
confers the resistance of breast cancer cells to paclitaxel 
through suppression of pro-apoptotic Bcl-2 antagonist 
killer 1 (Bak1) expression. The Journal of biological chem-
istry. 2010; 28528:21496–21507.
11. Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, 
Nuovo G, Tortoreto M, Sasso M, Plantamura I, 
Triulzi T, Taccioli C, Tagliabue E, Iorio MV, Croce CM. 
Oncosuppressive role of p53-induced miR-205 in triple neg-
ative breast cancer. Molecular oncology. 2012; 64:458–472.
12. Zhou J, Tian Y, Li J, Lu B, Sun M, Zou Y, Kong R, 
Luo Y, Shi Y, Wang K, Ji G. miR-206 is down-regulated 
in breast cancer and inhibits cell proliferation through the 
up- regulation of cyclinD2. Biochemical and biophysical 
research communications. 2013; 4332:207–212.
13. Petrelli A, Carollo R, Cargnelutti M, Iovino F, Callari M, 
Cimino D, Todaro M, Mangiapane LR, Giammona A, 
Cordova A, Montemurro F, Taverna D, Daidone MG, 
Stassi G, Giordano S. By promoting cell differentiation, 
miR-100 sensitizes basal-like breast cancer stem cells to 
hormonal therapy. Oncotarget. 2015; 64:2315–2330.
14. Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, 
del Basso De Caro M, Martinez-Montero JC, Incoronato M, 
Nuovo G, Croce CM, Condorelli G. miR-221/222 overex-
pession in human glioblastoma increases invasiveness by 
targeting the protein phosphate PTP[mu]. Oncogene. 2012; 
317:858–868.
15. Fornari F, Gramantieri L, Ferracin M, Veronese A, 
Sabbioni S, Calin GA, Grazi GL, Giovannini C, Croce CM, 
Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57 
and CDKN1B/p27 expression in human hepatocellular car-
cinoma. Oncogene. 2008; 2743:5651–5661.
16. Quintavalle C, Mangani D, Roscigno G, Romano G, 
Diaz-Lagares A, Iaboni M, Donnarumma E, Fiore D, De 
Marinis P, Soini Y, Esteller M, Condorelli G. miR-221/222 
Target the DNA Methyltransferase MGMT in Glioma Cells. 
PLoS ONE. 2013; 89:e74466.
Oncotarget12www.impactjournals.com/oncotarget
17. Cicalese A, Bonizzi G, Pasi CE, Faretta M, Ronzoni S, 
Giulini B, Brisken C, Minucci S, Di Fiore PP, Pelicci PG. 
The tumor suppressor p53 regulates polarity of self-
renewing divisions in mammary stem cells. Cell. 2009; 
1386:1083–1095.
18. Morrison SJ, Kimble J. Asymmetric and symmetric stem-
cell divisions in development and cancer. Nature. 2006; 
4417097:1068–1074.
19. Gaspar-Maia A, Alajem A, Meshorer E, Ramalho-
Santos M. Open chromatin in pluripotency and repro-
gramming. Nature reviews Molecular cell biology. 2011; 
121:36–47.
20. Deb-Rinker P, Ly D, Jezierski A, Sikorska M, Walker PR. 
Sequential DNA methylation of the Nanog and Oct-4 
upstream regions in human NT2 cells during neuronal dif-
ferentiation. The Journal of biological chemistry. 2005; 
2808:6257–6260.
21. Zhang HJ, Siu MK, Wong ES, Wong KY, Li AS, Chan KY, 
Ngan HY, Cheung AN. Oct4 is epigenetically regulated by 
methylation in normal placenta and gestational trophoblas-
tic disease. Placenta. 2008; 296:549–554.
22. Santi DV, Garrett CE, Barr PJ. On the mechanism of 
 inhibition of DNA-cytosine methyltransferases by cytosine 
analogs. Cell. 1983; 331:9–10.
23. Jones PA, Liang G. Rethinking how DNA methylation 
patterns are maintained. Nature reviews Genetics. 2009; 
1011:805–811.
24. Bachman KE, Rountree MR, Baylin SB. Dnmt3a and 
Dnmt3b are transcriptional repressors that exhibit unique 
localization properties to heterochromatin. The Journal of 
biological chemistry. 2001; 27634:32282–32287.
25. Meissner A, Gnirke A, Bell GW, Ramsahoye B, Lander ES, 
Jaenisch R. Reduced representation bisulfite sequencing for 
comparative high-resolution DNA methylation analysis. 
Nucleic acids research. 2005; 3318:5868–5877.
26. Bertos NR, Park M. Breast cancer - one term, many 
entities? The Journal of clinical investigation. 2011; 
12110:3789–3796.
27. He L, Hannon GJ. MicroRNAs: small RNAs with a big 
role in gene regulation. Nature reviews Genetics. 2004; 
57:522–531.
28. Sassen S, Miska EA, Caldas C. MicroRNA: implications 
for cancer. Virchows Archiv : an international journal of 
pathology. 2008; 4521:1–10.
29. Song SJ, Poliseno L, Song MS, Ala U, Webster K, 
Ng C, Beringer G, Brikbak NJ, Yuan X, Cantley LC, 
Richardson AL, Pandolfi PP. MicroRNA-antagonism 
regulates breast cancer stemness and metastasis via TET-
family-dependent chromatin remodeling. Cell. 2013; 
1542:311–324.
30. Lo WL, Yu CC, Chiou GY, Chen YW, Huang PI, Chien CS, 
Tseng LM, Chu PY, Lu KH, Chang KW, Kao SY, 
Chiou SH. MicroRNA-200c attenuates tumour growth 
and metastasis of presumptive head and neck  squamous 
cell carcinoma stem cells. The Journal of pathology. 2011; 
2234:482–495.
31. Williams LV, Veliceasa D, Vinokour E, Volpert OV. miR-
200b inhibits prostate cancer EMT, growth and metastasis. 
PLoS One. 2013; 812:e83991.
32. Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM, 
Rosen JM. Expression of miR-200c in claudin-low breast 
cancer alters stem cell functionality, enhances chemosen-
sitivity and reduces metastatic potential. Oncogene. 2015 
Mar 9. [Epub ahead of print] PMID: 25746005.
33. Lu YX, Yuan L, Xue XL, Zhou M, Liu Y, Zhang C, 
Li JP, Zheng L, Hong M, Li XN. Regulation of colorectal 
 carcinoma stemness, growth, and metastasis by an miR-
200c-Sox2-negative feedback loop mechanism. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2014; 2010:2631–2642.
34. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 
family determines the epithelial phenotype of cancer cells 
by targeting the E-cadherin repressors ZEB1 and ZEB2. 
Genes & development. 2008; 227:894–907.
35. Garofalo M, Quintavalle C, Romano G, Croce CM, 
Condorelli G. miR221/222 in cancer: their role in tumor 
progression and response to therapy. Current molecular 
medicine. 2012; 121:27–33.
36. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, 
Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. 
miR-221 overexpression contributes to liver tumorigenesis. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2010; 1071:264–269.
37. Garofalo M, Quintavalle C, Di Leva G, Zanca C, 
Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. 
MicroRNA signatures of TRAIL resistance in human non-
small cell lung cancer. Oncogene. 2008; 2727:3845–3855.
38. Pallante P, Visone R, Ferracin M, Ferraro A, 
Berlingieri MT, Troncone G, Chiappetta G, Liu CG, 
Santoro M, Negrini M, Croce CM, Fusco A. MicroRNA 
deregulation in human thyroid papillary carcinomas. 
Endocrine-related cancer. 2006; 132:497–508.
39. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, 
Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, 
Gasparini P, Gonelli A, Costinean S, Acunzo M, 
Condorelli G, Croce CM. miR-22&222 regulate TRAIL 
resistance and enhance tumorigenicity through PTEN and 
TIMP3 downregulation. Cancer cell. 2009; 166:498–509.
40. Wu X, Zeng R, Wu S, Zhong J, Yang L, Xu J. 
Comprehensive expression analysis of miRNA in breast 
cancer at the miRNA and isomiR levels. Gene. 2015; 
5572:195–200.
41. Miller TE, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro 
CL, Jacob S, Majumder S. MicroRNA-221/222 confers tamox-
ifen resistance in breast cancer by targeting p27Kip1. The 
Journal of biological chemistry. 2008; 28344:29897–29903.
Oncotarget13www.impactjournals.com/oncotarget
42. Nassirpour R, Mehta PP, Baxi SM, Yin MJ. miR-221 
 promotes tumorigenesis in human triple negative breast 
cancer cells. PLoS One. 2013; 84:e62170.
43. Lambertini E, Lolli A, Vezzali F, Penolazzi L, Gambari R, 
Piva R. Correlation between Slug transcription factor 
and miR-221 in MDA-MB-231 breast cancer cells. BMC 
 cancer. 2012; 12:445.
44. Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, 
White BA. Prolonged mammosphere culture of MCF-7 
cells induces an EMT and repression of the estrogen recep-
tor by microRNAs. Breast cancer research and treatment. 
2012; 1321:75–85.
45. Ke J, Zhao Z, Hong SH, Bai S, He Z, Malik F, Xu J, Zhou L, 
Chen W, Martin-Trevino R, Wu X, Lan P, Yi Y, Ginestier C, 
Ibarra I, Shang L, et al. Role of microRNA221 in regulat-
ing normal mammary epithelial hierarchy and breast cancer 
stem-like cells. Oncotarget. 2015; 66:3709–3721.
46. Bestor TH. Activation of mammalian DNA methyltransfer-
ase by cleavage of a Zn binding regulatory domain. The 
EMBO journal. 1992; 117:2611–2617.
47. Bestor TH, Gundersen G, Kolsto AB, Prydz H. CpG islands 
in mammalian gene promoters are inherently resistant to de 
novo methylation. Genetic analysis, techniques and applica-
tions. 1992; 92:48–53.
48. Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with 
the Dnmt3 family of de novo DNA methyltransferases to 
establish maternal imprints in mice. Development. 2002; 
1298:1983–1993.
49. Okano M, Bell DW, Haber DA, Li E. DNA methyltrans-
ferases Dnmt3a and Dnmt3b are essential for de novo 
methylation and mammalian development. Cell. 1999; 
993:247–257.
50. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment 
and maintenance of genomic methylation patterns in mouse 
embryonic stem cells by Dnmt3a and Dnmt3b. Molecular 
and cellular biology. 2003; 2316:5594–5605.
51. Tsumura A, Hayakawa T, Kumaki Y, Takebayashi S, 
Sakaue M, Matsuoka C, Shimotohno K, Ishikawa F, 
Li E, Ueda HR, Nakayama J, Okano M. Maintenance of 
self-renewal ability of mouse embryonic stem cells in the 
absence of DNA methyltransferases Dnmt1, Dnmt3a and 
Dnmt3b. Genes to cells : devoted to molecular & cellular 
mechanisms. 2006; 117:805–814.
52. Li JY, Pu MT, Hirasawa R, Li BZ, Huang YN, Zeng R, 
Jing NH, Chen T, Li E, Sasaki H, Xu GL. Synergistic 
 function of DNA methyltransferases Dnmt3a and Dnmt3b 
in the methylation of Oct4 and Nanog. Molecular and 
 cellular biology. 2007; 2724:8748–8759.
53. Esteller M. Cancer epigenomics: DNA methylomes and 
histone-modification maps. Nature reviews Genetics. 2007; 
84:286–298.
54. Issa JP. CpG island methylator phenotype in cancer. Nature 
reviews Cancer. 2004; 412:988–993.
55. Gao Q, Steine EJ, Barrasa MI, Hockemeyer D, Pawlak  M, 
Fu D, Reddy S, Bell GW, Jaenisch R. Deletion of the de 
novo DNA methyltransferase Dnmt3a promotes lung 
tumor progression. Proceedings of the National Academy 
of Sciences of the United States of America. 2011; 
10844:18061–18066.
56. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, Wang YC. 
Alteration of DNA methyltransferases contributes to 5′CpG 
methylation and poor prognosis in lung cancer. Lung can-
cer. 2007; 552:205–213.
57. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, 
Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation 
and in vitro propagation of tumorigenic breast cancer cells 
with stem/progenitor cell properties. Cancer research. 2005; 
6513:5506–5511.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
miR-340 predicts glioblastoma survival and modulates key 
cancer hallmarks through down-regulation of NRAS
Danilo Fiore1, Elvira Donnarumma2, Giuseppina Roscigno1,3, Margherita Iaboni1, 
Valentina Russo1, Alessandra Affinito1, Assunta Adamo1, Fabio De Martino1, 
Cristina Quintavalle4, Giulia Romano5, Adelaide Greco6,7, Soini Ylermi8, Arturo 
Brunetti6,7, Carlo M. Croce5, Gerolama Condorelli1,3
1Department of Molecular Medicine and Medical Biotechnology, “Federico II” University of Naples, Naples, Italy
2 IRCCS-SDN, Naples, Italy
3IEOS, CNR, Naples, Italy
4 Institute of Pathology, Molecular Pathology Division, University of Basel, Basel, Switzerland
5 Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive 
Cancer Center, The Ohio State University, Columbus, OH, USA
6 Department of Advanced Biomedical Science, University of Naples Federico II, Naples, Italy
7 Ceinge, Biotecnologie Avanzate, Scarl, Naples, Italy
8 Cancer Center of Eastern Finland, University of Eastern Finland, Kuopio, Finland
Correspondence to:  Gerolama Condorelli, e-mail: gecondor@unina.it
Keywords: microRNAs, glioblastoma, survival, NRAS, signal-transduction
Received: August 10, 2015 Accepted: January 01, 2016 Published: January 21, 2016
ABSTRACT
Glioblastoma is the most common primary brain tumor in adults; with a survival 
rate of 12 months from diagnosis. However, a small subgroup of patients, termed 
long-term survivors (LTS), has a survival rate longer then 12–14 months. There 
is thus increasing interest in the identification of molecular signatures predicting 
glioblastoma prognosis and in how to improve the therapeutic approach. Here, we 
report miR-340 as prognostic tumor-suppressor microRNA for glioblastoma. We 
analyzed microRNA expression in > 500 glioblastoma patients and found that although 
miR-340 is strongly down-regulated in glioblastoma overall, it is up-regulated in 
LTS patients compared to short-term survivors (STS). Indeed, miR-340 expression 
predicted better prognosis in glioblastoma patients. Coherently, overexpression of 
miR-340 in glioblastoma cells was found to produce a tumor-suppressive activity. 
We identified NRAS mRNA as a critical, direct target of miR-340: in fact, miR-340 
negatively influenced multiple aspects of glioblastoma tumorigenesis by down-
regulating NRAS and downstream AKT and ERK pathways. Thus, we demonstrate that 
expression of miR-340 in glioblastoma is responsible for a strong tumor-suppressive 
effect in LTS patients by down-regulating NRAS. miR-340 may thus represent a novel 
marker for glioblastoma diagnosis and prognosis, and may be developed into a tool 
to improve treatment of glioblastoma.
INTRODUCTION
Malignant glioma (glioblastoma or GBM) is the 
most common and aggressive primary brain tumor 
[1, 2]. Despite continuous improvement in treatment 
approaches, with a combination of surgery, radiotherapy 
and chemotherapy, average survival of GBM patients has 
improved only slightly [3]. In fact, GBM patients tend to 
have an extremely poor prognosis, with a median survival 
rate from diagnosis ranging from 12 to 14 months [4, 5]. 
Different factors are involved in GBM aggressiveness and 
poor prognosis, such as rapid cell proliferation, resistance 
to drug-induced apoptosis and enhanced invasiveness. 
Nevertheless, a small subset of patients presents a 
better outcome, surviving longer than 14 months: these 
patients are termed long-term survivors (LTS) [4]. The 
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molecular events associated with the LTS phenotype are 
not well elucidated. Better understanding of these events 
would be critical for the development of early detection 
methods, identification of new biomarkers, and improved 
therapeutic approaches. 
MicroRNAs (miRNAs or miRs) are a class of 
evolutionary conserved small non-coding RNAs that have 
great impact on a wide spectrum of biological processes. 
miRNAs act by affecting gene expression at the post-
transcriptional level [6]. Many studies have demonstrated 
a pivotal role for miRNAs in tumorigenesis, acting 
both as oncogenes or tumor suppressors [7–10]. During 
tumor initiation and progression, miRNAs may modulate 
proliferation, angiogenesis, invasion and survival [11]. 
Deregulation of miRNA expression has been found in 
many human cancers, including GBM [12–15].
NRAS is a member of the RAS oncogene family 
(which comprises KRAS, HRAS and NRAS); they encode 
small GTPases involved in cellular signal transduction. 
RAS is activated by a complex signal cascade and, in 
turn, triggers downstream signaling pathways such as the 
mitogen-activate protein kinases (MAPKs) pathway and 
the phosphatidylinositol 3-kinase (PI3K)/AKT pathway, 
to modulate cell growth and survival [16]. Various studies 
have demonstrated recurrent aberrant NRAS activation 
in GBM [17]. Recently, several miRNAs –such as miR-
181d, let-7 and miR-143– have been reported to suppress 
RAS expression, and thus act as tumor suppressors; this 
suggests that the dysregulation of miRNAs targeting NRAS 
may have an important role in carcinogenesis [8, 18–20]. 
For the present study, we investigated differential 
miRNA expression in long- and short-term GBM 
survivors. We identified miR-340 as a novel tumor 
suppressor miRNA that is up-regulated in LTS patients 
and predictive of better prognosis. Furthermore, we 
describe the oncosuppressive mechanisms induced by 
this miRNA: its ability to directly target NRAS, and thus 
silence downstream pathways, contributed in the blunting 
of the tumorigenic behavior of GBM cells.
RESULTS
miR-340 expression correlates with survival in 
GBM patients
To identify miRNAs de-regulated in long- vs short-
term GBM survivors, we profiled the miRNA signatures 
of primary GBM tissue harvested from 3 LTS and 3 STS 
patients. The analysis was performed with a microarray 
chip containing 1150 miRNA probes, including 326 
human and 249 mouse miRNAs, spotted in duplicate. 
Data obtained indicated that seven miRNAs (namely 
miR-193b, -340, -19b, -20a-b, -219-5p, -137 and -129-
3p) were significantly de-regulated (> 1.5-fold change) in 
LTS vs STS GBM patients (Supplementary Table 1). We 
decided to focus our attention on miR-340, because we 
and others have already demonstrated the oncosuppressive 
role of this miRNA in different human tumors [21–27]. 
Accordingly with microarray data, qRT-PCR for miR-
340 confirmed that it was up-regulated in LTS patients 
(Supplementary Figure 1A). 
We then analyzed miR-340 expression in a larger 
cohort of glioblastoma patients (n = 61), as well as in data 
collected from TCGA database (491 glioblastomas and 10 
normal brain samples). As expected, miR-340 expression 
was significantly decreased in STS compared to LTS 
(p < 0.05; Figure 1A, 1B), and in GBM compared to 
normal brain (p < 0.001; Figure 1C). Furthermore, Log-
Rank analysis of two different cohorts of GBM patients 
(43 GBM patients from our hospital and 327 from TCGA) 
indicated that patients with higher levels of miR-340 had 
longer overall survival, suggestive of a prognostic role of 
miR-340 (p < 0.05; p < 0.01). The Kaplan-Meier curves of 
the patient cohorts are given in Figure 1D–1E. Interestingly, 
higher levels of RNF130, the host gene of miR-340, was 
also predictive of a better prognosis in GBM patients 
(p < 0.05; fig1f, data from R2.aml database). Finally, we 
found that miR-340 expression did not correlate with 
different glioma tumor stages (Supplementary Figure 1B) 
and with MGMT methylation status (Supplementary 
Figure 1C).
NRAS mRNA is a direct target of miR-340
To identify possible miR-340 targets involved in 
the LTS phenotype, we parsed bioinformatics databases 
(Targetscan, Miranda, Pictar). We found the presence of 
two distinct putative miR-340 binding sites on the 3′UTR 
of NRAS mRNA (Figure 2A). To assess if miR-340 
directly bound to these two putative regions, we cloned 
them individually downstream of a luciferase reporter gene 
in the pGL3 vector. A549 NSCLC cells (expressing low 
endogenous level of miR-340) [25] were co-transfected 
with the reporter plasmids singularly or in combination, 
in the presence of either miR-340 or a control miRNA 
(scrambled). Luciferase activity of both reporters was 
repressed by the addition of miR-340 (Figure 2B); 
moreover, the effect was greater in cells co-transfected 
with both reporters, indicating that the two NRAS 3′UTR 
sites acted synergistically. Luciferase activity was not 
affected by miR-340 overexpression in the presence of 
mutant constructs, in which the seed sequences were 
cloned inversely (Figure 2A–2B).
To establish a causative effect between miR-340 and 
NRAS, we transfected different GBM cell lines (U251MG, 
U87MG and AM38 cells) with miR-340 and analyzed 
NRAS levels with qRT-PCR and Western blotting. We 
chose these three cell lines because they express low 
levels of miR-340, as assessed by qRT-PCR on a panel of 
11 different GBM cell lines (Supplementary Figure 1D). 
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Figure 1: miR-340 is down-regulated in GBM and correlates with GBM prognosis. miR-340 expression was evaluated using 
three independent patient cohorts (A) FFPE tissue from 36 LTS and 25 STS GBM patients; (B) 180 LTS and 172 STS GBM patients from 
TCGA database; (C) 10 normal brain specimens and 491 GBM tissues from TCGA database. A significant increase in miR-340 expression 
was identified between LTS vs STS in both cohorts and in normal brain vs GBM tissue. miR-340 expression was assessed by Real-Time 
PCR and normalized against U6. An arbitrary cut-off of 12 months was used to divide LTS and STS patients. Statistical significance was 
calculated using Student’s t-test. P < 0.05 was considered significant. (D, E), Kaplan-Meier survival curve analysis of the correlation 
between miR-340 and overall survival of: (D) the FFPE tissues from 16 highly and 27 poorly miR-340-expressing glioblastoma patients; (E) 
140 highly and 187 poorly miR-340-expressing glioblastoma patients collected from TCGA database. High miR-340 expression predicted 
a better prognosis in both cohorts. The patients were assigned to the high or low miR-340-expressing group using the media as a threshold. 
P was calculated using Log-Rank test. P < 0.05 was considered significant. (F) Kaplan-Meier survival curve analysis of the correlation 
between RNF-130 and overall survival of 347 highly and 30 poorly RNF-130-expressing glioblastoma patients from the R2.aml database. 
High RNF-130 expression predicted a better prognosis. P was calculated using Log-Rank test. P < 0.05 was considered significant.
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We found a consistent, strong decrease in NRAS mRNA 
and protein in all cell lines transfected (Figure 2C–2D). In 
contrast, anti-miR-340 induced an increase in NRAS levels 
in T98G cells (Figure 2C–2D). Interestingly, miR-340 
overexpression was also able to decrease NRAS protein 
levels in three different breast cancer cell lines (BT-549, 
MDA-MB-231, MCF7; Figure 2E) and two NSCLC cell 
lines (A549, Calu-1; Figure 2F). Furthermore, to test the 
ability of miR-340 to specifically target NRAS mRNA, 
we verified that both sequences binding this miRNA 
were not conserved in KRAS or HRAS 3′UTRs (data not 
shown); coherently, miR-340 overexpression did not 
decrease KRAS or HRAS mRNA levels in GBM cells 
(Supplementary Figure 2A–2B). 
Effects of miR-340 in GBM cell lines
We investigated the tumor suppressive role of miR-
340 in different GBM cell lines (U251MG, U87MG and 
AM38 cells) transfected with either miR-340 or a control 
miRNA. We analyzed the effects of miR-340 on cell 
cycle, cell proliferation and soft agar growth. miR-340 
transfection induced a significant S-phase block, as 
assessed by FACS analysis after PI staining (Figure 3A, 
plots for qualitative data analysis are reported in 
Supplementary Figure 3A), and a significant decrease 
in cell proliferation, as assessed by BrdU incorporation 
(Figure 3B; plots for qualitative data analysis are reported in 
Supplementary Figure 4A) and MTT assay (Figure 3C–3E). 
In contrast, expression of anti-miR-340 in T98G cells 
increased cell proliferation 72 h after transfection (Figure 3E). 
We next investigated whether miR-340 expression had an 
impact on anchorage-independent cell growth with a soft 
agar assay. We found that miR-340 induced a reduction in 
colony formation in U251MG, U87MG and AM38 cells 
(Figure 3F). These results clearly demonstrate that miR-340 
acts as tumor suppressor in GBM by blunting cell cycle, 
proliferation and anchorage-independent cell growth.
miR-340 sensitizes GBM cells to TMZ
Because adjuvant chemotherapy with temozolomide 
is limited by the action of O-6-methylguanine-DNA 
methyltransferase (MGMT), a contributing factor for very 
poor survival in GBM patients [28], we investigated a 
possible role of miR-340 in TMZ sensitivity. MTT and 
Caspase 3/7 assays showed that miR-340 induced an 
increase in sensitivity to TMZ in all the cells analyzed 
(Figure 4A, 4B). Coherently, miR-340 overexpression 
determined an increase of apoptosis in GBM cells, 
as assessed by PARP cleavage (Figure 4C) as well as 
Annexin V assay (Figure 4D, plots for qualitative data 
analysis are reported in Supplementary Figure 5A). These 
results suggest that miR-340 expression contributes to 
the establishment of a LTS phenotype by enhancing the 
response of GBM patients to alkylating drugs.
NRAS: a key target molecule of miR-340-
mediated effects
NRAS is a key oncogene deregulated in many human 
cancers [16, 17, 29–31]. To demonstrate a causative 
link between miR-340 and NRAS, we performed rescue 
experiments, transfecting U251MG cells with miR-340 
and with a construct expressing NRAS mRNA lacking 
the 3′UTR. Levels of transfected NRAS were detected 
by Western blotting (data not shown). Interestingly, 
expression of this NRAS counteracted the effects of 
miR-340 overexpression on proliferation (Figure 5A–5B; 
plots for qualitative data analysis are reported in 
Supplementary Figure 4B), cell cycle (Figure 5C; plots 
for qualitative data analysis are reported in Supplementary 
Figure 3B) and anchorage-independent cell growth (Figure 
5D). Coherently, NRAS knock-down with a specific NRAS 
siRNA mimicked the effects of miR-340 overexpression, 
blocking cell cycle (Figure 5E; plots for qualitative data 
analysis are reported in Supplementary Figure 3C), 
decreasing the phosphorylation of ERK and AKT kinases 
(Figure 5F), and reducing proliferation (Figure 5G).
We then analyzed NRAS expression in a cohort of 39 
GBM patients: we found that NRAS was down-regulated in 
LTS vs STS patients (p < 0.05, Supplementary Figure 6A). 
Moreover, NRAS expression was higher in 542 GBM 
samples compared to 10 normal brain specimens (data 
collected from the oncomine database; p < 0.001; 
Supplementary Figure 6B). Furthermore, Log-Rank 
analysis of 28 GBM patients showed that those with 
higher levels of NRAS had shorter overall survival 
(Supplementary Figure 6C). This finding was confirmed 
by data from the R2.aml database (504 tissues; p < 0.05; 
Supplementary Figure 6D). In conclusion, the anti-tumoral 
effects of miR-340 seem, at least in part, to be mediated by 
its targeting of NRAS.
Recently, miR-340 was reported to directly target 
two important oncogenes, SKP2 and ROCK1, respectively 
in lung cancer and in osteosarcoma [22, 25, 26]. We found 
that miR-340 decreased the expression of both these 
oncogenes in three different GBM cell lines, suggesting 
that miR-340 may affect GBM tumorigenesis also by 
targeting other mRNAs (Supplementary Figure 7A). 
miR-340 blocks cell cycle and cell proliferation 
via inhibition of signaling pathways downstream 
from NRAS
AKT and ERK1/2 pathways act as major 
downstream signals of RAS, promoting multiple 
oncogenic features of RAS, such as cell proliferation 
and apoptosis resistance. We assessed the levels of 
phosphorylated (activated) forms of AKT and ERK1/2 
(p-AKT and p-ERK1/2) by Western blotting in 
glioblastoma cells transfected with miR-340 or a control 
scrambled sequence. miR-340 drastically reduced p-AKT 
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Figure 2: miR-340 targets NRAS. (A) Predicted miR-340 binding sites on 2 sites on NRAS-3′UTR (3′UTR NRAS R1 and 3′UTR 
NRAS R2) found with the MIRANDA algorithm (www.microrna.org) and the designed mutant sequences (3′UTR NRAS R1mut and 
3′UTR NRAS R2mut). (B) NRAS luciferase constructs containing wild-type or mutated NRAS-3′UTR-R1 or -R2, were co-transfected alone 
or in combination with miR-340 or a scrambled miRNA in A549 cells. Luciferase activity was measured 24 h after transfection. Reporter 
activities of cells co-transfected with the scrambled miRNA sequence have been arbitrarily set as 100. The results were obtained from three 
independent experiments and are presented as mean ± SD. In (B) P was calculated using ANOVA and adjusted for multiple comparisons 
with Bonferroni’s post hoc testing. *p < 0.05; **p < 0.01; ***p < 0.001 (over Scr). Glioblastoma cell lines (U251MG, U87MG and AM38), 
breast cancer cell lines (BT-549, MDA-MB-231 and MCF7), and NSCLC cell lines (A549 and Calu-1) were transfected with a scrambled 
miRNA sequence and miR-340, or with a scrambled anti-miR-340 sequence and anti-miR-340 in T98G cells for 72 h. Real-time PCR 
(C) and Western blotting (D–F) were performed to analyze NRAS mRNA and protein levels. Western blot analyses are from representative 
experiments. Actin was used as loading control. The experiments were repeated at least three times. In (C) the results are presented as 
mean ± SD. P was calculated using Student’s t-test. *p < 0.05; **p < 0.01.
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and p-ERK1/2 levels in U251MG, U87MG and AM38 
cells (Figure 6A). In contrast, transfection with anti-
miR-340 induced an increase in p-AKT and p-ERK1/2 in 
T98G cells (Figure 6A). Interestingly, performing a more 
comprehensive analysis of the AKT and ERK pathways, 
we found that miR-340 overexpression decreased the 
phosphorylation of other kinases of both AKT (mTOR, 
GSK3β), and ERK pathway (ELK) (Figure 6B).
Figure 3: miR-340’s effects in glioblastoma cells. Glioblastoma cell lines (U251MG, U87MG and AM38) were transfected with 
miR-340 or with a control scrambled miRNA sequence. We then analyzed: (A) cell cycle by flow cytometry after propidium iodide staining 
72 h after transfection; (B) cell proliferation by BrdU incorporation assay, 3 days after transfection; (C–E) cell proliferation by MTT 
assay, 1, 3, 5 and 7 days after transfection (3 days for AM38); (F) anchorage-independent cell growth by Soft Agar assay, 14 days after 
transfection. (E) T98G cells were transfected with anti-miR-340 or a control with scrambled anti-miRNA sequence and cell proliferation 
analyzed with MTT 3 days after transfection. miR-340 overexpression blocked cell cycle and decreased cell proliferation and anchorage-
independent cell growth. The data are representative of three independent experiments. Data are mean values ± SD from three independent 
experiments. P was calculated using Student’s t-test. *p < 0.05; **p < 0.01; ***p < 0.001.
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Next, we wondered whether miR-340-mediated 
blockade of cell cycle and cell proliferation was mediated 
by inhibition of AKT and ERK1/2 signaling pathways 
downstream of NRAS. To this aim, we transfected 
U251MG cells with miR-340 and two constructs 
expressing constitutively active forms of AKT (AKT+) and 
Figure 4: miR-340 increases TMZ sensitivity in glioblastoma cells. Glioblastoma cell lines (U251MG, U87MG and AM38) were 
transfected with a scrambled miRNA sequence or miR-340 for 24 h, and then treated with 300 µM TMZ for 24 h. Cell death and apoptosis 
were analyzed respectively with the MTT assay (A) and caspase assay (B), western blot analysis for PARP (C), and Annexin V assay (D). 
miR-340 overexpression promoted TMZ-induced apoptosis. Data are mean values ± SD of three independent experiments. P was calculated 
using Student’s t-test. *p < 0.05; **p < 0.01.
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ERK1 (ERK+) for 48 h, either alone or in combination. 
Levels of transfected AKT+ and ERK+ were assessed 
by Western blotting (data not shown). AKT+ and ERK+ 
were individually able to partially counter the effects of 
miR-340 on cell cycle (Figure 7A; plots for qualitative 
data analysis are reported in Supplementary Figure 3D), 
proliferation (Figure 7B), and anchorage independent cell 
growth (Figure 7C); the effects were greater when AKT+ 
Figure 5: NRAS mediates the effects of miR-340 on cell cycle, proliferation and anchorage-independent cell growth. 
U251MG cells were co-transfected with miR-340 and either a vector carrying NRAS lacking 3′UTR or a control. Exogenous NRAS 
expression partially counteracted the effects of miR-340 on proliferation (A, B), cell cycle (C), and anchorage-independent growth (D). 
Moreover, NRAS knock-down reproduced the effects of miR-340 transfection in GBM cells. U251MG, U87MG, and AM38 cells were 
transfected with a control siRNA or with a specific siRNA targeting NRAS. NRAS silencing mimicked the effects of miR-340 on cell cycle 
(E) decreased the phosphorylation of AKT and ERK (F) and reproduced the block of proliferation induced by miR-340 transfection (G). 
The experiments were repeated at least three times. Presented data are mean values ± SD of three independent experiments. Western blot 
analyses are representative experiments. Actin was used as the loading control. In (A–D) P was calculated using ANOVA and adjusted for 
multiple comparison with Bonferroni’s post hoc testing (over Empty + Scr); in (E, G) P was calculated using Student’s t-test. *p < 0.05; 
**p <0.01; ***p < 0.001; ****p < 0.0001.
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and ERK+ were co-transfected (Figure 7A–7C). These 
results further support the notion that miR-340 acts as a 
tumor suppressor in GBM by targeting NRAS and, hence, 
blunting downstream AKT and ERK1/2 pathways.
Overexpression of miR-340 inhibits GBM 
growth in vivo
To analyze the possible role of miR-340 in GBM 
tumorigenesis, we assessed the effects of miR-340 
overexpression on tumor growth in vivo. To this end, 
we stably infected U251MG cells with a lentiviral 
construct expressing either miR-340 or control sequence 
(Supplementary Figure 8A–8B). In accordance with 
previous data, miR-340 stable infected cells showed 
a reduction of proliferation and a block of cell cycle 
(Supplementary Figure 8C–8D). These cells were 
subcutaneously injected into the left flank (2 × 106 cells 
per flank) of CD1 nude mice (n = 6 animals per group). 
Tumor volume and vessel formation were measured 
weekly by HFUS and color-doppler HFUS for 3 weeks. 
Tumor volume and vessel formation generated by 
miR-340-expressing U251MG xenografts were 
significantly less compared to those of control xenografts 
(Figure 8A, 8B). Coherently, Ki67 staining of tumor 
sections indicated a decrease of cell proliferation in miR-
340-expressing U251MG xenografts (Figure 8C). 
DISCUSSION
GBM is one of the most aggressive types of 
human cancer and the most lethal form in the brain. It is 
characterized by extremely bad prognosis, with a median 
survival rate of only 12 months from diagnosis [2]. 
Figure 6: miR-340 overexpression decrease the activation of molecular pathways downstream NRAS. Glioblastoma cell 
lines (U251MG, U87MG and AM38) were transfected with a scrambled miRNA sequence or miR-340, or with a scrambled anti miRNA 
sequence or anti miR-340, in T98G cells, for 72 h. Western blotting was performed to analyze pAKT and pERK1/2 (A) and pmTOR, 
pGSK3β, and pELK protein levels (B) Western blot analyses are representative experiments. Actin was used as the loading control. The 
experiments were repeated at least three times. 
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Figure 7: Molecular pathways downstream from NRAS mediate the effects of miR-340 GBM cells. U251MG glioblastoma 
cells were co-transfected with miR-340 and dominant active mutants constructs of ERK and AKT, alone or in combination, or with control 
vector. Exogenous dominant active expression of both ERKs and AKT was able to partially counteract the effects of miR-340 on cell 
cycle (A) proliferation (B) and anchorage independent cell growth (C) The experiments were repeated at least three times. Presented data 
are mean values ± SD of three independent experiments. In (A) P was calculated using Student’s t-test. In (B, C) P was calculated using 
ANOVA and adjusted for multiple comparisons with the Bonferroni’s post hoc testing. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 
(over Empty + Scr).
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Figure 8: miR-340 inhibits the growth of glioblastoma xenografts in vivo. U251MG cells stably transduced with a lentiviral 
vector encoding miR-340 or with control particles were subcutaneously injected into the left flank of CD1 nude mice (n = 6 per group). 
Tumor volume and vessel formation were measured weekly by HFUS and color-doppler HFUS (Vevo 2100 with a 40MHz probe) for three 
weeks. Data in (A) and (B) show that treatment with miR-340 reduced glioblastoma-derived xenograft growth and vessel formation. In (B) 
P was calculated using Student’s t-test. *p < 0.05. (C) Nuclear localization of KI67 staining and HE staining of xenograft mice injected 
with U251MG-Lenti-Empty expressing cells and U251MG-Lenti-miR340 overexpressing cells. A representative area of each tissue is 
represented. Two mice for each experimental point are represented. Magnification 40x (Figure 8C).
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Interestingly, a small subgroup of patients survives longer. 
Better understanding of the specific molecular features 
underlying this LTS phenotype may lead to improved 
diagnosis, prognosis, treatment and, ultimately, survival of 
GBM patients [4]. At present, several molecular markers 
have been correlated to GBM prognosis, but they need 
further validation before they can be used in the clinical 
setting [28]. However, despite great effort over the last 
years, the cellular and molecular features of LTS have not 
been properly elucidated.
In the last decade, microRNAs have been frequently 
found deregulated in different human cancers, acting both 
as oncogenes or tumor suppressors. miRNAs are involved 
in basic cellular functions, including proliferation, cell 
death, differentiation, metabolism and, importantly, 
tumorigenesis [7–11, 13]. In addition, these noncoding 
RNAs have the capacity to target tens to hundreds of genes 
simultaneously [6]. Thus, they are attractive candidates 
as prognostic biomarkers and therapeutic tools/targets 
in cancer. Several studies have demonstrated that the 
expression of miRNAs is deregulated in gliomas [12, 14, 
15, 18] and may affect GBM tumorigenesis [32–34]. More 
importantly, several reports have established a direct link 
between miRNA signatures and GBM prognosis [35–38]. 
In the present study, we identify miR-340 as a tumor-
suppressive miRNA in GBM. Our experimental data, 
together with that obtained from TCGA database, show 
that miR-340 expression is significantly higher in LTS 
compared to STS patients, and in normal brain compared 
to GBM. Furthermore, statistical analysis revealed that 
patients with higher miR-340 expression had a longer 
survival rate and, thus, a better prognosis. Taken together, 
these data suggest that higher expression of miR-340 is a 
significant predictor of good prognosis in GBM.
Our functional studies show that overexpression 
of miR-340 in GBM cells determines a significant block 
of cell cycle, inhibition of cell proliferation, decrease of 
anchorage-independent cell growth, and an increase in 
sensitivity to TMZ. Furthermore, miR-340 directly binds 
to two different sites on the 3′UTR of NRAS mRNA to 
strongly inhibit NRAS protein expression. The RAS 
protein family consists of 4 highly homologous enzymes 
(NRAS, HRAS, KRAS4A and KRAS4B) that act as 
signaling molecules for the regulation of cell fate: they 
couple receptor activation to downstream effector 
pathways controlling different cellular responses, such 
as proliferation, resistance to therapy and survival [16]. 
Activating mutations of RAS proteins are common in 
human cancers, especially in hematopoietic cancers, 
colorectal cancer and melanoma [29–31]. In glioblastoma, 
NRAS activation could be caused by a direct mutation 
(5%) or by other alterations, such as amplification, 
overexpression of growth factor receptor or aberrations in 
other RAS pathway genes [17]. Recently, several miRNAs 
– including miR-181d, let-7 and miR-143– were reported 
to suppress RAS expression and function as tumor 
suppressors, suggesting that miRNAs targeting RAS may 
have an important role in carcinogenesis [18–20]. Our 
findings indicate that miR-340’s targeting of NRAS leads 
to a decrease in the activation of downstream pathways 
(namely AKT and ERKs). Experiments using dominant 
positive mutants of AKT and ERKs clearly show that 
both these pathways are down-regulated by a miR-340-
mediated effect in GBM. Thus, we have identified a new 
link between miR-340 and NRAS, a novel player in GBM 
tumorigenesis.
miR-340 has been shown to have a tumor-
suppressive activity also in other types of cancer. Wu 
et al. reported that miR-340 suppressed cell growth in 
breast cancer [21]; in osteosarcoma, miR-340 was found 
down-regulated compared to normal tissue, and ROCK-1 
was identified as a miR-340 target [22, 26]; Poenitzsch 
et al. demonstrated for the first time the pleiotropic 
regulation of the RAS-RAF-MAPKs pathway by miR-340 
in melanoma, which resulted in a strong tumor-suppressive 
activity [24]; Fernandez et al. characterized the tumor-
suppressive activity of miR-340 in lung cancer, where it 
mediated cell growth inhibition and apoptosis activation 
via the accumulation of p27 [25]; Yamashita et al. reported 
that miR-340 suppressed the stem-like cell function of 
glioma-initiating cells in vitro and in nude mouse brain 
– their findings indicated that miR-340 acted as a tumor 
suppressor in glioma-initiating cells, particularly affecting 
gliomagenesis and extensive tumor invasion [23]. 
Recently Huang et al. reported that miR-340 was able to 
inhibit glioblastoma tumorigenesis [27].
In the present study, we show that lentiviral 
vector-mediated overexpression of miR-340 in GBM 
cells inhibits cell growth in nude mice, suggestive of its 
possible therapeutic use.
In conclusion, we have observed for the first time 
a direct link between miR-340 expression and survival 
in GBM, demonstrating that miR-340 has a powerful 
oncosuppressive effect in vitro and in vivo. The mechanism 
is mediated, at least in part, by the targeting of NRAS and 
the consequential blunting of downstream ERKs and AKT 
pathways. We propose miR-340 as a novel biomarker for 
GBM prognosis, as well as a new therapeutic agent for the 
amelioration of GBM patient survival.
MATERIALS AND METHODS
Cells and tissue specimens
Glioblastoma cell lines T98G, U87MG, LN229 and 
LN18, breast cancer cell lines BT549, MDA-MB-231, 
MCF7, and NSCLC cell lines A549 and CALU-1 were 
obtained from American Type Culture Collection (ATCC), 
(LG Standards, Milan, Italy); U251MG, LN428, LN308, 
SF767 and A172 were kindly donated by Frank Furnari 
(La Jolla University, San Diego, CA, USA). U87MG, 
U251MG, T98G, AM38, A172, LN319, LN308, LN428, 
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SF767, MCF7 and Calu-1 were grown in Dulbecco’s 
modified eagle’s Medium, LN18 and LN229 in Advanced 
Dulbecco’s modified eagle’s Medium, and BT-549, 
MDA-MB-231 and A549 in RPMI Medium. Media were 
supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) –5% FBS for LN229 and LN18– 2 mM 
L-glutamine and 100 U/ml penicillin/streptomycin. All 
media and supplements were from Sigma Aldrich (Milan, 
Italy).
A total of 61 formalin-fixed, paraffin-embedded 
(FFPE) tissue samples were collected from the archives 
of the Department of Pathology, University Hospital 
of Kuopio, Finland. Among the 61 samples, survival 
information for 43 cases was available. Permission to use 
the material was obtained from the National Supervisory 
Authority for Welfare and Health of Finland, and the study 
was accepted by the ethical committee of the Northern 
Savo Hospital District, Kuopio, Finland. Informed consent 
was obtained from each subject or subject’s guardian.
TCGA data analysis
The collection of data from The Cancer Genome 
Atlas (TCGA) platform was compliant with laws and 
regulations for the protection of human subjects, and 
necessary ethical approvals were obtained. Analysis of 
all data was done using GraphPad Prism 6 (San Diego, 
CA, USA). For differential expression analysis and 
determination of the effect of miR-340 and NRAS on 
patient’s survival, we downloaded Agilent 8 × 15 miRNA 
expression (level 2) and HT_HG-U133A (level 3) along 
with clinical information from the TCGA database in April 
2014. 
Cell transfection
For transient overexpression of miRNAs and 
siRNAs, cells at 50% confluence were transfected using 
Oligofectamine (Invitrogen, Milan, Italy) and 100 nM 
of pre-miR-340, scrambled miRNA, anti-miR-340, 
scrambled anti-miRNA (Ambion®, Life Technologies), 
siNRAS or a siRNA control (Santa Cruz Biotechnologies, 
MA, USA). For transient overexpression of 4 µg of 
pcDNA3-NRAS, pcDNA3-AKT+, pcDNA3-ERK+ or 
pcDNA3, cells were transfected using X-tremeGENE 
9 DNA Transfection Reagent (Roche, Milan, Italy). 
Temozolomide (TMZ) was purchased from Sigma Aldrich 
(Milan, Italy).
RNA extraction and real-time PCR
Cell culture: Total RNA (microRNA and mRNA) 
was extracted using Trizol (Invitrogen, Milan, Italy) 
according to the manufacturer’s protocol. Tissue 
specimens: total RNA (miRNA and mRNA) from FFPE 
tissue specimens was extracted using RecoverAll Total 
Nucleic Acid isolation Kit (Ambion, Life Technologies, 
Milan, Italy) according to the manufacturer’s protocol. 
Reverse transcription of total RNA was performed 
starting from equal amounts of total RNA/sample (500 ng) 
using miScript reverse Transcription Kit (Qiagen, Milan, 
Italy) for miRNA analysis, and with SuperScript® III 
Reverse Transcriptase (Invitrogen, Milan, Italy) for mRNA 
analysis. Quantitative analysis of miR-340 and RNU6A 
(the latter as an internal reference) were performed by 
RT-PCR using specific primers (Qiagen, Milan, Italy) 
and miScript SYBR Green PCR Kit (Qiagen, Milan, 
Italy). RT-PCR was also used to assess the mRNAs 
of NRAS, KRAS, HRAS and β-actin (the latter as an 
internal reference), using iQTM SYBR Green Supermix 
(Bio-Rad, Milan, Italy). The primer sequences were: 
NRAS-Fw: 3′-CGCACTGACAATCCAGCTAA-5′; 
NRAS-Rv: 3′-TCGCCTGTCCTCATGTATTG-5′; 
K-RAS-Fw: 3′-ACTGGGGAGGGCTTTCTTTG-5′; 
K-RAS-Rv: 3′-GGCATCATCAACACCCTGTCT-5′; 
H-RAS: Fw: 3′-TATAAGCTGGTGGTGGTGGG-5′; 
H-RAS-Rv: 3′- TGATGGCAAACACACACAGG-5′; 
Act-FW: 5′-TGCGTGACATTAAGGAGAAG-3′; Act-Rv: 
5′-GCTCGTAGCTCTTCTCCA-3′. 
The reaction for detection of mRNAs was performed 
in this manner: 95°C for 5 min, 40 cycles of 95°C for 
30 s, 60°C for 30 s and 72°C for 30 s. The reaction for 
detection of miRNAs was performed in this manner: 
95°C for 15 min, 40 cycles of 94°C for 15 s, 55°C for 
30 s and 70°C for 30 s. All reactions were run in triplicate. 
The threshold cycle (CT) was defined as the fractional 
cycle number at which the fluorescence passed the fixed 
threshold. For relative quantization, the 2(−ΔΔCT) method 
was used. Experiments were carried out in triplicate for 
each data point, and data analysis was performed with 
Applied Biosystems’StepOnePlus™ Real-Time PCR 
System.
miRNA expression microarray and data analysis
From each sample, 5 µg of total RNA (from 
3 long- and 3 short-term GBM survivors) was reverse 
transcribed using biotin end-labeled random octamer 
oligonucleotide primer. Hybridization of biotin-labeled 
cDNA was performed on an Ohio State University custom 
miRNA microarray chip (OSU_CCC version 3.0), which 
contained 1150 miRNA probes, including 326 human 
and 249 mouse miRNA genes, spotted in duplicates. The 
hybridized chips were washed and processed to detect 
biotin-containing transcripts with a streptavidin-Alexa647 
conjugate and scanned on an Axon 4000B microarray 
scanner (Axon Instruments, Sunnyvale, CA, USA). Raw 
data were normalized and analyzed with GENESPRING 
7.2 software (zcomSilicon Genetics, Redwood City, 
CA, USA). Expression data were median-centered with 
the GENESPRING normalization option and with the 
BIOCONDUCTOR package (www.bioconductor.org) 
global median normalization tool, with similar results. 
Statistical comparisons were done with the GENESPRING 
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ANOVA tool, predictive analysis of microarray and the 
significance analysis of microarray software (http://www.
stat.stanford.edu/Btibs/SAM/index.html).
Establishment of glioblastoma cells stably 
expressing miR-340
Lentiviral vectors encoding an expression 
cassette containing a puromycin resistance gene, the 
green fluorescent protein (GFP) gene and the miR-340 
sequence under the hCMV promoter were purchased 
from GE Healthcare Dharmacon (Milan, Italy). U251MG 
cells were infected with the miR-340 lentiviral vector 
or with an empty, control vector (which lacked the 
miR-340 sequence) at a final concentration of 20 MOI. 
After culturing in selection media supplemented with 
puromycin, GFP was detected by fluorescence microscopy 
(original magnification 10x; scale bar 100 µm), and 
representative images were collected using the Leica 
Application Suite X (LAS X) software (Leica, Milan, 
Italy). Finally, puromycin-resistant, GFP-positive clones 
were picked.
Protein isolation and Western blotting
Cells were lysed in JS buffer (50 mM HEPES, 
pH 7.5, containing 150 mM NaCl, 1% glycerol, 1% Triton 
X-100, 1.5 mM MgCl2, 5 mM EGTA, 1 mM Na3VO4, 
and 1X protease inhibitor cocktail). Protein concentration 
was determined with the Bradford assay (BioRad, Milan, 
Italy) using bovine serum albumin as the standard, and 
equal amounts of proteins were analyzed by SDS-
PAGE (12% acrylamide). Gels were electroblotted into 
nitrocellulose membranes (G & E Healthcare, Milan, 
Italy). Membranes were blocked for 1 h with 5% non-
fat dry milk in tris-buffered saline (TBS) containing 
0.1% Tween-20, and incubated at 4°C overnight with 
the primary antibody. Detection was performed by 
peroxidase-conjugated secondary antibodies, using the 
enhanced chemiluminescence system (Thermo Euroclone, 
Milan, Italy). Primary antibodies used were: anti-NRAS, 
anti-ERK1, anti-SKP2, anti-ROCK1 (Santa Cruz 
Biotechnologies, MA, USA), anti-pP42/44, anti-pAKT, 
anti-AKT, anti-pmTOR, anti-mTOR, anti-pGSK3β, anti-
GSK3β, anti-pELK, anti-ELK (Cell Signaling, Danvers, 
MA, USA), and anti-βactin (Sigma Aldrich, Milan, Italy).
MTT assay
Cell vitality was evaluated with the CellTiter 96® 
AQueous One Solution Cell Proliferation Assay 
(Promega, Madison, WI, USA), according to the 
manufacturer’s protocol. The assay is based on reduction of 
3-(4,5-dimethylthiazol-2-yl)-5-(3- carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) to a 
colored product that is measured spectrophotometrically. 
After 24 h from miRNA or siRNA transfection, cells 
(1 × 103) were plated in 96-well plates in triplicate and 
incubated at 37°C in a 5% CO2 incubator. Metabolically 
active cells were detected by adding 20 μl of MTS to each 
well; after 30 min of incubation, the plates were analyzed 
on a Multilabel Counter (Bio-Rad, Richmond, VA, USA).
BrdU incorporation assay
Cell proliferation was evaluated with the In Situ Cell 
Proliferation Kit, FLUOS (Sigma Aldrich, Milan, Italy), 
according to the manufacturer’s protocol. The assay is based 
on the incorporation of BrdU only in actively proliferating 
cells. Cells were plated in p100 plates and transfected with 
miR-340 or scrambled sequence. After 72 h, proliferating 
cells were detected by adding BrdU to each plate; after 
4 h of incubation, the cells were fixed and labeled with 
anti-BrdU antibody conjugated with fluorescein for 
45 min. Then, BrdU incorporation were detected with a 
Becton Dickinson FACScan flow cytometer.
Cell cycle analysis
Cell cycle was analyzed via propidium iodide (PI) 
incorporation in permeabilized cells by flow cytometry. 
The cells (5 × 104) were washed in PBS and resuspended 
in 200 μl of a solution containing 0.1% sodium citrate, 
0.1% triton X-100 and 50 μg/ml propidium 6 iodide 
(Sigma Aldrich, Milan, Italy). Following incubation at 
4°C for 30 min in the dark, nuclei were analyzed with 
a Becton Dickinson FACScan flow cytometer. Cellular 
debris was excluded from analyses by raising the forward 
scatter threshold, and the DNA content of the nuclei 
was registered on a logarithmic scale. The percentage of 
elements in the hypodiploid region was calculated.
Soft-agar assay
1 × 104 cells were plated in 60mm dishes in a 
solution containing Dulbecco’s modified Eagle’s medium 
2 × (Sigma, St Louis, MO, USA), TPB buffer (Difco, 
BD, Franklin Lakes, NJ, USA), and 1.25% Noble Agar 
(Difco, BD, Franklin Lakes, NJ, USA). Briefly, cells were 
harvested and counted, then a layer of 7 ml of Noble 
Agar solution was left to polymerize on the bottom of 
the dishes. Then cells were resuspended in 2 ml of same 
solution and plated. Cells were left to grow for 2 weeks in 
the incubator.
Cell death quantification and caspase assay
Cells were transfected with miRNAs as described 
and were plated in 96-well plates in triplicate, treated, and 
incubated at 37°C in a 5% CO2 incubator. Temozolomide 
was used at a final concentration of 300 µM for 24 h. Cell 
viability was assessed using the CellTiter 96® AQueous 
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One Solution Cell Proliferation Assay (Promega, 
Madison, WI, USA), as described above. Apoptosis 
activation was analyzed with the Caspase-Glo® 3/7 Assay 
System (Promega, Madison, WI, USA), as reported in 
the instruction manual. Briefly, cells were incubated 
with medium supplemented with caspase 3/7 reagent; 
luminescence was measured following incubation for 
30 min at room temperature.
Apoptosis assessment by Annexin V staining
GBM cells were transfected with miR-340 or 
scrambled sequence. After 48 h, cells were treated with 
300 μM of TMZ for 24 h, harvested, washed twice with 
cold PBS, and stained with Annexin V-FITC Apoptosis 
Detection Kit 1 (BD Pharmingen, Milan, Italy). Briefly, 
cells were resuspended in 100 μL of 1 × binding buffer 
and 5 μL of Annexin V and then incubated for 15 min at 
room temperature. Apoptotic cells were analyzed by flow 
cytometry.
Rescue experiments
To determine whether NRAS mediated the effect of 
miR-340, rescue experiments were performed in which 
the effects of miR-340 were measured in the setting of 
overexpression of a deletion mutant of NRAS, i.e., one 
lacking the 3′ untranslated region (UTR). Cells were 
transfected with miR-340 and with the mutant NRAS 
vector, using X-tremeGENE 9 DNA Transfection Reagent 
(Roche, Milan, Italy), as described. Growth and cell cycle 
were assessed as above.
In vivo tumor formation
Five-week-old female CD1 nude mice (Charles 
River, Milan, Italy) were maintained in special pathogen 
free conditions for one week. The animal protocols used 
in this work were evaluated and approved by the Animal 
Use and Ethic Committee (OBA) of the Institute Ceinge, 
Biotecnologie Avanzate s.c.a.r.l. (Protocol 15/1/14_n 4). 
The animals protocols were performed in accordance with 
FELASA guidelines and the guidelines defined by the 
European Communities Council directive (2010/63/EU). 
The investigators adhere to widely accepted national 
standards. U251MG cells stably expressing either miR-340 
or miR-Empty were injected subcutaneously into the left 
flank of the nude mice (2 × 106 cells in 100 µl). Tumor 
size was assessed weekly with a Vevo 2100 equipment 
(FUJIFILM VisualSonics, Inc., Toronto, Ontario, Canada), 
an high-frequency ultrasound (HFUS) system mounting 
a 40 MHz probe, 1, 2, and 3 weeks after cells injection. 
The procedures were performed under general anesthesia 
with 2% isoflurane in 100% oxygen at 0.8 L/min. For each 
tumor, mediolateral, anteroposterior and craniocaudal 
diameters were measured. Tumor volume (TV) was 
calculated according to the formula V = (height × width × 
length × 3.16)/6.
Immunohistochemical staining and evaluation
Xenograft fresh frozen tissue were embedded 
in OCT compound and were cut in sections of 5 μm 
thickness. Staining was performed with an automatic 
Benchmark XT staining machine (Ventana Medical 
Systems Inc.,Tucson, AZ, USA) with an antihuman KI67 
(Ventana) antibody according to manufacture procedure. 
KI67 nuclear staining intensity was evaluated by one 
expert pathologist. For H & E staining, 2.5 µm sections 
of all fixed samples were mounted on superfrost slides 
and performed using standard methodology.
Luciferase assay
The two predicted regions on the 3′UTR of 
the human NRAS gene (R1 and R2) containing 
the putative miR-340 binding site were PCR 
amplified using the following primers: NRAS-R1-FW: 
3′-GCTCTAGATGGCATCTGCTCTAGATTCATAAA-5′; NRAS-
R1-Rv: 3′-GCTCTAGATGGCATCTGCTCTAGATTCATAAA-5′; 
NRAS-R2-FW: 3′-GCTCTAGACTATTTTAGTGGGCCCATGTT-5′; 
NRAS-R2-Rv: 3′-GCTCTAGACAAGAAGCAGAACGCACC-5′, 
and cloned downstream of the Renilla luciferase stop 
codon in a pGL3 control vector (Promega, Milan, Italy). 
An inverted sequence of the miRNA-binding sites was 
used as the negative control. A549 cells were transfected 
with miR-340 or a scrambled miRNA for 6 h. Then, the 
cells were co-transfected with 1.2 μg of 3′UTR NRAS-R1 
or -R2 plasmids, or relative mutant constructs, plus 
400 μg of a Renilla luciferase expression construct, pRL-
TK (Promega, Milan, Italy), with Lipofectamine 2000 
(Life Technologies, Milan, Italy). Cells were harvested 
24 h post-transfection, and the luciferase activity assayed 
with Dual Luciferase Assay (Promega, Milan, Italy), 
according to the manufacturer’s instructions. Three 
independent experiments were performed in triplicate.
Statistical analysis
All experiments were repeated at least three times. 
Continuous variables are given as mean ± 1 standard 
deviation (SD). For two-groups comparison, Student’s 
t-test was used to determine differences between mean 
values for normal distribution. Comparisons among more 
than two groups were determined by one-way ANOVA 
followed by Bonferroni’s post hoc testing. Survival was 
illustrated by Kaplan-Meier curves; survival differences 
between groups were examined with log-rank test. All 
data were analyzed for significance using GraphPadPrism 
6 software (San Diego, CA, USA); a probability level 
< 0.05 was considered significant throughout the 
analysis.
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Introduction
Members of the tumor necrosis factor (TNF) superfamily of 
cytokines bind to cognate receptors, called death receptors, 
on the surface of cells. Since their first discovery, more than 
20 human TNF ligands and more than 30 corresponding 
receptors have been identified.1 Members of this superfamily 
have a wide tissue distribution and regulate broad physiologi-
cal processes such as immune responses, hematopoiesis, 
morphogenesis, and cell death, thus playing a key role in 
homeostasis, up to their role in tumorigenesis.2 Key members 
of this family include TNF, CD95L (FasL), and TNF-related 
apoptosis-inducing ligand (TRAIL).
The clinical application of TNF ligands as cytotoxic agents 
for cancer is limited due to their toxicity. For example, TNF 
induces systemic toxicity.3 In vivo use of CD95L is also limited 
by its lethal hepatotoxicity resulting from massive hepatocyte 
apoptosis.4,5 TRAIL, instead, has been developed as a prom-
ising antitumor agent because it induces apoptosis in several 
tumor-derived cell types, but not in normal cells.6,7 However, 
tumors often develop resistance to TRAIL monotherapy. 
Resistance to drug treatment is mainly due to deregulation 
of apoptosis-related proteins such as PED, a death effector 
domain (DED) family member of 15 KDa having a variety of 
effects on cell growth and metabolism.8 PED has a broad 
anti-apoptotic function, being able to inhibit both the intrinsic 
and the extrinsic apoptotic pathways. In the extrinsic pathway, 
its interaction with Fas-associated protein with death domain 
(FADD) and pro-caspase-8 acts as competitive inhibitor of 
these pro-apoptotic molecules during the assembly of the 
death-inducing signaling complex (DISC).9–13 PED has been 
shown to be overexpressed in TRAIL-resistant human non-
small cell lung cancer (NSCLC) cells.14 An important mecha-
nism of protein expression regulation involves microRNAs 
(miRNAs).15,16 Toward this end, we found that miR-212 nega-
tively modulates PED expression and sensitizes NSCLC cells 
to TRAIL-induced apoptosis. In fact, miR-212 levels in resis-
tant cell lines of NSCLC were downregulated and inversely 
correlated with PED levels.17 Consistently, transfection of a 
miR-212 mimic resulted in sensitization of resistant cancer 
cells to TRAIL-induced apoptosis. This occurred, at least in 
part, through PED downregulation.17
A major obstacle to the translation of RNAi drugs (e.g., 
miRNA mimics) into the clinic is the absence of an effective 
targeted delivery system. In addition to their ability to inhibit 
the function of their targets, in the past decade much atten-
tion has been focused on aptamers as delivery vehicles for 
targeted therapy.18–20 Aptamers are highly structured single-
stranded RNA molecules that bind to their cognate molecu-
lar targets (including transmembrane receptors) with high 
affinity and selectivity.21,22 Aptamers have been successfully 
adapted for the targeted delivery of active molecules both 
in vitro and in vivo, including anticancer drugs, toxins, radio-
nuclides, siRNAs, and, more recently, miRNAs.23-25 Aptamer-
siRNA or aptamer-miRNA chimeras are characterized by low 
immunogenicity, easy chemical synthesis and modification, 
and superior target selectivity.23,26–28
In previous studies, an internalizing RNA aptamer 
(GL21.T)29 has been identified, through a cell-SELEX (sys-
tematic evolution of ligands by exponential enrichment) 
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TNF-related apoptosis-inducing ligand (TRAIL) is a promising antitumor agent for its remarkable ability to selectively induce 
apoptosis in cancer cells, without affecting the viability of healthy bystander cells. The TRAIL tumor suppressor pathway 
is deregulated in many human malignancies including lung cancer. In human non-small cell lung cancer (NSCLC) cells, 
sensitization to TRAIL therapy can be restored by increasing the expression levels of the tumor suppressor microRNA-212 (miR-
212) leading to inhibition of the anti-apoptotic protein PED/PEA-15 implicated in treatment resistance. In this study, we exploited 
a previously described RNA aptamer inhibitor of the tyrosine kinase receptor Axl (GL21.T) expressed on lung cancer cells, as 
a means to deliver miR-212 into human NSCLC cells expressing Axl. We demonstrate efficient delivery of miR-212 following 
conjugation of the miR to GL21.T (GL21.T-miR212 chimera). We show that the chimera downregulates PED and restores TRAIL-
mediate cytotoxicity in cancer cells. Importantly, treatment of Axl+ lung cancer cells with the chimera resulted in (i) an increase 
in caspase activation and (ii) a reduction of cell viability in combination with TRAIL therapy. In conclusion, we demonstrate that 
the GL21.T-miR212 chimera can be employed as an adjuvant to TRAIL therapy for the treatment of lung cancer.
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methodology.30 GL21.T aptamer is able to bind and inhibit 
the signaling of Axl receptor, belonging to the TAM family of 
tyrosine kinase receptors. Axl family members are activated 
by growth-arrest-specific gene 6 (GAS6), a member of the 
vitamin K–dependent protein family, that resembles blood 
coagulation factors rather than typical growth factors.31 Axl 
overexpression has been reported in many human cancers 
and is associated with invasiveness and/or metastasis in 
lung,32 prostate,33 breast,34 gastric,35 and pancreatic cancers,36 
renal cell carcinoma,37 as well as glioblastoma.38 Importantly, 
we have recently described the combinatorial potential of a 
chimera composed of GL21.T aptamer and a miRNA com-
bining the clinical benefits of both moieties.24 Here, we dem-
onstrate selective delivery of miR-212 to Axl+ lung cancer 
cells with GL21.T resulting in restoration of TRAIL-mediated 
sensitivity in NSCLC cells. Treatment of Axl+ cells with the 
GL21.T-miR212 chimera resulted in caspase activation and in 
a concomitant reduction of cancer cell viability. In conclusion, 
we describe a novel aptamer-miRNA chimera as a means to 
sensitize lung cancers to TRAIL therapy.
Results
Chimera design
To conjugate GL21.T aptamer and miR-212, a molecular chi-
mera (termed GL21.T-miR212) was designed using the RNA 
structure 5.3 program. GL21.T is a 34-mer truncated version 
of the original GL21 aptamer, corresponding to the functional 
portion of the aptamer able to bind to and to antagonize Axl 
receptor.29 GL21.T was used as a delivery carrier of human 
miR-212. For this purpose, the GL21.T sequence was elon-
gated at its 3′ end, by a covalent bond, with the sequence 
of the passenger strand of miR-212, and annealed to the 
guide strand. Even if full complementary miRNA sequences 
have been shown to be sufficient for targeted gene silenc-
ing,27,28 several recent reports on the use of molecular 
Figure 1 Chimeras structure prediction and binding and internalization analysis. Secondary structure prediction of chimeras using RNA 
structure 5.3 program. (a) GL21.T aptamer; (b) GL21.T-miR212; (c) GL21.Tscr-miR212. MiR mature sequence is indicated with an asterisk. 
(d) Internalization assay for the 5′-[32P]-labeled GL21.Tscr-miR212 and GL21.T-miR212 chimeras performed on A549 (Axl+) and MCF7 
(Axl−) cells. The percentage of the RNA internalized over bound was obtained subtracting the counts relative to the scrambled chimera  GL21.
Tscr-miR212 used as negative control. Each bar shows the mean ± SD values from three wells. (e) Internalization analysis of GL21.T,  GL21.
Tscr-miR212, and GL21.T-miR212 was monitored using quantitative RT-PCR (qRT-PCR) and normalizing to an internal RNA reference control 
for the PCR. The percentage of internalization has been expressed as the amount of internalized RNA relative to total bound RNA. Statistics 
were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001. Each bar shows the mean ± SEM values from three wells.
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aptamer-siRNA chimeras have shown that silencing efficacy 
and specificity can be improved by introducing internal par-
tial complementarities and increased length extension with 
respect to the mature sequence in order to obtain a more 
effective Dicer substrate.26,39,40 Therefore, in order to encour-
age correct strand selection and thereby encourage target 
specificity, passenger and guide strands presented an imper-
fect pairing, consisting in a portion of stem-loop structure 
making the double strand similar to the pre-miR. A scrambled 
chimera, GL21.Tscr-miR212, was also designed, with the 
GL21.T sequence substituted by an unrelated sequence of 
the same length elongated with the miR-212 mimic passen-
ger strand and annealed to the full complementary miR-212 
guide strand. In both types of chimera, the antisense strand 
presented two overhanging bases (UU) at 3′ end necessary 
for Dicer processing (Figure 1). Since, based on its predicted 
structure, the folding of GL21.T appears to be preserved also 
in the context of the chimera, we experimentally assessed 
the selective binding and the internalization potential of 
GL21.T-miR212 on Axl-expressing cells. Binding and inter-
nalization assays were performed using A549 (Axl+) cells, 
while MCF7 cells were used as negative control since they 
do not express Axl. As shown in Figure 1, GL21.T-miR212 
was able to bind to and internalize into A549 respect to the 
scrambled chimera used as control, but not in MCF7 cells, 
as assessed by two different methods (Figure 1d,e). Note-
worthy, a similar percentage of internalization was obtained 
 comparing GL21.T-miR212 and GL21.T alone (Figure 1e). 
These results indicate that, as previously reported for the 
GL21.T aptamer,29 in the GL21.T-miR212 conjugate, the 
binding specificity of the GL21.T aptamer moiety is pre-
served and the conjugate is internalized into target cells in a 
receptor-dependent manner.
Dose–response effects and dicer processing of GL21. 
T-miR212 chimera
In order to characterize the effects of the chimera treatment 
on the miR-212 target, PED protein, A549 cells were treated 
with increasing amounts of GL21.T-miR212 and of control, 
GL21.Tscr-miR212, for 48 hours (Figure 2a). By western 
blot, we observed that PED levels were reduced in a dose–
response manner by a concentration of 200 nM.
To test the specificity of the GL21.T-miR212 chimera and 
simultaneously evaluate the broad applicability of our delivery 
Figure 2 MiR-212 effect, aptamer-mediated specific delivery, and Dicer processing of GL21.T-miR212 chimera. (a) A549 cells 
were treated with different final concentrations (50, 100, 200, and 300 nM) of chimera and scrambled chimera for 48 hours. (b) A549 cells 
were incubated with GL21.T-miR340, GL21.T, and GL21.T-miR212 or alternatively were transfected with pre-miR-212 and pre-miR-340. 
(c) A549 cells were transfected with the aptamer alone, GL21.Tscr-miR212 and GL21.T-miR212. (d) A549 cells were transfected with control 
scrambled or  pre-miR-212 or treated with the aptamer alone or GL21.T-miR212 in presence or absence of Dicer-siRNA. After 48 hours, the 
efficiency of si-Dicer transfection (left panel) was controlled by immunoblotting using anti-Dicer and anti-α-tubulin antibodies. The effect on 
the downregulation of target protein (right panel) was analyzed by immunoblotting with anti-PED and anti-β actin antibodies. Values below 
the blots indicate signal levels relative to (a) scrambled chimera-treated cells, arbitrarily set to 1 (with a different number of asterisks for each 
dose), or (b,d) to untreated cells (indicated as “WT”), and (c) to GL21.T-treated cells arbitrarily set to 1 (with asterisk). Intensity of bands was 
calculated using ImageJ (v1.46r). For a, b, and c, cell lysates were immunoblotted with anti-PED and anti-β actin antibodies.
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platform, we conjugated the Axl aptamer to a different miR, 
miR-340. We have recently described that miR-340 has an 
onco-suppressive role in NSCLC by targeting PUM1, PUM2, 
and SKP2. The downregulation of these three genes was 
inversely correlated to p27 expression.41 Treatment of A549 
cells with GL21.T-miR340 resulted in an increase in miR-340 
expression levels suggesting the proper internalization of the 
chimera. The effect on SKP2 downregulation, as well as on 
the increase of p27 levels, confirmed the effectiveness of the 
conjugate (Supplementary Figure S1). This effect was simi-
lar to that observed with transfection of A549 cells with miR-
340 (used as positive control). In contrast, as anticipated, 
the aptamer alone and the aptamer conjugated to miR-340 
(GL21.T-miR340) did not reduce PED protein levels under 
the same experimental conditions. By western blot, results 
showed that GL21.T-miR340 was not able to modify PED 
levels, thus indicating that PED downregulation was merely 
dependent on miR-212 moiety (Figure 2b).
To demonstrate that GL21.Tscr-miR212 was not functional 
due to the aptamer portion and not to inactivation of the miR 
sequence, A549 cells were transfected with the aptamer 
alone, GL21.Tscr-miR212 and GL21.T-miR212. As shown, 
following transfection, the scrambled chimera was as effec-
tive as the GL21.T-miR212 at downregulating PED protein 
levels (Figure 2c).
In order to investigate the mechanism by which the chimera 
was functional, A549 cells were transfected with a Dicer-specific 
siRNA and, then, treated with GL21.T-miR212. The co-transfec-
tion of pre-miR-212 was used as positive control. The efficiency 
of si-Dicer transfection and the effect on the downregulation of 
target protein were determined by immunoblotting (Figure 2d). 
As shown, in the presence of a Dicer-specific siRNA, GL21.T-
miR212 was not able to reduce PED protein level, suggesting 
that Dicer was necessary for chimera processing.
Cell-type specificity of chimera treatment
To test whether PED downregulation was cell-type specific, 
A549 (Axl+) and MCF7 (Axl-) cells were treated with GL21. 
T-miR212 and GL21.Tscr-miR212. Transfection of pre-
miR-212 and treatment with GL21.T aptamer were used as 
positive and negative controls, respectively. In A549 cells, 
GL21.T-miR212 downregulated PED both at mRNA level 
(measured using qRT-PCR) and protein level (assessed by 
immunoblotting with specific antibodies). As expected, no 
effect of the chimeras on PED expression was observed in 
MCF7 (Axl-negative) cells (Figure 3a,b). To confirm that the 
effects on PED protein levels were mediated by miR-212 
upregulation, the same samples were evaluated by qRT-PCR 
to analyze miR-212 expression (Figure 3c). GL21.T deliv-
ered miR-212 inside the target cells, resulting in miR-212 
Figure 3 Cell-type specificity of chimera treatment. (a) A549 and MCF7 cells were treated with 300 nM of GL21.T-miR212 for 48 hours. 
GL21.Tscr-miR212 and GL21.T aptamer were used as negative controls, whereas transfection with 100 nM of pre-miR-212 was used as 
positive control. Control scrambled was used to assure transfection efficiency. Cell lysates were immunoblotted with anti-PED and anti-β actin 
antibodies for PED protein levels while (b) PED expression levels were analyzed by qRT-PCR. (c) The same samples were subjected to  qRT-
PCR for miR-212 expression levels analysis. Bands’ intensity has been calculated as in Figure 2. In b and c each bar shows the mean ± SD 
values from three wells. Statistics were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.05.
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upregulation. Furthermore, despite the fact that the intra-
cellular levels of miR-212 were lower in cells treated (no 
transfection reagent used) with GL21.T-miR212 compared 
with cells transfected with the pre-miR, the effects on PED 
downregulation were comparable. Results indicate that the 
efficiency of the conjugate to deliver functional miR-212 and 
thus modulate the expression of miRNA target genes is simi-
lar to that observed with transfection. We also validated the 
effect of GL21.T-miR212 on PED downregulation in other 
NSCLC Axl+ cell lines, Calu-1 and HCC827-ER3 (Figure 4).
Receptor-dependent internalization of GL21.T-miR212 
chimera
To confirm receptor-dependent internalization of GL21. 
T-miR212 chimera, we silenced Axl  levels in A549 cells 
with RNAi. Following 48 hours of si-Axl  transfection, we 
tested the binding and internalization potential of GL21. 
T-miR212. As expected, we observed a statistically signifi-
cant decrease in bound/internalized GL21.T aptamer and 
chimera in A549 (siAxl)-treated cells. In contrast, no dif-
ferences in binding/internalization were observed for the 
scrambled chimera (Figure 5a). The efficiency of si-Axl 
transfection and the effect on the downregulation of target 
protein were determined by immunoblotting (Figure 5b). 
Alternatively, Axl  levels were transiently upregulated 
transfecting Axl  cDNA. Following Axl  overexpression, the 
treatment with GL21.T-miR212 increased miR-212 levels 
by twofold compared with parental A549. Simultaneously, 
the conjugate decreased PED levels to the same extent in 
parental and transfected A549 cells (Figure 5c). Thus, we 
conclude that the functional delivery of miR-212 is depen-
dent on the amount of Axl on the cell surface and that the 
additional miR-212 delivered is not necessary to increase 
the effect on PED downregulation. We next assessed 
whether internalization of the conjugate was Axl mediated. 
MCF7 cells were transiently transfected with Axl cDNA 
and levels of miR-212 evaluated following treatment with 
the conjugate. As predicted, miR-212 levels were higher in 
cells treated with GL21.T-miR212, compared with the treat-
ment with GL21.Tscr-miR212 or the aptamer alone, thus 
indicating that internalization of GL21.T-miR212 chimera is 
receptor dependent (Supplementary Figure S2).
Figure 4 Effects of GL21.T-miR212 on additional Axl+ non-small cell lung cancer (NSCLC) cell lines. (a,d) Calu-1 and HCC827-ER3 
cells were treated with 300 nM of GL21.T-miR212, GL21.Tscr-miR212, and GL21.T aptamer or, alternatively, transfected with 100 nM of  pre-
miR-212. After 72 hours for Calu-1 or 48 hours for HCC827-ER3, cells were collected and cell lysates were immunoblotted with anti-PED and 
anti-β actin antibodies for PED protein levels. (b) The same samples of HCC827-ER3 were subjected to qRT-PCR for miR-212 and (c) for 
PED expression levels analysis. In a,d values below the blots indicate signal levels relative to untreated cells (indicated as “WT”), arbitrarily 
set to 1 (with asterisk). Bands’ intensity has been calculated as in Figure 2. In b and c each bar shows the mean ± SD values from three wells. 
Statistics were calculated using Student’s t-test, ****p < 0.0001; ***p < 0.001; *p < 0.05.
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GL21.T-miR212 regulates TRAIL-induced cell death
We have previously shown that the TRAIL-resistant pheno-
type in NSCLC is related to aberrant elevated levels of PED. 
Furthermore, we showed that ectopic expression of miR-
212 (achieved with a miR mimic) downregulates PED and 
re-establishes sensitivity to TRAIL.14,17 To investigate whether 
treatment with the chimera induced sensitivity to TRAIL, we 
treated A549 cells with GL21.T-miR212. GL21.Tscr-miR212 
and transfected pre-miR-212 were included as negative and 
positive controls, respectively. Caspase-8 activation was 
evaluated following treatment with TRAIL for 3 hours by west-
ern blot (Figure 6a). As shown, cleavage of caspase-8 was 
evident in cells treated with GL21.T-miR212 or, alternatively, 
transfected with pre-miR-212, but not with the GL21.Tscr-
miR212, and accompanied by the activation of caspase 3/7, 
assessed by Caspase-Glo® 3/7 Assay (Figure 6b). Thus, 
sensitization to TRAIL upon treatment with the chimera was 
selective for Axl-expressing cells as demonstrated by the 
activation of caspase 3/7. To further confirm that the chimera 
sensitizes cancer cells to TRAIL-induced apoptosis, we eval-
uated the percentage of apoptotic cells after TRAIL treatment 
(Figure 7a). Transfected or treated cells were labeled with 
Annexin V-FITC and propidium iodide and analyzed using 
flow cytometry. GL21.T-miR212 increased the percentage of 
apoptotic (Annexin V—positive, PI—negative) cells following 
TRAIL treatment, as miR-212 was used as positive control. 
In addition, we measured cell viability using an MTT assay 
that showed the same results (Figure 7b). GL21.T-miR340 
treatment did not produce any gain in TRAIL sensitivity 
 (Figure 7c). In summary, the GL21.T-miR212 chimera was 
able to increase the activation of caspase3/7 and, conse-
quently, TRAIL-induced cell death in A549 cells, but not in 
MCF7 cells. TRAIL sensitization mediated by GL21.T-miR212 
treatment was also confirmed on additional NSCLC cell lines, 
Calu-1 and HCC827-ER3, which display a TRAIL-resistant 
phenotype (Figure 8).
Discussion
NSCLC represents about 80% of all lung cancers and is 
mostly diagnosed at an advanced stage (either locally 
advanced or metastatic disease). Because of resistance 
to therapeutic drugs, standard treatment of this tumor has 
Figure 5 Receptor-dependent internalization of GL21.T-miR212 chimera. (a) A549 cells were transfected with si-Axl or siRNA control for 
24 hours and, then, treated with GL21.T-miR212, the scrambled chimera or with the aptamer alone to perform the binding (upper panel) and 
internalization (lower panel) assays. Each bar shows the mean ± SEM values from three wells. (b) The efficiency of si-Axl transfection and 
the effect on the downregulation of target protein were evaluated after 48 hours of treatment by immunoblotting with anti-Axl and anti-tubulin, 
in the upper panel, and with anti-PED and anti-β actin antibodies, in the lower panel. Values below the blots indicate signal levels relative to 
untreated cells (indicated as “WT”), arbitrarily set to 1 (with asterisk). Bands’ intensity has been calculated as in Figure 2. (c) A549 (Axl+) 
cells, following 24-hour transfection with Axl TruClone (Axl), were treated with 300 nM of GL21.T-miR212, GL21.Tscr-miR212, or GL21.T for 
additional 48 hours. miR-212 (upper panel), PED and Axl (lower panel) levels were quantified by RT-qPCR. Each bar shows the mean ± SD 
values from three wells. Statistics were calculated using Student’s t-test, ****p < 0.0001; **p < 0.01.
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only a 20% to 30% positive clinical response. Over the last 
years, the discovery of the pivotal of epidermal growth fac-
tor receptor (EGFR) in tumorigenesis has opened the way to 
a new class of targeted therapeutic agents: the EGFR tyro-
sine kinase inhibitors (EGFR TKIs). Since their introduction 
in therapy, in advanced NSCLC patients harboring EGFR 
mutations, the use of EGFR TKIs in first-line treatment has 
provided an unusually large progression-free survival ben-
efit with a negligible toxicity when compared with cytotoxic 
chemotherapy. Nevertheless, resistance invariably occurs.42 
In this setting, TRAIL emerged as a novel therapeutic agent. 
TRAIL (ApoL/TNF-related apoptosis-inducing ligand) is a rel-
atively new member of the tumor necrosis factor (TNF) ligand 
family, which induces apoptosis in a variety of cancers.
Initial promising studies demonstrated its remarkable speci-
ficity in inducing apoptosis in tumor cell lines, but not in nor-
mal cells both in vitro and in vivo.7 This unique property makes 
TRAIL an attractive candidate for targeted cancer therapy.43,44 
However, resistance to TRAIL-induced apoptosis poses a 
challenge for effective anticancer strategies. To overcome this 
problem, drug cocktails in combination with TRAIL therapy 
have been proposed in order to induce synergism or sensitize 
resistant cancer cells. Toward this end, a number of combinato-
rial treatments with chemotherapeutic agents are in phase 1/2 
of clinical studies.45–47 More recently, aptamer-siRNA/miRNA 
chimeras have been proposed as novel adjuvants to standard 
chemotherapy.48,49 Unlike nontargeted drugs, the advantage of 
these new class of biodrugs is that they are specifically deliv-
ered into target cells where they release their therapeutic cargo, 
thus limiting toxicity to normal cells.
In this study, we designed a chimera composed of a RNA 
aptamer to Axl (GL21.T) and miR-212 as a means to deliver 
functional miR-212 into TRAIL-resistant Axl+ A549 cells, but 
not into Axl- MCF7 cells. Indeed, GL21.T-miR212 selectively 
sensitizes the A549 cells to TRAIL-induced apoptosis, prov-
ing to be a unique tool to synergize with TRAIL in mediating 
cell death.
To increase specificity and facilitate large-scale chemical 
synthesis,24,26,50 we conjugated a truncated version of the GL21 
aptamer (GL21.T) to the tumor suppressor miR-212 duplex 
sequence. We demonstrated that in the context of the chimera, 
the active sequence (sequence required for binding to Axl) of 
GL21 is preserved, thus providing high binding affinity and the 
subsequent selective internalization of the conjugate into Axl+ 
cells. The miRNA moiety is a 25/27mer duplex having two over-
hanging bases (UU) at the 3′ end of the passenger strand, thus 
adopting the conformation described as Dicer substrate for 
duplex siRNAs.51 By using a similar approach with miRNAs, we 
have recently shown that nonperfect duplex miRNAs are cor-
rectly processed by Dicer, increasing the gene target specificity 
of the miRNA moiety.24 Indeed, the optimal loading of the guide 
strand into RNA-induced silencing complex (RISC) is thought 
to reduce off-target effects that result from inappropriate incor-
poration of both miRNA strands into the silencing complex.52
A major limitation to the use of RNA-based drugs in vivo is 
the rapid degradation (within few minutes) of natural RNAs in 
serum or blood. As previously described, in order to protect the 
GL21.T aptamer from degradation, it was generated as a 2′-F-
Py containing RNA.29 Therefore, in order to increase the stabil-
ity of the entire GL21.T-miR212 molecule, we substituted the 
Figure 6 Caspases activation induced by GL21.T-miR212. (a) A549 cells were transfected with 100 nM of pre-miR-212 or alternatively 
treated with 300 nM of GL21.T-miR212 for 48 hours. Scrambled miR and scrambled chimera were used as negative controls. Cells were, then, 
treated for 3 hours with TNF-related apoptosis-inducing ligand (TRAIL) 50 ng/ml, and cell lysates were immunoblotted with anti-caspase-8 
antibody (upper panel). Band intensity is represented in the diagram of the lower panel as a ratio of cleaved over total caspase-8, both 
quantization normalized over β-actin. (b) A549 and MCF7 cells were transfected with pre-miR-212 or treated with the unconjugated aptamer, 
the scrambled chimera and GL21.T-miR212 for 48 hours and then incubated with 50 ng/ml of TRAIL for 6 hours. The activation of caspase 3/7 
was measured by Caspase-Glo® 3/7 Assay. Each bar shows the mean ± SD values from three wells. Statistics were calculated using Student’s 
t-test, ****p < 0.0001; ***p < 0.001; **p < 0.01.
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pyrimidines with 2′-F-Py at all positions. This modification is well 
characterized in humans and is reported to be well tolerated 
with little toxicity.53 RNA aptamers with this modification have 
already been approved for their use in humans (Macugen), 
with many more quickly moving through the clinical pipeline.54 
Although we cannot completely rule out potential intracellular 
toxicity of 2′-F-Py-modified RNAs leading to nonspecific immu-
nostimulation, experiments in vivo demonstrated that problem-
atic toxicity in humans is not expected.24,26
The silencing moiety of the chimera is constituted by the 
miR-212, a tumor suppressor miRNA that acts by negatively 
modulating PED expression, an onco-protein with a broad 
anti-apoptotic action. Indeed, the presence of elevated cel-
lular levels of PED has been shown to contribute to resis-
tance to TRAIL-induced cell death in several human tumors, 
including breast and lung cancer.17,55 The DED domain of 
PED acts as a competitive inhibitor for pro-apoptotic mole-
cules during the assembly of a functional DISC and inhibiting 
the activation of caspase-8, which take place following treat-
ment with different apoptotic cytokines (CD95/FasL, TNF-α, 
and TRAIL). These data demonstrate that GL21.T-miR212 is 
a functional molecule that upon internalization, downregu-
lates PED in a dose-dependent manner, reaching a plateau 
at around 200 nM. In turn, target cells become sensitive to 
TRAIL and upon treatment undergo apoptosis following cas-
pase-8 and caspase-3 activation.
Based on the suppressive action of miR-212 on PED 
expression as a means to sensitize cancer cells to TRAIL, 
here we demonstrated that GL21.T-miR212 chimera can 
sensitize target cells in a high selective manner. Specifically, 
exogenous miR-212 delivered by GL21.T aptamer led to 
TRAIL sensitization via activation of the apoptotic cascade 
selectively in A549, NSCLC Axl+ cells. In conclusion, the 
approach presented in this work indicates an innovative tool 
for a combined therapy that makes use of an aptamer-based 
molecular chimera to selectively sensitize TRAIL-resistant 
target tumor cells.
Materials and methods
Cell lines and transfection. A549 and HCC827-ER3 cells 
were grown in RPMI 1640 while MCF7 and Calu-1 cells were 
grown in Dulbecco's modified Eagle's medium. A549, MCF7, 
and Calu cells were from American Type Culture Collection, 
while HCC827-ER3 were kindly provided by Dr. Balazs Hal-
mos (Columbia University Medical Center, New York, NY). 
Their media were supplemented with 10% heat-inactivated 
fetal bovine serum, 2 mM of glutamine, and 100 U/ml of peni-
cillin/streptomycin. For miRNAs transient transfection, cells 
were transfected with 100 nM (final concentration) of miRNA 
stem-loop precursor hsa-miR212, hsa-miR340, or negative 
control 1 (Ambion, Foster City, CA) using Oligofectamine (Invi-
trogen, Carlsbad, CA). Also si-control and si-Axl (Santa Cruz 
Biotechnology, Santa Cruz, CA) were transfected using Oligo-
fectamine (Invitrogen), according to the manufacturer’s proto-
col. For aptamer and chimeras transient transfection, cells were 
transfected with 100 nM (final concentration) of RNAs, using 
Lipofectamine 2000 (Invitrogen). Also Axl TruClone (Origene, 
Rockville, MD) and si-Dicer (Cell Signaling Technology, Beverly, 
MA) were transfected with Lipofectamine 2000, according to 
the manufacturer’s protocol.
Aptamer-miRNA chimeras. The following sequences were used 
for the chimera production: GL21.T-miR212 passenger strand: 
Figure 7 TNF-related apoptosis-inducing ligand (TRAIL) 
sensitization induced by GL21.T-miR212. (a) A549 cells were 
transfected with pre-miR-212 and control scrambled or treated 
with the chimera, the scrambled chimera and the unconjugated 
aptamer for 48 hours. Cells were, then, incubated with TRAIL for 24 
hours, and the percentage of apoptotic cells was evaluated by flow 
cytometry. (b) A549 and MCF7 cells were treated with 300 nM of 
GL21.T-miR212 and GL21.Tscr-miR for 48 hours and were exposed 
to TRAIL for 24 hours at 50 ng/ml as final concentration. (c) A549 
cells were treated with the unconjugated aptamer, GL21.T-miR212 
or GL21.T-miR340 for 48 hours and were exposed to TRAIL for 24 
hours at 50 ng/ml as final concentration. For b and c cell viability 
was evaluated with MTT assay. In a, b, and c each bar shows the 
mean ± SD values from three wells. Statistics were calculated using 
Student’s t-test, ****p < 0.0001; **p < 0.01.
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5 ′GGGAUGAUCAAUCGCCUCAAUUCGACAGGAGG 
CUCACGGUACCUUGGCUCUAGACUGCUUACUUU. miR- 
212 guide strand: 5′ AGUAACAGUCUCCAGUCACGGCC 
ACC. GL21.Tscr-miR212 passenger strand: 5′GGGUUCGU 
ACCGGGUAGGUUGGCUUGCACAUAGAACGUGUCAGG 
CCGUGACUGGAGACUGUUAUU. miR-212 (1g) guide 
strand: 5′ UAACAGUCUCCAGUCACGGCC. GL21.T: 5′ GGG 
AUGAUCAAUCGCCUCAAUUCGACAGGAGGCUCAC. 
GL21.T-miR340 passenger strand: 5′GGGAUGAUCAAUCG 
CCUCAAUUCGACAGGAGGCUCACAAUCAGUCUCA 
UUGCUUUAUAAUU. miR-340 guide strand: 5′ UUAUAAA 
GCAAUGAGACUGAUU.
All RNAs were custom synthesized by TriLink Biotechnolo-
gies (San Diego, CA) as 2′-fluoropyrimidine RNAs. UU in 
bold are 3′-overhang. The control conjugate is composed of 
an unrelated aptamer sequence linked to the fully comple-
mentary miR-212 duplex. In the context of the control conju-
gate, it was necessary to use a fully complementary miR-212 
to stabilize the functional miR duplex and prevent unwanted 
intramolecular interactions with the scrambled aptamer 
sequence.
To prepare GL21.T-miR212, GL21.Tscr-miR212, and 
GL21.T-miR340, 5 µM of aptamer-passenger RNA strand 
was denatured at 98 °C for 20 minutes, combined with 5 µM 
of the appropriate guide strand at 55 °C for 10 minutes in 
binding buffer 10× (200 mM N-2-Hydroxyethylpiperazine-N'-
2-Ethanesulfonic Acid, pH 7.4, 1.5 M NaCl, 20 mM CaCl2) and 
then warmed up to 37 °C for 20 minutes.
Cell binding and internalization assays. Aptamer binding and 
internalization have been assessed by two different methods, 
by radioactivity labeling or by quantitative reverse transcrip-
tion-PCR (qRT-PCR)
Radioactivity labeling. A549 and MCF7 cells were plated in 24 
multiwell plates in triplicate. RNAs were 5′-[32P]-labeled and 
incubated at 200 nM as final concentration on cells at 37 °C for 
15 minutes. After several washings, the amount of 32P-labeled 
RNA recovered in SDS 1% was determined by scintillation 
counting. In contrast, to check the endocytosis rate, after the 
incubation with radiolabeled chimeras, the cells were subjected 
to a stringent high-salt wash, with High Salt phosphate-buffered 
saline (PBS; 0.5 M NaCl), to remove any unbound RNAs or 
RNAs bound to the cell surface. Following 5-minute treatment 
at 4 °C, the amount of 32P-labeled RNA internalized was recov-
ered in Sodium Dodecyl Sulfate  1% and determined by scintil-
lation counting. In both assays, results were normalized for cell 
Figure 8. TNF-related apoptosis-inducing ligand (TRAIL) sensitization induced by GL21.T-miR212 in additional Axl+ non-small cell 
lung cancer (NSCLC) cell lines. Calu-1 and HCC827-ER3 cells were transfected with pre-miR-212 or treated with the unconjugated 
aptamer, the scrambled chimera and GL21.T-miR212. (a,b) After 72 hours for Calu-1 or 48 hours for HCC827-ER3 of treatment or 
transfection, cells were incubated with TRAIL (100 ng/ml in Calu-1 and 50 ng/ml in HCC827-ER3) for 6 hours. The activation of caspase 3/7 
was measured by Caspase-Glo® 3/7 Assay. (c) The same samples of HCC827-ER3 were exposed to TRAIL for 24 hours, and cell viability 
was evaluated with MTT assay. Each bar shows the mean ± SD values from three wells. Statistics were calculated using Student’s t-test, 
****p < 0.0001; ***p < 0.001; *p < 0.05.
5
4
R
at
io
 o
f c
as
pa
se
 3
/7
 a
ct
ivi
ty
ov
e
r 
co
n
tro
l
100
80
60
40
20
0
Ce
ll v
ia
bi
lity
 %
 o
ve
r 
u
n
tre
at
ed
R
at
io
 o
f c
as
pa
se
 3
/7
 a
ct
ivi
ty
ov
e
r 
u
n
tre
at
ed
3
2
1
0
Transf.
TRAIL 100 ng/ml
Calu-1
HCC827-ER3
HCC827-ER3
4.5
4
3.5
3
2.5
2
1.5
1
0.5
0
***
***
TRAIL 50 ng/ml
****
***
TRAIL 50 ng/ml
*
***
Treated
W
T
sc
r
GL
21
.T
m
iR
-21
2
GL
21
.T-
m
iR
21
2
GL
21
.Ts
cr-
mi
R2
12
Transf. Treated
W
T
sc
r
GL
21
.T
m
iR
-21
2
GL
21
.T-
m
iR
21
2
GL
21
.Ts
cr-
mi
R2
12
Transf. Treated
W
T sc
r
GL
21
.T
m
iR
-21
2
GL
21
.T-
m
iR
21
2
GL
21
.Ts
cr-
mi
R2
12
a
b c
Molecular Therapy—Nucleic Acids
Aptamer and Cancer Therapy
Iaboni et al.
10
number. The background values obtained with the scrambled 
chimera were subtracted from the values obtained with GL21.T-
miR212. Finally, the resulting recovered RNAs were plotted as 
percent of RNA internalized over RNA bound.
qRT-PCR method. Target (A549) and nontarget (MCF7) cells 
were incubated with 100 nM of aptamer or chimeras for 15 
minutes at 37 °C with 5% CO2. Cells were washed with ice-
cold PBS or incubated with High Salt PBS (0.5 M NaCl) at 
4 °C for 5 minutes, and RNA was recovered using TRIzol 
reagent (Invitrogen). Samples were normalized to an inter-
nal RNA reference control. Specifically, 0.5 pmol per sample 
CL4 aptamer56 was added to each sample along with TRIzol 
as a reference control. Recovered RNAs were quantitated 
using Reverse Transcriptase M-MuLV (Roche Life Science, 
Basel, Switzerland) with SYBR Green (BioRad) with a Biorad 
iCycler. All reactions were done in a 25-ml volume in trip-
licate with specific primers (GL21.T 5′: TAATACGACTCAC-
TATAGGGATGATC; 3′: GTGAGCCTCCTGTcGAAT; GL21.
Tscr 5′: TTCGTACCGGGTAGGTT; 3′: TGACACGTTCTAT-
GTGCA) and CL4 reference control (CL4 5′: TAATACGACT-
CACTATAGGGGCCTTA; 3′: GCCTCCTGTCGAATCG).
For each cell line, the percentage of internalization has 
been expressed as the amount of internalized RNA relative 
to total bound RNA without normalizing for background. The 
same protocol was used for the experiment on A549 cells 
upon transfection with si-control and si-AXL.
Protein isolation and immunoblotting. Cells were treated with 
chimeras for 48 hours, or alternatively Calu-1 for 72 hours, and 
then were washed twice in ice-cold PBS and lysed in Lysis buf-
fer (50 mM N-2-Hydroxyethylpiperazine-N'-2-Ethanesulfonic 
Acid pH 7.5 containing 150 mM NaCl, 1% GLYCEROL, 1% 
Triton 100×, 1.5 mM MgCl2, 5 mM ethylene glycol tetraacetic 
acid, 1 mM Na3VO4 and 1X protease inhibitor cocktail). Protein 
concentration was determined by the Bradford assay (Bio-
Rad, Hercules, CA) using bovine serum albumin as the stan-
dard, and equal amounts of protein were analyzed by Sodium 
Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (15% 
acrylamide). Gels were electroblotted onto nitrocellulose mem-
brane (Merck Millipore, Billerica, MA). For immunoblot experi-
ments, membranes were blocked for 1 hour with 5% non-fat 
dry milk in tris-buffered saline containing 0.1% Tween-20 and 
incubated at 4 °C overnight with primary antibody. Detection 
was performed by peroxidase-conjugated secondary anti-
bodies using the enhanced chemiluminescence system (GE 
Healthcare Life Sciences, Pittsburgh, PA). Primary antibodies 
used were anti-PED,57 anti-Caspase-8, anti-p27, and anti-Dicer 
from Cell Signaling Technology, anti-α tubulin from Santa Cruz 
Biotechnology, anti-β actin from Sigma-Aldrich (St. Louis, MO), 
and anti-Axl from R&D Systems (Minneapolis, MN).
RNA extraction and Real-time PCR. Cells were treated with 
300 nM of chimeras for 48 hours, and then total RNAs (miRNA 
and mRNA) were extracted using TRIzol (Invitrogen) accord-
ing to the manufacturer’s protocol. Reverse transcription of 
total miRNA was performed starting from equal amounts of 
total RNA/sample (1 µg) using miScript reverse Transcription 
Kit (Qiagen, Hilden, Germany). Quantitative analysis of miR-
NAs and RNU6B (as an internal reference) was performed by 
real-time PCR using specific primers (Qiagen) and miScript 
SYBR Green PCR Kit (Qiagen). The reaction for detection 
of miRNAs was performed as follows: 95 °C for 15 minutes, 
40 cycles of 94 °C for 15 seconds, 55 °C for 30 seconds, 
and 70 °C for 30 seconds. All reactions were run in triplicate. 
For reverse transcription of mRNA, we used SuperScript® 
III Reverse Transcriptase (Life Technologies). Quantitative 
analysis of PED, AXL, and actin (as an internal reference) 
was performed by real-time PCR using specific primers and 
iQTM SYBR Green Supermix (BioRad). The threshold cycle 
(CT) is defined as the fractional cycle number at which the 
fluorescence passes the fixed threshold. For quantization 
has been used the 2(-ΔCT) method, where ΔCt is the differ-
ence between the amplification fluorescent thresholds of the 
miRNA of interest and the miRNA of U6 used as an internal 
reference. Instead, fold changes were calculated with 2(-ΔΔCT) 
method as previously described.58 Experiments were carried 
out in triplicate for each data point, and data analysis was 
performed by using software (Bio-Rad).
Cell death quantification. A549, MCF7, and HCC827-ER3 cells 
were treated with GL21.T-miR212 and GL21.Tscr-miR212 
300 nM for 3 hours. Then, cells were plated in 96 multiwell 
plates in triplicate for 48 hours and incubated with TRAIL (Vinci-
Biochem, Firenze, Italy) at a final concentration of 50 ng/ml for 
24 hours. Cell viability was assessed with CellTiter 96 Aque-
ous One Solution Cell Proliferation Assay (Promega, Madison, 
WI). Metabolically active cells were detected by adding 20 µl 
of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium) to each well, and plates were 
analyzed in a Multilabel Counter (BioTek, Winooski, VT).
Caspase 3/7 assay. The assay was performed with the use of 
Caspase-Glo ® 3/7 Assay (Promega) according to the manu-
facturer’s protocol. Briefly, A549, MCF7, and HCC827-ER3 
cells were before transfected with pre-miR-212 or treated with 
GL21.T, GL21.Tscr-miR212, GL21.T-miR212 for 48 hours, or 
alternatively Calu-1 for 72 hours, and, then, incubated for 6 
hours with TRAIL. An equal volume of Caspase-Glo 3/7 reagent 
was added to each well for 30 minutes in the dark, and lumi-
nescence was measured by luminometer (Turner BioSystems-
Promega). The ratio of caspase 3/7 activity over control was 
calculated normalizing treated samples over untreated ones.
Flow cytometry. Apoptosis was analyzed via Annexin V-FITC 
Apoptosis Detection kit I (BD Biosciences, San Diego, CA). 
A549 cells were transfected with pre-miR-212 or treated with 
GL21.T, GL21.Tscr-miR212, GL21.T-miR212 for 48 hours 
and, then, incubated for 24 hours with TRAIL. The cells were 
washed in PBS, resuspended in binding buffer 10×, and 
labeled with Annexin V-FITC and propidium iodide accord-
ing to the manufacturer’s protocol. After incubation at room 
temperature for 15 minutes in the dark, cells were analyzed 
with a BD AccuriTM C6 Flow cytometry (BD Biosciences). To 
calculate the percent of apoptotic cells, the gate was placed 
on annexin V-positive, PI-negative cells, and thus double pos-
itive cells were excluded from the analysis.
Supplementary material
Figure S1. GL21.T-miR340 characterization.
Figure S2. Internalization of the GL21.T-miR212 conjugate 
in MCF7 exogenously expressing Axl.
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